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Abstract 
Inclusion Complexes of Betamethasone-Related 
Steroids with p- and y-Cyclodextin Studied Using HPLC 
Cyclodextrin complexes of steroids have been used to enhance solubility, improve 
dissolution rates, increase drug product stability, and improve chromatographic 
selectivity. While many applications of steroid : cyclodextrin complexes have been 
reported, very little is know about the nature of these complexes. It is possible for either 
the steroidal AlB-ring or CID-ring to be included into the cyclodextrin cavity. The 
structural features of a steroid that stabilize the complex are not well understood. In this 
work, the key regions that promote inclusion with cyclodextrin have been elucidated. 
The use of two separate HPLC techniques provided a way to determine accurate and 
reproducible apparent association constants (Kr) for thirteen betamethasone-related 
steroids with a variety of cyclodextrins. A novel method to calculate Kr values using a 
modified Hummel-Dreyer approach was developed. Some practical considerations for 
using the Hummel-Dreyer method were investigated. The mobile phase temperature and 
the organic content of the sample diluent were found to critically affect the results 
obtained using this method. Kr values were also calculated by monitoring the rate of a 
reaction of a steroid as the concentration of cyclodextrin in solution was varied. The Kr 
value determined in this way was found to be lower than the rate observed by HPLC. 
This data indicates that two different 1: 1 complexes exist between cyclodextrin and 
betamethasone-related steroids. 
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Chapter 1. 
Introduction - Cyclodextrin Chemistry 
Physical Properties of Cyclodextrins 
Cyclodextrins are cyclic polymers containing a.-l,4 linked D-glucopyranose units. 
They were first discovered by Villiers1 in 1891, but it wasn't until 1903 that they were 
prepared and isolated by Schardinger.2 Interest in cyclodextrins escalated in the early 
1950's when Cramer noted spectral changes of colored molecules in the presence of 
cyclodextrins? The first inclusion complexes of cyclodextrins were discovered. Over 
the past fifty years, many researchers have studied cyclodextrin systems in an effort to 
understand the mechanism of inclusion with cyclodextrins and to capitalize on the 
properties of the resulting complexes. The cyclodextrins that are most commonly studied 
are a.-, 13-, and y-cyc1odextrin which are composed of 6, 7, and 8 D-glucopyranose units, 
respectively. Numerous derivatives of these compounds have also been studied.4 The 
structures for each of the native cyclodextrins are shown in Figure 1-1. These two 
dimensional representations of cyclodextrin do not illustrate the most important feature of 
these molecules - they form a toroidal shape, much like a basket. It is the fixed toroidal 
shape of these compounds that gives them such interesting characteristics. The 
secondary hydroxyl groups located at C(2) and C(3) positions of each sugar monomer 
form the wider rim of the torus. The narrower rim is composed of the primary hydroxyl 
groups located at the C(6) position. The chirality inherent in each monomer unit imparts a 
unique asymmetry to the cycIodextrin molecule. The inside of the torus is composed of 
1 

Figure 1-1 Structures of a-cyclodextrin (A), l3-cyclodextrin (B), and y-cyclodextrin 
(C). 
A B c 

2 

the C(3) and C(S) hydrogens and the glycosidic linkages between C(l) and C(S) within 
each monomer and between C(1) and C(4) of adjacent monomers. The lack of polar 
functional groups within the cyclodextrin cavity makes this region highly lipophilic. The 
presence of hydroxyl groups along the rims of the torus result in a hydrophilic exterior 
for the molecule. 
A simple illustration of the cyc10dextrin torus is shown in Figure 1-2. The size of 
the cyclodextrin cavity depends on the number of D-glucopyranose units making up the 
polymer. The diameter of the secondary hydroxyl rim of the cyclodextrin cavity ranges 
from S.7 A for a-cyclodextrin to 9.S A for y-cyc1odextrin. The depth of the torus for all 
three cyclodextrins is about 7.9 A to 8.0 A. a-, p-, and y-cyc1odextrin are soluble in water 
to varying degrees. Table 1-1 summarizes some of the physical characteristics of these 
cyclodextrins. The values listed for cavity diameter are measured halfway between the 
primary and secondary hydroxyl rims. It is interesting to note that the solubility for p­
cyclodextrin is much lower than the solubility for the other cyclodextrins.5 The reason 
for this has not been clearly established. Coleman et al. have proposed that the 7-fold 
symmetry of p-cyc1odextin interrupts the hydrogen bond structure of water while the 
even symmetries of a- and y-cyclodextrin do not.6 However, this does not account for the 
high solubility of 8-cyclodextrin which contains nine D-glucopyranose units.7 Szejt1i has 
proposed that the low solubility of p-cyc1odextrin is due to the intramolecular hydrogen 
bonding along the rim of the cyclodextrin.8 This seems likely since an increase in 
solubility is observed for derivatized p-cyclodextrins such as hydroxypropyl-P­
cyclodextrin where these hydroxyl groups are no longer present. 
3 
Figure 1-2 Molecular dimensions of a-cyc1odextrin (A), l3-cyc1odextrin (B), and y­
cyc10dextrin (C). 
Secondary 
hydroxyIs"a. 
1.37nm 
0.57 
1.63nm 1.•8nm 
0.78 0.8& 
· /Pnmary 
hydroxyls A B c 
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Table 1-1 Some physicochemical properties of cyclodextrins (adapted from 
reference 9). 
a-CD ~-CD y-CD 

# of glucose units 6 7 8 

molecular weight 972 1135 1297 

solubility, g/100mL water 14.5 1.85 23.2 

solubility, mollL water 0.15 0.016 0.18 

cavity diameter, A 4.7 - 5.3 6.0 - 6.5 7.5 - 8.3 

cavity height, A 7.9 - 8.0 7.9 - 8.0 7.9 - 8.0 

pKa value (25°C) 12.32 12.2 12.08 

5 

Native cyclodextrins are fairly stable in solution under normal experimental 
conditions. Hydrolysis of ~-cyclodextrin at low pH values and elevated temperatures has 
been observed.8 The result is glucose and a series of acyclic maltosaccharides. About 
1.5% of ~-cyclodextrin was reported to be lost after 24 hours at 40°C in 0.115 N HC!. 
The Nature of Cyclodextrin Inclusion Complexes 
Lipophilic compounds in an aqueous solution will often form inclusion complexes 
with cyclodextrin. The primary limitation of inclusion is size. This becomes obvious 
upon considering the dimensions of the cavity for various cyclodextrins. If a compound 
is too big to enter the cavity then no inclusion can occur. If a compound is too small, it 
may pass through the cyclodextrin cavity without interacting with it. Inclusion can occur 
at a particular region of a molecule. It is not necessary for the entire molecule to be 
included. A general rule is that a-cyclodextrin can include compounds the size of 
benzene, ~-cyclodextrin can include compounds the size of naphthalene, and y­
cyclodextrin can include compounds the size of anthracene. A compound included in a 
cyclodextrin cavity is commonly referred to as a guest, while the cyclodextrin is called a 
host. 
Li and Purdy summarize the four binding forces involved in the formation of 
cyclodextrin inclusion complexes as (i) van der Waals interaction between the portion of 
the guest compound included and the interior of the cyclodextrin cavity, (ii) hydrogen 
bonding between the hydroxyl groups located along the rim of the cyclodextrin cavity 
and polar regions of the guest compound in the proximity of the rim, (iii) the release of 
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"high energy water" from the cavity of the cyclodextrin upon inclusion of the guest 
compound, and (iv) the release of ring strain in the molecular framework of cyclodextrin 
as it rearranges to accommodate the guest molecule. 10 The authors point out that it is not 
necessary for hydrogen bonding to occur for complex formation to be successful. For 
example, benzene can form stable complexes with cyclodextrin. 
The strength of an inclusion complex is determined by several factors. The 
lipophilicity of the guest molecule or the region of the guest molecule included into the 
cyclodextrin cavity will affect the stability of the complex. However, the location and 
orientation of polar functional groups near the region that actually sits in the cavity is also 
a critical parameter. For example, p-nitroaniline has been shown to form more stable 
inclusion complexes with f3-cyclodextrin than o-nitroaniline and m-nitroaniline. 11 In this 
case, the location of the nitro group relative to the amine group significantly affects the 
strength of the inclusion complex. 
Other parameters that can alter the strength of the complex are temperature and 
the nature of the solution in which complexation is occurring. In general, a decrease in 
temperature will increase the strength of an inclusion complex with cyclodextrin. This is 
typical for interactions that involve hydrogen bonding. Lower temperatures increase the 
strength of hydrogen bonding. A decrease in the organic content of a solution in which 
complexation is occurring will typically increase the strength of inclusion. The type of 
organic modifier has also been shown to have an effect on complex formation. 12,13 
Cyclodextrin complexes are usually strongest in aqueous solutions. 
7 
The most common cyclodextrin inclusion complexes have been found to form 
with one guest molecule associated with one cyclodextrin molecule. Complexes of this 
type are referred to as having 1: 1 stoichiometry. Using this convention, the first number 
refers to the guest compound and the second number refers to the cyclodextrin. 
Complexes with multiple binding stoichiometries have been observed. Connor and 
Pendergast studied ten sym-l ,4-disubstituted benzenes using a-cyclodextrin as a host and 
found that all but one formed 1:2 complexes in water. 14 Herkstroeter et ai. characterized 
several inclusion complexes of a dye with y-cyclodextrin. 15 Complex stoichiometries of 
1: 1, 1:2, and 2: 1 were all observed. In addition, the dye; y-cyclodextrin; and hexane 
sulfonate formed a 1: 1 : 1 complex. This ternary complex was found to be more stable 
than the 1: 1 complex between the dye and y-cyclodextrin but less stable than the 2: 1 
complex. Hamai also observed a 1: 1: 1 complex of pyrene, p-cyclodextrin, and 1­
pentanol. 16 
In order to discuss the relative strengths of inclusion complexes formed by the 
binding of various guests into the cyclodextrin cavity its is necessary to establish an 
equilibrium constant for the process of inclusion. This process can be described as: 
G + CD = G-CD (1-1) 
where G is a guest compound, CD is a cyclodextrin, G-CD is the resulting complex with 
a 1:1 stoichiometry. An equilibrium constant can be determined for this process. It is 
convenient to refer to this equilibrium constant as a formation constant since it describes 
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a guest compound forming a complex with cyclodextrin. The formation constant (Kr) is 
defined as: 
Kr = [G-CD] / ([G] [CD]) (1-2) 
Kr is also referred to as the association constant of the guest with cyclodextrin. These 
terms will be used interchangeably. Compounds that have a higher affinity for 
cyclodextrin will have a higher value of Kr. This results in a greater amount of the 
compound residing within the cyclodextrin cavity. When discussing the value of Kr 
determined under a given set of conditions, such as a particular temperature and solution 
composition, it is proper to refer to Kr as the apparent formation constant (or apparent 
association constant). Sometimes the dissociation constant (~) is used to describe the 
inclusion complex. ~ is equal to 11 Kr, so a lower ~ describes a stronger inclusion 
complex. 
Measuring Kr - Methods for Studying Inclusion Complexes 
I 
Techniques used to determine Kr values can be separated into three majorI catagories: (i) phase solubility techniques, (ii) spectroscopic techniques, (iii)
I 
chromatographic techniques. Various researchers have devised other, less commonI 
methods to measure Kr. These methods include flow microcalorimetry and kinetics II 
I techniques. All of the techniques for determining Kr share one thing in common - the , 
I ability to measure a change in some physical parameter between the compound in the free 
I 
I 
state and the compound included in the cyclodextrin cavity. Kr values are extracted from 
! 
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I 

l 
1 
I 
experimental data by relating the observed change to the concentration of cyclodextrin 
necessary to achieve the change. 
Phase Solubility Diagrams 
I 
The earliest technique used to measure Kf for cyclodextrin inclusion complexes is 
the phase solubility technique. Developed by Higuchi and Lachl7 and later refined by 
Higuchi and Connors I 8, this technique involves saturating a solution with a guest 
compound at various concentrations of cyclodextrin. A solution is equilibrated with an 
excess of guest compound for each concentration of cyclodextrin being studied. Aliquots 
of each solution are then filtered and analyzed by UV spectroscopy or some other 
quantitative technique to determine the amount of guest compound present in solution. 
Due to the formation of an inclusion complex, the solubility of the guest compound will 
increase as the concentration of cyclodextrin increases. Phase solubility diagrams are 
constructing by plotting the concentration of the guest molecule in solution against the 
concentration of the cyclodextrin. The two most common forms of the phase solubility 
plot are AL-type and Bs-type. Examples of both of these solubility plots are shown in 
Figure 1-3. Trace A in Figure 1-3 shows an example of AL-type solubility. In this case, 
the stoichioimetry of the inclusion complex does not change over the range of 
cyclodextrin studied. The addition of more cyclodextrin results in a proportional increase I 
I 
I in the amount of guest present in solution. The increase is observed to be linear and Kf 
I can be obtained from the following equation: 
I Kf= slope / ((y-intercept * (I-slope» (1-3)I 
I 10 
i 
1 
The result will be the Kf for a I: I complex with units of M-1• The second type of 
solubility common to cyclodextrin complexation is the Bs-type shown in trace B of 
Figure 1-3. This plot begins in a similar fashion to the type-AL plot but the stoichiometry 
of the complex changes to 1:2 at some concentration of cyclodextrin. Increasing the 
concentration of cyclodextrin beyond this point no longer increases the concentration of 
the guest in solution. Instead, the additional cyclodextrin molecules now associate with 
the 1: 1 complex already in solution. A plateau region of the phase solubility curve 
represents this change in stoichiometry. Higher orders of complex stoichiometry can be 
formed in this region, but these complexes are not always readily observed. As more 
cyclodextrin is added to the solution, the maximum solubility of the 1:2 (or higher order) 
complex will eventually be reached. The solid 1:2 (or higher order) complex will begin 
to precipitate out of solution, taking its encapsulated guest along with it. This results in a 
decrease in the concentration of the guest in solution that is observed in the phase 
solubility diagram. A Kf value for the association of the first cyclodextrin molecule with 
a guest molecule can be calculated from a Bs-type curve in the same way it is from a 
type-AL curve. Only the portion of the curve to the left of the plateau is considered. 
Connors and Rosanske describe a technique for determining Kf for the association of a 
second cyclodextrin with a 1: 1 complex from Bs-type phase solubility diagrams. This 
technique requires the determination of the amount of cydodextrin present in the solid 
state. 20 This rigorous treatment of phase solubility is beyond the scope of this work and 
will not be discussed here. Examples of the use of phase solubility specific to this 
dissertation are described in Chapter 2. 
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Figure 1-3 Typical phase solubility diagrams obtained for AL-type (A) and Bs-type 
(B) dependencies (adapted from reference 19). 
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Spectroscopic Techniques 
Benesi and Hildebrand introduced a double inverse graphical method for 
determining association constants in 1942Y They were studying the complexation of 
iodine with benzene and mesitylene in solutions of carbon tetrachloride and n-heptane. 
An intense absorption band was observed to form between 280 nm and 350 nm when 
iodine was added to pure benzene or pure mesitylene. This band was not observed when 
iodine was added to pure carbon tetrachloride or n-heptane indicating that the absorption 
was a unique property of a complex of iodine with benzene and mesitylene. The authors 
made solutions of iodine in carbon tetrachloride and n-heptane and varied the 
concentration of mesitylene or benzene in these solutions. They were able to relate the 
equilibrium constant for complex formation to the extinction coefficient of the complex 
by the following equation: 
[h] I I log loll = 1 I (K [A] Ec) + I lEe (1-4) 
where log loll is the extinction of a layer of solution I cm deep, K is the equilibrium 
constant, Ec is the molar extinction coefficient of the iodine complex, and [A] is the 
concentration of benzene or mesitylene. This equation has the form y mx + b. The 
molar extinction coefficient of the complex can be obtained from the intercept of a plot of 
[h] I I log loll against 1 I [A] Ec. This allows the equilibrium constant to be determined 
from the slope of the line or directly from (4). The system studied by Benesi and 
Hildebrand monitored the formation of an absorbance band where none was present 
before. Free iodine in solution does not significantly contribute to the absorbance 
observed between 280 nm and 350 nm in the presence of benzene or mesitylene. 
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Ketelaar et al. later extended this method to account for the minimal absorbance of free 
iodine in this region.22 The Ketelaar equation is 
where (;1 is the molar extinction coefficient of iodine measured in the presence of [A] and 
(;f is the molar extinction coefficient of free iodine in the absence of A. Ketelaar's results 
were the same as those obtained by Benesis and Hildebrand at low concentrations of 
iodine. However, more accurate results were achieved at higher concentrations of iodine 
when equation (5) was used. 
Molecules included in the cyclodextrin cavity have different molar extinction 
coefficients than the same molecules free in solution. This is most apparent when it is the 
chromophore of the guest that is included in the cyclodextrin cavity. Typically, a 
bathochromic shift in the wavelength of maximum absorbance is also observed. It has 
been demonstrated that this is due to the less polar environment of the interior of the 
cyclodextrin cavity. 23 Ketelaar's equation is used to determine Kf for cyclodextrin 
complexes since the region in which absorbance is being measured for the complex is 
only slightly different from the region in which absorbance of the free guest compound 
occurs. Matsui and Mochida used this method to determine the inhibitory effect of 
various alcohols on the association of azo dyes with a- and \3-cyclodextin?4 Kralova and 
Mitterhauszerova determined Kf values for corticosterone with \3-cyclodextrin in water 
using the Ketelaar equation?5 Connors and Rosanske measured the spectral shift 
observed upon the addition of a-cyclodextrin to a solution containing cinnamic acid and 
determined formation constants for 1: 1 and 1:2 complexes using a successive 
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approximation method instead of the double inverse graphical method of Ketelaar.2o 
Other authors have used techniques similar to those described above to analyze changes 
in the fluorescence26-29 and circular dichroism27 of a guest molecule upon inclusion. 
These techniques have also been used to qualitatively characterize many different 
ninclusion complexes without calculating Kr values.30- IR spectroscopy has also been 
used to characterize cyclodextrin complexes33-34 but no references could be found in 
which changes in IR spectra were used to calculate Kr. 
Nuclear magnetic resonance (NMR) spectroscopy was first used to study 
cyclodextrin complexes by DeMarco and Thakkar in 1970.35 They observed changes in 
the chemical shift of the protons attached to the C(3) and C(5) positions of cyclodextrin 
when various guest molecules were introduced. These protons are located inside the 
cavity of cyclodextrin. This data was the first direct spectroscopic evidence for the 
formation of inclusion complexes where the guest molecule actually resides inside the 
cyclodextrin cavity. While NMR has been widely used to characterize inclusion 
complexes, the calculation of Kr values from this data is not common. Bergeron et al. 
used the following modification of the Hildebrand-Benesi equation to extract Kr values 
from their NMR data: 
[CD] + do [G] =[CD] + [G] + Kd (1-6) 
do Q2 Q 
where [CD] and [G] are the concentration of cyclodextrin and guest compound, 
respectively; dO is the change in the chemical shift measured at a particular [CD] relative 
to 0 in the absence of cyclodextrin; and Q oe -00, the difference between the chemical 
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shift for a particular proton of the guest compound in the cyclodextrin complex and the 
chemical shift for a particular proton of the guest compound in its free state. The value of 
Q was determined using the method of successive approximation. The authors used 
equation (6) to determine the strengths of a-cyclodextrin complexes of 3,5-dimethyl-4­
hydroxybenzoic acid; 3,5-dimethyl-4-hydroxycinnamic acid; and 3,5-dimethyl-4­
hydroxyhydrocinnamic acid at various pH values.36 Djedaini and Perly used a computer­
assisted iterative process to obtain Kfvalues from Job's plots of ~o [CD] against XeD, the 
mole fraction of cyclodextrin in solution.37 The minimal use of NMR to calculate Kf 
illustrates the difficulties involved in the process. The spectrum of ~-cyclodextrin is 
fairly complex, containing numerous signals between chemical shifts of 3 ppm and 5 
ppm. Add to this spectrum the potentially complex signals of a guest compound and 
interpretation becomes very difficult. Very expensive high-resolution NMR systems 
need to be used to obtain precise, measurable changes in chemical shifts. The qualitative 
data that NMR provides is a far more valuable asset for gaining insights into the host­
guest complex than the qualitative data NMR provides. This has been demonstrated by 
Mularz, et al. 38 ; Wood, et a1. 39 ; and others40. An extensive review of the use ofNMR to 
study inclusion complexes ofcyclodextrins has been published by Inoue.41 
Chromatographic Techniques 
Cyclodextrins were first used in a chromatographic separation by Hinze and 
Armstrong in 1980.42 Using TLC, they found that the Rfvalues obtained for a series of 
substituted benzoic acids decreased as the concentration of a-cyclodextrin in the mobile 
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phase increased. This was due to the fonnation of inclusion complexes, which allowed 
the authors to separate ortho-, meta-, and para-substituted benzoic acids. The past twenty 
years have seen a proliferation in the use of cyclodextrins in chromatography, both as 
mobile phase modifiers and as stationary phases. The inherent chirality of the 
cyclodextrin structure means that one enantiomer of a guest compound can be 
preferentially included over the other depending on the orientation of the substituents 
around the chiral center. Cyclodextrin containing stationary phases for TLC, GC, HPLC, 
and, most recently, CEC are commercially available. Separation of a wide array of 
compounds is possible on cyclodextrin stationary phases. Reviews of many 
chromatographic separations obtained using cyclodextrins have been published. 1o,43,44 
But the usefulness of chromatography, specifically HPLC, does not end with the 
separation of enantiomers and other compounds. HPLC is a powerful tool for 
investigating molecular interactions45 such as complexation of a guest compound with 
cyclodextrin. 
Fujimura et al. detennined Kf values of ~-cyclodextrin complexes for 27 
substituted phenols and anilines using HPLC.46 The authors derived an equation to relate 
the retention factor for the guest compound at varying concentrations of cyclodextrin to 
Kf . An equilibrium constant for the distribution of the guest compound between the 
stationary phase and mobile phase in the absence of cyclodextrin can be written: 
Ko = [(G)s] I [(G)m] (1-7) 
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where (G)5 and (G)rn denote the guest compound in the stationary phase and mobile 
phase, respectively. This value relates to leo, the retention factor obtained in the absence 
of cyc10dextrin in the following way: 
where q, is the phase ratio of the HPLC column. When cyclodextrin is added to the 
mobile phase, the distribution of guest compound in the mobile phase will increase due to 
inclusion with cyclodextrin. This leads to a decrease in the observed retention factor. 
The following expression can be derived for the new retention factor: 
k = J.. [(G)5] (1 9) 
'I' [(G)m] +[(G -CD)m] ­
This equation is only valid when the cyclodextrin inclusion complex does not associate 
with the stationary phase. Substituting (2) and (7) into (9) and rearranging gives the 
following expression for k in terms of Kr: 
k =q, Kol Kf (1-10)
1I Kf + ([(CD)T] - [(G - CD)mD 
In this equation, (CDh refers to the total amount of cyclodextrin, which includes both the 
free cyc10dextrin and the cyclodextrin involved in complexation. The value of [(CD)r] is 
much greater than [(G-CD)rn] because the concentration of the guest compound is 
minimal compared to the concentration of cyclodextrin in the mobile phase. By 
eliminating [(G-CD)rn] from (l0) and taking the inverse of both sides, an equation in the 
form ofy = mx + b is obtained: 
1 =[(CD)T] Kf + 1 (1-11)
k ko ko 
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F or a 1: 1 complex, a plot of 11k against the concentration of cyclodextrin in the mobile 
phase will yield a straight line with a slope equal to Kt/ko and an intercept equal to IIko, 
assuming that the complex is not retained by the stationary phase. Armstrong et al. 
expanded this model to mathematically describe complexes with 1:2 stoichiometry.47 
The technique of extracting Kf values for cYclodextrin complexes from changes in 
HPLC retention is often credited to Fujimura et al. and Armstrong et al. in the literature. 
However, it is worthwhile to note that other researchers published papers using this 
model prior to 1986. Uekama et al. calculated Kf values from chromatographic in 
1977.48 Cline Love and Arunyanart presented an analysis of the inclusion complexes of 
several aromatic compounds with ~-cyclodextrin at the 188th Meeting of the American 
Chemical Society in August of 1984.49 They extracted Kfvalues from plots of 11k versus 
[CD] using an equation originally derived from micellar chromatography. 
Another method for determining Kf values from chromatographic data was 
developed by Hummel and Dreyer in 1962.50 Although this method is older than the one 
described by Fujimura, it is less frequently used to study cyclodextrin inclusion 
complexes. This is because only one guest compound can be studied at a time. 
Fujimura's method can screen a mixture of guest compounds at the same time. The 
Hummel-Dreyer method involves equilibrating an HPLC column with a mobile phase 
containing the guest compound. A solution containing the cyclodextrin of interest is 
injected. A positive peak will be observed in the chromatogram followed by a negative 
peak, assuming that the complex elutes through the column faster than the free guest 
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compound. The positive peak is the guest compound complexed with cyclodextrin. The 
negative peak is the deficiency of the guest compound in the system due to complexation. 
When the cyclodextrin is introduced to the mobile phase, it associates with the guest 
compound present in solution. The complex moves rapidly through the column, leaving 
a region of mobile phase in which the concentration of guest is low. This disrupts the 
equilibrium of the guest compound between the mobile phase and stationary phase 
causing some of the guest compound on the stationary phase to move into the mobile 
phase. This results in the formation of a "hole" on the stationary phase which is "filled" 
by guest molecules in the mobile phase. This process continues down the length of the 
column until a negative peak is observed at the retention time the guest compound elutes 
if injected into the HPLC system. The apparent association constant can be calculated 
from the amount of guest consumed in the complex is calculated by the following 
equation: 
QG-CDKr = ----'---- (1-12)[(G)m] (QCD - QG-CD) 
QCD is the amount of cyclodextrin injected, QG-CD is the amount of the inclusion complex 
that is formed, and (G)m is the concentration of the guest compound in the mobile phase. 
QeD can be calculated since the concentration of the cyclodextrin solution and the 
injection volume are both known. [(G)ml is also known. It is the amount of complex that 
forms, QG-CD, which needs to be determined. 
There are two different approaches to calculating the amount of complex formed. 
The area of the positive peak resulting from the complex may be used to calculate QG-CD 
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or the area of the negative peak may be used. Typically, the negative peak is used 
because the response of the guest compound changes when the compound is complexed 
with cyclodextrin. This affects the response of the positive peak. In order to use the 
positive peak it is necessary to know the extent of this change in response. 51 Internal and 
external calibration methods have been developed to relate the area of the negative peak 
to QG_CD. 52,53 The details of these procedures will be explored in Chapter 4. 
Other Techniques for Determining Kj 
The techniques described above are the most widely used methods for 
determining Kr values of cyclodextrin complexes. However, other methods have been 
developed. As stated previously, the only requirement for measuring Kr is that a change 
in some physical parameter between the compound in the free state and the compound 
included in the cyclodextrin cavity can be observed. 
Potentiometric techniques have been used by two different research groups. 
Connors and Rosanske measured the change in the pKa of cinnamic acid as the 
concentration of a-cyclodextrin was varied?O Their approach to extracting Kr from this 
data was similar to the approach used for spectroscopic methods. Interpretation of their 
data was complicated by the presence of both a 1: 1 and 1:2 complex of cinnamic acid 
with a-cyclodextrin. However, the results generated in this way compared favorably to 
results obtained using spectroscopic and solubility techniques. Valsami et al. studied the 
complexation of six tricyclic antidepressant drugs with a- and IJ-cyclodextrin using ion­
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selective electrodes. 54 Solutions containing the drugs were titrated with cyclodextrin 
solutions. They were able to calculate Kr using nonlinear fitting of Scatchard plots for 
the data. 55 When applied to cyclodextrin inclusion, the Scatchard model describes a I: I 
complex as: 
r/[(G)FJ = Kr - rKr (1-13) 
where r = [(G-CD)] / [(CDh] and [(G)FJ is the concentration of the guest compound not 
associated with cyclodextrin. Kr can be extracted form a plot of r/[(G)F] versus r. 
Tan and Lindenbaum used flow micro calorimetry to investigate the inclusion 
complexes of thirteen bile salts with p-cyclodextrin.56 For I: I complexes, the value of Kr 
could be determined directly from a complex formula relating AH to Kr. A successive 
approximation method was used to analyze the data for complexes with 1:2 
stoichiometry . 
In 1967, Van Etten et al. published a study of the catalytic properties of a- and p­
cyclodextrin on the hydrolysis of a series of substituted phenyl acetates. 57 Kr values were 
obtained using a graphical evaluation originally described by Eadie58: 
(1-14) 
where kobs is the pseudo first-order rate constant of a reaction measured in the presence of 
a given concentration of cydodextrin, [(CDh]; kl is the pseudo first-order rate constant 
of a reaction measured in the absence of cyclodextrin; and k2 is the pseudo first-order rate 
constant of the reaction involving the guest : cyclodextrin inclusion complex. This 
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method has been used by Yoshida et al. to investigate the inclusion complexes of 
digitoxin with ~-cyclodextrin and several ~-cyclodextrin derivatives.59 This system was 
difficult to characterize because digitoxin can form several products upon hydrolysis. 
The Kr value obtained using the kinetics method was comparable to the Kr value achieved 
using phase solubility techniques. This technique will be discussed in greater detail in 
Chapter 5. 
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Chapter 2. 
Historical- Cyclodextrin : Steroid Inclusion Complexes 
Steroids 
Steroids display a wide variety of biological functions in all eucaryotic organisms. 
The most common steroid is cholesterol, which influences the fluidity of cell membranes 
and serves as a precursor for steroid hormones and bile acids. Steroid hormones are 
responsible for such processes as the maintenance ofpregnancy, the development of male 
and female secondary characteristics, and the promotion of gluconeogenesis. Bile acids, 
such as glycocholate and taurocholate, solubilize dietary lipids.6o 
Steroid hormones are categorized into five major classes, depending on their 
function: progestagens, androgens, estrogens, mineralocorticoids, and glucocorticoids. 
Progestagens are essential for the maintenance of pregnancy. Progesterone, the most 
common progestagen, prepares the lining of the uterus for implantation of an ovum. 
Testosterone is an example of an androgen. Androgens are responsible for the 
development of secondary male characteristics, while estrogens are required for the 
development of secondary female characteristics. Mineralocorticoids, primarily 
aldosterone, increase the reabsorption ofNa+ and the excretion ofK+ and W by acting on 
the distal tubules of the kidney. The formation of glycogen and the degradation of fat 
and protein are promoted by glucocorticoids. Glucocorticoids allow animals to respond 
to situations of stress of inflammation. It is this last class of steroid hormones, 
glucocorticoids, which will be focused upon in this dissertation. 
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Most steroids share the perhydro-cyclopentano-phenanthrene ring system shown 
in Figure 2-1 A. Some steroids do not possess either or both of the methyl groups located 
outside of the four ring systems. The structure for betamethasone is shown in Figure 2­
IB. Betamethasone is a glucocorticoid that is used in pharmaceutical products for its 
anti-inflammatory, anti-pruritic, and vasoconstrictive actions. The nomenclature for the 
ring systems of steroids and the numbering of each carbon in the steroid backbone is 
shown, using betamethasone as an example. The betamethasone-related steroids 
investigated in this dissertation contain different functional groups at the carbon atoms 
highlighted in bold font in Figure 2-1B. Four main rings make up a steroid. They are 
referred to as the A-ring, B-ring, C-ring, and D-ring. A substituent that is above the plane 
defined by the ring structure is called a-oriented, whereas a substituent that is below the 
plane is called ~-oriented. A dashed bond represents a-orientation and a solid bond 
represents ~-orientation. If the group located at a ring junction, such as the 5-, 9-, or 14­
position, is in the a-orientation then those rings are said to be in a trans conformation. A 
cis conformation occurs when a group that is located at a ring junction is ~-oriented. 
This terminology will be used throughout this dissertation. 
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Figure 2-1 Structures of the perhydro-cyclopentano-phenanthrene ring system (A) 
and betamethasone (B). 
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Steroid : Cyclodextrin Complexes 
Interactions of steroids with cyclodextrins have been studied for almost forty 
years. Lach and Pauli investigated the solubilizing effect of ~-cyclodextrin (~-CD) on 
testosterone (Figure 2-2A) and cortisone 21-acetate (Figure 2_2B).61 Phase solubility 
diagrams generated using water as a solvent show Bs-type plots for both steroids. The 
plateau region was observed at a concentration of about 2mM ~-CD for cortisone 21­
acetate and 0.5 mM ~-CD for testosterone. Above these concentrations, 1:2 complexes 
are formed. Kf values were calculated using the data presented by Lach and Pauli, using 
the slopes from the solubility plots in the region before the plateau. The Kf values were 
reported to be 7140 M-1and 1765 M-1for testosterone and cortisone acetate, respectively. 
The authors suggested that the difference in the strength of the inclusion complexes of 
these two steroids may be due to the bulk that is present in the 17-position of cortisone 
acetate. Testosterone has a 17-0H group, whereas cortisone acetate has an additional 
-COCOOCH3 in the 17-position. However, since only two steroids were analyzed, no 
definitive conclusions could be drawn from this data. 
It was not until the 1980s when many other research groups began to investigate 
steroid : cyclodextrin complexes in greater detail that more rigorous studies were 
performed. The renewed interest in this subject was due to the beneficial properties that 
were observed for pharmaceutical formulations containing cyclodextrins. Cyclodextrins 
were found to increase dissolution rates in solid dosage forms and to improve membrane 
transport for a variety of steroids. 
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Figure 2-2 Structures of testosterone (A) and cortisone 21-acetate (B). 
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Steroid: Cyclodextrin Complexes in Pharmaceutical Formulations 
Seo et al. prepared inclusion complexes of spironolactone with a-cyclodextrin (a­
CD), P-CD, and y-cyclodextrin (y_CD).33 Spironolactone is a steroidal aldosterone 
antagonist used in the treatment of essential hypertension, edematous states, and primary 
hyperaldosteronism. The complexes were precipitated out of solution by the adding an 
excess of cyclodextrin to solutions containing spironolactone. This method for preparing 
a solid cyclodextrin complex results in the formation of higher order (typically 1 :2) 
complexes that are observed in the Bs-type phase solubility diagrams. The authors found 
that the dissolution rate of the compressed spironolactone : cyclodextrin complexes were 
much greater than the dissolution rate of the compressed spironolactone alone. 
Additionally, the permeation of spironolactone through a cellophane membrane was 
found to be much faster for the P-CD and y-CD complexes of spironolactone than for 
spironolactone alone. A greater net amount of spironolactone passed through the 
membrane when the steroid was present as a complex with P-CD or y-CD. The serum 
concentrations of a metabolite of spironolactone was found to be as much as two and a 
half times greater when the steroid was introduced to dogs in the form of a cyclodextrin 
complex. 
Other research groups observed an increase in the rate of dissolution for steroids 
when the cyclodextrin complexes were used. Lin et at. observed an order of magnitude 
increase in the rate of dissolution of hydrocortisone acetate (Figure 2-3B) when the 
steroid was ground with p-CD.34 
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Figure 2-3 Structures of spironolactone (A), hydrocortisone acetate (B), and 
hydrocortisone butyrate (C). 
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A Kf value of approximately 2690 M- I was reported for the hydrocortisone acetate : ~-CD 
complex in water at 37°C. Chun and Tun reported a similar increase in the rate of 
dissolution for hydrocortisone butyrate (Figure 2-3C) complexes with ~-CD, y-CD, and 
dimethyl-~-cyc1odextrin (DM-~_CD).62 The authors showed that the enhanced rates of 
dissolution were not observed for mixtures of the steroid and cyc1odextrin. A small 
improvement in the total amount of hydrocortisone butyrate released into solution was 
seen when cyc10dextrins were present in solution, but only when the steroid was present 
as an encapsulated complex with the cyclodextrin did the rate of dissolution become very 
rapid. The reported Kf values obtained in water from phase solubility curves for 
hydrocortisone butyrate complexes with ~-CD and y-CD were 2688 M- I and 3297 M- I , 
respectively. Ahmed showed that marked improvements in the dissolution rate and the 
solubility of 19-norprogesterone occur when the steroid was complexed with ~-CD, 
hydroxyethyl-~-cyclodextrin (HE-~-CD), or hydroxypropyl-~-CD.63 
The improvements in drug delivery observed for cyclodextrin complexes of 
steroids are not limited to solid oral dosage forms such as compressed tablets. The 
release of betamethasone 17,21-dipropionate (Figure 2-4B) was found to be faster from 
an ointment base when the steroid was present in the ointment as a 1:2 complex with y­
CD.64 The vasoconstrictor activity of betamethasone 17,21-dipropionate in man was 
found to increase by complexation with y-CD. Usayapant and Iyer showed that the 
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Figure 2-4 Structures of 19-norprogesterone (A), betamethasone Il,21-dipropionate 
(B), and betamethasone I7-valerate (C). 
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rate of release of five steroids from polyethylene glycol (PEG) was significantly 
65increased when HP-~-CD was present. PEG is a common excipient used in suppository 
formulations. However, the rate of release of the same steroids from cocoa butter base 
was not affected by the presence of HP-~-CD. The rate of diffusion across a synthetic 
membrane was enhanced for all of the steroids when HP-~-CD was present. 
Another benefit of cyclodextrin complexation is a change in the stability of a 
steroid. T orricelli et al. found an increase in the stability of kneaded mixtures of a 
steroidal drug with ~_CD.66 No improvement in stability was observed for coground 
mixtures of the steroid and ~_CD.67 This would indicate that it is the inclusion of the 
steroid into the cyclodextrin cavity that stabilizes the steroid, not simply the presence of 
the cyc1odextrin. Andersen and Bundgaard studied the degradation of betamethasone 17­
valerate (Figure 2-4C) in basic aqueous solution in the presence and absence of 
cyclodextrin.68 Their work illustrates the complicated nature of steroid : cyclodextrin 
inclusion complexes. They found that the rate of degradation was increased when ~-CD 
was present in solution, but decreased when y-CD was present in solution. The 
difference in the size of the cyclodextrin cavity determines whether the reaction is 
catalyzed or suppressed. 
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Steroid: Cyclodextrin Complexes in Chromatography 
F our years after Hinze and Annstrong published the first paper in which 
cyclodextrins were used as mobile phase additives to achieve a chromatographic 
separation42, Annstrong, et al. were using cyclodextrin bonded phases in HPLC to 
analyze a variety of compounds, including steroids. II They were able to separate estriol 
(Figure 2-5A), two epimers, and a diasteriomer using a methanol: water mobile phase. 
In addition, 5-a-androstane-3~, 17~-diol (Figure 2-5B) was separated from an epimer 
and four geometric isomers were separated from each other. D-(+)-norgestrel (Figure 2­
5C) and L-(-)-norgestrel (Figure 2-5D) were separated by Gazdag et al. using a mobile 
phase modified with y_CD.69 A conventional ODS stationary phase was used. They also 
showed that a-CD was an ineffective complexation agent for steroids like norgestre1.70 
Unfortunately, Kf values were not calculated for the compounds this group investigated. 
As a result, they mistakenly concluded that complex formation was more efficient on a 
cyanopropylsilica stationary phase than on an ODS stationary phase, based on the relative 
change in retention factors observed on both columns. No difference in Kf should be 
obtained since neither column should retain the steroid: cyclodextrin complex. 
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Figure 2-5 	 Structures of estriol (A), 5a-androstane-3p, 17P-diol (B), D-(+)-norgestrel 
(C), and L-(-)-norgestrel (D). 
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Shimada's research group at the Kanazawa University in Japan used cyclodextrins 
extensively as mobile phase modifiers. The separation of isomeric cardenolides was 
achieved using y_CD. 71 Six estrogen glucoronides were resolved with ~-CD added to a 
mobile phase of acetonitrile: acetate buffer.72 ~-CD was shown to enhance the response 
of fluorophore-Iabeled bile acids while improving the separation observed.73 Shimada 
and Nonaka demonstrated the utility of ~-CD and y-CD for the analysis of C21 steroids.74 
Lamparczyk et at. applied Shimada's work for the analysis of estrogenic steroids in 
human urine by HPLC.75 
Other Applications a/Steroid: Cyclodextrin Complexes 
The unique characteristics of steroid : cyclodextrin complexes are being realized 
in other arenas of chemistry. Two examples are the use of cyclodextrin based molecular 
imprinted polymers (MIP) for the analysis of steroids and the use of novel cyclodextrin 
derivatives as shielding groups in steroid hydroxylation reactions. 
Sreenivasan synthesized a MIP using cholesterol as a template molecule.76 2­
hydroxy ethyl methacrylate (HEMA) was covalently bound to ~-CD. The modifier ~-CD 
monomer was copolymerized with HEMA and ethylene glycol dimethacrylate. One 
hundred milligrams of the resulting polymer absorbed 4.68 ± 0.05 mg of cholesterol 
(Figure 2-6A), but only absorbed 1.37 ± 0.04 mg of testosterone (Figure 2-6B). The 
same amount of a control polymer prepared in the absence of a template molecule 
absorbed 1.76 ± 0.06 mg of cholesterol and 1.43 ± 0.03 mg of testosterone. This data 
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shows that a P-CD based MIP will preferentially bind the imprinted template steroid. 
The presence of P-CD in the MIP results in some non-selective interactions with other 
steroids. A HEMA-based MIP was imprinted for cholesterol in the absence of p-CD. 
Only 0.4 mg ofcholesterol and 0.015 mg of testosterone were absorbed by 100 mg of this 
polymer. The selectivity is greater in the absence of p-CD, but the capacity is far greater 
for the P-CD based MIP. 
Hishiya et aZ. prepared a MIP using native P-CD copolymerized with toluene 2, 4­
diisocyanate.77 The resulting MIPs were found to selectively recognize the template 
steroid when an alkyl group was present in the 17-position, as with cholesterol and 
stigmasterol (Figure 2-6C). Selectivity was determined by comparing the binding 
activity ofan imprinted polymer to a non-imprinted polymer. The selectivity of the MIPs 
for nonsteroidal compounds was found to be low for small compounds such as phenol 
and 2-phenylphenoL Larger compounds, like 4-hydroxyazobenzene and 1­
phenylazonapthalene, were found to bind to the imprinted polymer more than they bound 
to the non-imprinted polymer. It was again shown that a P-CD MIP imprinted for 
cholesterol gave poor selectivity for testosterone. 
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Figure 2-6 Structures of cholesterol (A), testosterone (B), and stigmasterol (B). 
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The hydroxylation of androstane-3~, 17~-diol (Figure 2-7 A) was studied by 
Breslow et al. 78 The reaction was catalyzed using a Mn(III) complex of a 
tetrafluorophenylporphorin derivative with four ~-CD molecules anchored on opposite 
sides of the molecule. The use of this catalyst results in the stereoselective hydroxylation 
of the 6-position of androstane-3~, 17~-diol, yielding androstane-3~, 6a, 17~-triol 
(Figure 2-7B). A 95% yield was reported. The proposed mechanism for the reaction 
involves the complexation of the steroid with two cyclodextrins located across the 
catalyst. The Mn(III) complex can then facilitate the hydroxylation. Because of the 
geometry of the complex, the correct orientation of the steroid is maintained while 
hydroxylation occurs at the 6-position. 
Understanding the Nature of Steroid: Cyclodextrin Complexes 
All of the applications that have been described capitalize on the properties of 
steroid : cyclodextrin complexes. Improved dissolution of pharmaceutical dosage forms, 
enhanced solution solubility, and modified chromatographic selectivity are all achieved 
due to the inclusion of a steroid molecule into the cyclodextrin cavity. It is apparent that 
understanding the nature of the steroid: cyclodextrin complex will result in more focused 
applications and a more educated use of cyclodextrins as an analytical tool. Some work 
has been done to determine which structural features of a steroid promote stronger 
complexes with various cyclodextrins. 
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Figure 2-7 Structures of 5a-androstane-3p, 17P-diol (A) and 5a-androstane-3p, 60" 
17p-triol (B). 
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The first comprehensive study of steroid : cyclodextrin complexes was reported 
by Uekama et ai. 19 Phase solubility diagrams were used to calculate Kf values for 
eighteen steroids with a-CD, P-CD, and y-CD. In general, Kf values were found to be 
greater for y-CD than p-CD, with a-CD yielding the lowest values. However, there were 
exceptions to this trend. For example, hydrocorisone acetate (Figure 2-8C) and 
prednisilone acetate (Figure 2-8D) both formed stronger complexes with p-CD. While 
these discrepancies are not addressed in the paper, the overall trend described by Uekama 
et ai. is that binding strength increases as the hydrophobicity of the guest compound 
increases. However, the author noted there was no linear correlation between the 
partition coefficients and Kf. The location of hydrophilic and hydrophobic regions of a 
guest molecule plays an important role in determining the strength of the resulting 
cyclodextrin inclusion complex. Analysis of the data provided shows that while more 
hydrophobic steroids are likely to yield more stable cyclodextrin complexes, it is 
impossible to predict the Kf value based on this factor alone. Betamethasone 17-valerate 
(Figure 2-4C) was found to have a Kf of 9850 M· l in water with y-CD, while the Kr for 
betamethasone (Figure 2-1B) was reported to be 21600 M· l . In this case, the 17-hydroxy 
group of betamethasone is replaced by a butyl ester, resulting in a more hydrophobic 
compound. Another example of the complexity of the inclusion process is illustrated by 
comparing the results reported for dexamethasone (Figure 2-8E) and paramethasone 
(Figure 2-8F). The only difference between these two compounds is the location of the 
fluorine atom on the steroid backbone, yet their Kf values show a notable variance. 
Dexamethasone, with a 9-a-fluorine, had a Kr of 26600 M· I in water with y-CD. Moving 
the fluorine to the 6-position results in a decrease in Kf of 18290 M· l . 
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Figure 2-8 Structures of cortisone (A), hydrocortisone (B), hydrocortisone acetate 
(C), prednisilone acetate (D), dexamethasone (E), and paramethasone (F). 
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NMR studies performed by Uekama, et al. I9 suggest that the A-ring of 
hydrocortisone (Figure 2-8B) is included into the cyclodextrin cavity. The magnitude of 
the cyclodextrin-induced chemical shift changes of hydrocortisone was measured for the 
C4-H and the CIs- and CI9-methyl protons. The upfield shift was found to be greater for 
the C4-H and the CI9-methyl protons than the CIs-methyl protons. The protons that are 
shifted further up field upon complexation are located on the A-ring of hydrocortisone and 
at the AlB-ring juntion. The CIs-methyl group is located at the CID-ring junction. 
Liu et al. proposed that inclusion occurs at the D-ring of hydrocortisone.79 This 
conclusion was based on Kf values for the formation of a 1: 1 complex and for the 
addition of a second P-CD to the I: I complex (Kf2). Cortisone (Figure 2-8A) was found 
to have Kf2 > Kf, whereas Kf > Kf2 for hydrocortisone. The II-hydroxyl group of 
hydrocortisone is reported to form an intramolecular hydrogen bond with the 17-keto 
group. If complexation occurs at the D-ring then this hydrogen bond will be disrupted, 
leading to a more polar surface with which a second cyclodextrin molecule could 
associate; therefore, the Kf2 would be lower than Kf. The authors propose that Kf2 is 
higher for cortisone due to the absence of the II-hydroxy group, which results in a less 
polar surface after complexation with one cyclodextrin molecule. Thus complexation 
with a second P-CD would be more favorable than with the first. 
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Sadleg-Sosnowska investigated a series of fourteen steroid hormones and found 
that the A-ring plays an important role in the strength of the inclusion complex, but the 
D-ring does affect the value of Kr.51 Two sets of steroids studied differed only in the A­
ring. Estradiol (Figure 2-9B) and ethinyloestradiol (Figure 2-9D) posess a phenolic A­
ring, while nandrolone (Figure 2-9E) and norethisterone (Figure 2-9F) have a double 
bond conjugated with a keto group. The Kr values obtained with P-CD for the former 
compounds (containing phenolic A-rings) were found to be five and eight times larger 
than for the latter compounds (without phenolic A-rings). With y-CD, the increase in Kr 
for the estradiol and ethinyloestradiol were only two and three times greater. This seems 
to indicate that it is the A-ring that sits in the cyclodextrin cavity. This conclusion is 
strengthened by the findings that the addition of a 6-methyl group weakened the 
complexes of two steroids with p-CD. However, significant differences in Kr were 
observed for estradiol and ethinyloestradiol and also for estriol (Figure 2-9C) and estrone 
(Figure 2-9A). These two pairs of steroid differ only by the structure of the D-ring 
substituents. The difference in Kr values was found to be more pronounced with y-CD 
than with p-CD. 
Lam and Malikin investigated the effect of the conformation of the AlB-ring 
junction and the orientation of hydroxy groups in the 3- and 17-positions.80 The 
complexes of eight diasteriomers of androstanediol with P-CD were used. Their results 
show that the steroids with a trans conformation of the AlB-ring junction form more 
stable complexes with P-CD than those with a cis conformation. It is proposed that this 
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Figure 2-9 Structures of estrone (A), etradiol (B), estriol (C), ethinyloestradiol (D), 
nandrolone (E), and norethisterone (F). 
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is due to the planar arrangement of the trans conformation. Similar results for the 
dependence of the conformation of the AlB-ring was reported by Shimada et al.8l Here is 
another piece of data pointing to the inclusion of the A-ring into the cyclodextrin cavity. 
But perhaps a more interesting finding that was not expanded on by the authors was the 
very high Kf value for one of the diasteriomers studied. The Kf for 5-a.-androstane-3p, 
17p-diol (Figure 2-5B) was 3808 M-l . The seven other diasteriomers had Kf values 
ranging from 107 M- l to 324 M- l . Comparing 5-a.-androstane-3p, 17P-diol and 5-a.­
androstane-3p, 17a.-diol shows that the change in orientation of the 17-hydroxy group 
from p to a. results in a decrease in Kf from 3808 M- l to 215 M- I . 
Spencer and Purdy determined Kf values for estrone (Figure 2-10A), equilin 
(Figure 2-1OB), 16a.-hydroxy-estrone (Figure 2-10C), 2-hydroxyestrone (Figure 2-10D), 
and 4-hydroxyestone (Figure 2_1OE).82 They found that the addition of a second alcohol 
group in the A-ring lowered the Kf when in the 2-position but increased Kfwhen in the 4­
position. The Kf was found to decrease when an alcohol was added in the 16-position. 
The authors suggest that the difference in inclusion complex strength between 2­
hydroxyestrone and 4-hydroxyestone is due to the inclusion of the AlB-rings, while the 
difference in between estrone and 16a.-hydroxyestrone is due to the inclusion of the C/D­
rings. This could only be the case if two 1: 1 complexes are formed since 1:2 complexes 
were not observed. 
46 

Figure 2-10 Structures of estrone (A), equilin (B), 16a-estrone (C), 2-hydroxyestrone 
(D), and 4-hydroxyestrone (E). 
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Conclusions 
The utility of steroid : cyclodextrin complexes have been demonstrated by 
numerous research groups. Successful applications of steroid : cyclodextrin inclusion 
chemistry include enhanced pharmaceutical product dissolution and stability, improved 
chromatographic selectivity, and increased solution solubility. However, the factors 
which govern the strength of the steroid : cyclodextrin complex are still ambiguous. 
Attempts to relate the relative hydrophobicity of a steroid to the strength of the inclusion 
complex have failed to demonstrate good correlation. 19 Mathematical models developed 
to relate characteristics of steroids to the Kr values observed for cyclodextrin complexes 
have proven unsuccessful. 83-86 Little insight has been gained even when factors such as 
melting points, water solubilities, octanol/water partition coefficients, and steric 
parameters are included in the calculations. 87 One of the main goals of the research 
presented in this dissertation was to determine the relationship between steroid structure 
and complex strength for a group of betamethasone-related steroids. The two widely 
used HPLC techniques for determining Kr values were evaluated as a part of this 
research. The potential for the formation of two different inclusion complexes between 
steroids and cyclodextrins is intriguing. However, HPLC is limited to measuring any 
interactions between a given steroids and cyclodextrin. The technique cannot distinguish 
between inclusion at the AlB-ring or the CID-ring of the steroid. For this reason, a 
kinetics technique was used to determine if two complexes could be observed. UV 
spectroscopy was also used to study steroid: cyclodextrin complexes. 
48 

Chapter 3. 
Using Fujimura's Method to Determine Kr 
Summary 
Kf values were determined for thirteen betamethasone-related steroids using the 
method described by Fujimura et al. 46 The steroid set studied was designed to gain 
insight into the mechanism of inclusion complex formation with cyclodextrins. ~-CD; 
HE-~-CD, HP-~-CD, sulfated-~-CD, y-CD, and HP-y-CD were investigated. It was 
found that the betamethasone-related steroids formed the most stable complexes with y­
CD. The cavity size of ~-CD is too restrictive for a good fit of the steroid ring structure. 
The effects of the nature of the halide at the 9-position, the location of a double bond 
within the C-ring, substitution at the 9- and II-positions, and modification of the D-ring 
of the steroid backbone were studied. The 11- and I7-positions were found to be 
critically involved in the inclusion process. The stability of all of steroid : y-CD 
complexes increased when the acetonitrile content of the mobile phase was decreased. A 
Van't Hoff analysis was performed to probe the thermodynamics of the inclusion 
process. Column temperature was varied between 10°C and 80°C. A linear relationship 
between the natural logarithm of Kf and the inverse of absolute temperature was 
observed. This indicates that no change in the mechanism of inclusion is occurring in the 
temperature range studied. The phenomenon of enthalpy-entropy compensation was 
demonstrated by eleven of the thirteen steroids studied. Non-linear Van't Hoffplots were 
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obtained for natural logarithm of k versus the inverse of absolute temperature. This is 
due to the competition between the process of retention and the process of inclusion. 
Introduction 
When cyclodextrin is added to a mobile phase retention factors decrease. This is 
due to the formation of inclusion complexes between the cyclodextrin and the analytes 
being chromatographed. This complexation increases the solubility of the analyte in the 
mobile phase and thus decreases its residency time in the HPLC column. Fujimura, et 
al. described a method for determining Kr by monitoring this change in retention factor as 
the concentration of cyclodextrin in the mobile phase is varied.46 The following 
expression is true when the inclusion complex has no retention in the HPLC system: 
~ = KI[(CD)T] + _1 (3-1) 
k ko ko 
where k is the retention factor at a particular concentration of cyclodextrin, (CDh and leo 
is the retention factor in the absence of cyclodextrin. For a compound with a 1: I 
stoichiometry with cyclodextrin, a plot of 11k vs. [(CDh] yields a straight line which has 
a slope equal to Ktlleo. 
A set of thirteen betamethasone-related steroids was assembled to investigate the 
nature of steroid: cyclodextrin complexes. The set was chosen so that changes in the Kr 
values obtained could be related to changes in the structure of various regions of the 
steroid structure. Using Fujimura's method, Kr values were generated for thirteen 
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steroids with six different cyclodextrins. The effects of the acetonitrile concentration in 
the mobile phase and the column temperature were determined. 
Experimental 
Apparatus 
The HPLC systems used were Hewlett Packard 1050 Series HPLCs (Agilent 
Technologies, Palo Alto, CA) with in-line degassers. One system was equipped with a 
variable wavelength detector while the other had a diode array detector. Symmetry C18 
columns, 150 mm x 4.6 mm I.D., 5 Jim particle size (Waters Corporation, Milford, MA) 
were used. Refrigerated circulating baths (Neslab Instruments, Portsmouth, NH) were 
used to control column temperature. Depending on the organic composition of the 
mobile phase, flow-rates of 1.0 mL/min or 1.8 mL/min were used to maintain reasonable 
run times. The steroids studied possess a UV absorption maxima at a wavelength of 240 
nm so this wavelength was used for detection. Turbochrom 4.0 (Perkin-Elmer, Norwalk, 
CT) was used to acquire and process the chromatographic data. All of the retention 
factors obtained for the experiments reported in this chapter are listed in Appendix A. 
The 1 I k versus [CD] plots used to determine Kf are also shown. 
Chemicals 
HPLC grade acetonitrile, methanol, and water (Fisher Scientific, Springfield, NJ) 
were used without further purification. p-CD, hydroxyethyl-p-cyclodextrin (HE-P-CD; 
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average degree of substitution 5), hydroxypropyl-P-cyclodextrin (HP-P-CD; average 
degree of substitution 5.9), and y-CD were purchased from Cerestar USA, Inc. 
(Hammond, IN). Hydroxypropyl-y-cyclodextrin (HP-y-CD; average degree of 
substitution = 4.6) was purchased from Fluka Chemical Corporation (Milwaukee, WI). 
Mobile phases were prepared by mixing the appropriate amount of acetonitrile and water 
and then dissolving cyclodextrin in the resulting solution with the aid of an ultrasonic 
bath (Fisher Scientific). Mobile phases containing cyc10dextrin were filtered through two 
Metrigard glass fiber filters (Gelman Sciences, Ann Arbor, MI). 
The Schering-Plough Research Institute (Kenilworth, NJ) generously provided all 
of the corticosteroids studied, except dexamethasone and dexamethasone 2 I-acetate, 
which were purchased from Fluka Chemical Corporation (Milwaukee, WI). Stock 
solutions containing approximately 2 mM of each steroid were made in acetonitrile 
except for beclomethasone (3), the 9-bromo analogue (4), and the 9, ll-epoxide alcohol 
compound (5) (see Figure 3-1) which were prepared in methanol. Test mixtures were 
prepared by transferring 1.0 mL of the stock solutions to 50 mL volumetric flasks and 
diluting to volume with acetonitrile: water (35:65, v/v). Three test mixtures containing 
different steroids were prepared in this way. Betamethasone (1), the 9-bromo analogue 
of betamethasone (4), the All,12 compound (6), betamethasone 21-acetate (8), the 9,11­
epoxide, 21-acetate compound (10), and betamethasone 21-monopropionate (11) were 
added to one flask (Test Mixture A). Beclomethasone (3), the 9,1l-epoxide alcohol 
compound (5), betamethasone 17-monopropionate (12), and betamethasone 11,21­
diacetate (13) were added to a second flask (Test Mixture B). Dexamethasone (2), the 
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A9,11 compound (7), and dexamethasone 21-acetate (9) were added to a third flask (Test 
Mixture C). The identity of each peak was confirmed by injecting solutions containing 
the individual steroid. The 9-bromo analogue of betamethasone (4) was found to 
irreversibly convert to the 9,11-epoxide compound (5) in solution over a period of about 
24 hours at room temperature. Betamethasone 17-monopropionate (12) converts more 
slowly to betamethasone 21-monopropionate (11) in solution. The change in 
concentration of these steroids in the test mixtures was not observed to affect the 
retention factor for either compound in the presence of absence of cyclodextrin in the 
mobile phase. 
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Results and Discussion 
Experimental Design Considerations 
Figures 3-1 shows the chemical structures of the steroids selected for this study. 
The series was developed to illustrate the effect of changing various regions of a steroid 
on complex formation with cyclodextrin. It is possible to gain a better understanding of 
the process of inclusion complexation by monitoring the effect that changes in the 
functionality in various regions of the steroid backbone has on the value of Kr with 
different cyclodextrins. The effect of the halide in the 9-position was investigated using 
betamethasone (1), beclomethasone (3), and the 9-bromo analogue ofbetamethasone (4). 
These compounds contain an a-fluorine atom, an a-chlorine atom, and an a-bromine 
atom in the 9-position; respectively. Dexamethasone (2), an epimer ofbetamethasone (1), 
was also investigated. Dexamethasone (2) differs from betamethasone (1) only by the 
orientation of the I6-methyl group. It was chosen to determine if such a small change on 
the D-ring of the steroid structure would impact the strength of the inclusion complex 
formed with cyclodextrin. Betamethasone 17 -monopropionate (12), betamethasone 21­
monopropionate (11), and betamethasone 2I-acetate (8) are alkyl ester derivatives of 
betamethasone (1). They were included in this study to determine the significance of 
substitution at the 17- and 21-positions in the inclusion process. The addition of bulk to 
the D-ring of the steroid backbone will help to determine if inclusion occurs primarily at 
the A-Brings or the C-D rings. If inclusion occurs at the A-B rings of the steroid, then 
the structure of the C-ring and the nature of the groups located at the II-position should 
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Figure 3-1 	 Structures of steroids analyzed: betamethasone (1); dexamethasone (2); 

beclomethasone (3); 9-bromo analogue (4); 9,II-epoxide alcohol (5); 

~1l,l2 compound (6); ~9,11 compound (7); betamethasone 21-acetate (8); 

dexamethasone 21-acetate (9); 9,1l-epoxide, 21-acetate (10); 

betamethasone 21-monopropionate (11); betamethasone 17­
monopropionate (12); betamethasone 11 ,21-diacetate (13). 
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have a dramatic impact on the inclusion process because this region should closely 
interact with the hydroxyl rim of the cyclodextrin. To determine if this is the case, the 
9,1l-epoxide alcohol compound (5) and the 9,1l-epoxide, 21-acetate compound (10) 
were used for comparison to betamethasone (1) and betamethasone 21-acetate (8), 
respectively. Betamethasone 11,21-diacetate (13) was also investigated. The 89,1l 
compound (7) and the 8 11 ,l2 compound (6) possess unsaturated C-rings. Dexamethasone 
2 I-acetate (9) was also investigated. 
The method developed by Fujimura was chosen to monitor Kf values. Multiple 
compounds can be studied in one injection using this method. This method was ideal 
since thirteen steroids were to be studied. Some initial experiments needed to be 
performed to determine how best to analyze all of the compounds chosen for this work. 
Retention factors are the data necessary for determining Kr using Fujimura's method. 
However, elution order reversal is quite common as the concentration of cyclodextrin in 
the mobile phase increases. This is illustrated in Figure 3-2. A solution containing all 
thirteen steroids was injected into a system using a mobile phase of acetonitrile: water 
(35:65, v/v) containing no y-CD and 7.5 mM y-CD. Peak identities were determined by 
injecting thirteen solutions containing only one steroid. It was clear that Kr values could 
not be easily determined with all of the steroids present in one solution. Three different 
solutions were prepared to minimize coelution and elution order reversal. The test 
8 11mixtures used were: (A) betamethasone (1); the 9-bromo analogue (4); the ,12 
compound (6); betamethasone 21-acetate (8); the 9,11-epoxide, 21-acetate compound 
(10); and betamethasone 21-monopropionate (11); (B) beclomethasone (3); the 
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Figure 3-2 Chromatograms of thirteen steroids without cyclodextrin in mobile phase 
(A) and with 7.5 mM y-CD in mobile phase (B). Peak identity: 
betamethasone (1); dexamethasone (2); beclomethasone (3); 9-bromo 
A11analogue (4); 9,11-epoxide alcohol (5); ~9,1l compound (6); ,12 
compound (7); betamethasone 21-acetate (8); betamethasone 17­
monopropionate (9); dexamethasone 21-acetate (10); 9, l1-epoxide, 21­
acetate (11); betamethasone 11,21-diacetate (12); betamethasone 21­
monopropionate (13). 
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9,1l-epoxide alcohol compound (5); betamethasone 17-monopropionate (12); and 
betamethasone 11,21-diacetate (13); (C) dexamethasone (2); the /:l9,11 compound (7); and 
dexamethasone 21-acetate (9). When analyzed in three separate test mixtures, only one 
pair of compounds was observed to reverse elution order when cyclodextrins were added 
to the mobile phase. The 9-bromo analogue (4) elutes after betamethasone (1) when no 
cyclodextrin is present in the mobile phase, but was found to elute before betamethasone 
(1) upon the addition of cyclodextrin. The change in elution order is due to differences in 
Kf values. Large Kf values translate to a greater mobile phase residency and thus a 
shorter retention on the HPLC column. The 9-bromo analogue (4) was found to have a 
much larger Kf than betamethasone (1). This is discussed in more detail later in this 
chapter. Throughout all of the studies performed, it was easy to determine the identity of 
each of these peaks because the 9-bromo compound (4) degrades in solution to form the 
9,1l-epoxide alcohol compound (5). The difference in peak areas between 
betamethasone (1) and the 9-bromo compound (4) revealed which peak belonged to 
which compound. The degradation of the 9-bromo compound (4) also served to 
demonstrate that lowering the concentration of the steroids in solution did not affect the 
retention factor observed in the presence or absence of cyclodextrin in the mobile phase 
for the experiments described herein. 
Because the 1050 series HPLCs that were going to be used for this work contain 
four mobile phase reservoirs, it was desirable to calculate Kf values using only three 
concentrations of cyclodextrin. This would leave one channel for a mobile phase 
containing no cyclodextrin. In this way, Kf values could be generated in an overnight 
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run. However, before this could be done it was necessary to demonstrate that the use of 
three data points would provide the same information that could be obtained using a 
larger number data points. The validity of using three mobile phase concentrations of 
cyclodextrin was established by comparing the results collected using seven different 
concentrations of cyclodextrin against the average of five sets of data collected using 
only three sets of mobile phase concentrations. The y-CD concentrations studied were 
0.5 mM, 0.75 mM, 1.0 mM, 1.25 mM, 2.5 mM, 5.0 mM, and 7.5 mM. Only the last three 
concentrations were prepared when three mobile phases containing y-CD were used to 
determine Kf. Table 3-1 shows the results obtained. Within experimental error, the 
results generated with seven concentrations of y-CD are equivalent to those obtained with 
three concentration of y-CD. 
An experiment was performed to demonstrate that the Kf results measured using 
Fujimura's technique are due solely to the formation of inclusion complexes with 
cyclodextrin. Mobile phases were prepared using D-(+)-glucose instead of cyclodextrin. 
Concentrations of 17.5 mM, 35 mM, and 70 mM were used. These concentrations are 
equivalent to 2.5 mM, 5.0 mM, and 10 mM of ~-CD, which contains seven glucose units. 
The three test mixtures were analyzed using each of these mobile phases in addition to a 
mobile phase which contained no D-(+)-glucose. The chromatograms obtained for Test 
Mixture A are shown in Figure 3-3. This data shows that no significant change in 
retention was observed for any of the steroids using mobile phases containing D-(+)­
glucose, compared to the retention factors obtained for the steroids using a mobile phase 
containing no D-(+)-glucose. This experiment demonstrated that the glucose monomer of 
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Table 3-1 Kf values determined for y-CD complexes in acetonitrile: water (35:65, 
v/v). Average values determined based on five sets of data calculated 
using three concentrations of y-CD. Standard deviations are shown for 
each average value. 
Component Set 1- Set 2- Set 38 Set 4· Set 58 Average Set Ib 
9-bromo analogue 977 937 970 895 970 950 ± 34 937 
beclomethasone 621 604 617 586 634 612 ± 18 610 
betamethasone 213 208 211 206 221 212 ± 5.8 220 
dexamethasone 216 213 214 209 223 215±5.1 205 
9, l1-epoxide alcohol 142 144 144 141 150 144 ± 3.5 147 
,6,9,11 compound 151 150 151 148 154 151 ± 2.2 150 
,6,11,12 compound 93 101 103 101 107 101±5.l 107 
betamethasone 21-acetate 148 147 149 146 151 148 ± 1.9 154 
dexamethasone 21-acetate 146 147 148 147 150 148 ± 1.5 142 
9, ll-epoxide, 21-acetate 178 178 179 178 182 179 ± 1.7 186 
betamethasone 17-monopropionate 100 102 102 101 106 102 ± 2.3 105 
betamethasone 21-monopropionate 118 127 128 126 130 126 ±4.6 131 
betamethasone 11,21-diacetate 42 48 47 48 51 47 ± 3.3 48 
a Calculated using three concentrations ofy-CD 

b Calculated using seven concentrations ofy-CD 
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Figure 3-3 	 Chromatograms of Test Mixture A using mobile phases of acetonitrile: 
water (30:70, v/v) modified with no D-(+)-glucose (A), 17.5 mM D-(+)­
glucose (B), 35 mM D-(+)-glucose (C), and 70 mM D-(+)-glucose (D). 
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cyclodextrin does not affect the retention of the steroids being studied. Only when the 
glucose units are present as linked cyclic polymers does retention decrease. This 
decrease is due solely to the formation ofan inclusion complex. 
Since retention factors are used to calculate Kf, it is critical that the void volume 
for the HPLC system used is known. Any error in the void volume will lead to an error 
in the value of Kf. For example, a 10% variation in the void volume results in a 25% 
variation in the Kf obtained for the 9-bromo analogue (4) due to its low capacity in the 
system, especially at high concentrations of cyclodextrin. Comparisons can be made 
between Kf values for different steroids obtained using the same system even if 
inaccuracies exist in the measurement of the void volume. The effects of the structural 
features of a set of compounds can still be evaluated. However, if comparisons are to be 
made between different techniques of determining Kf (such as phase solubility, 
spectroscopic methods, etc.) or between results generated by different labs for a similar 
set of compounds, then an error in void volume will confound any conclusions that might 
be made. For this reason, the minor disturbance method described by Kazakevich and 
McNair was used to determine the actual void volume of the HPLC column used.88 The 
void volume was determined by making a minor disturbance to the amount of acetonitrile 
or water equilibrated with the column and measuring the retention time for the resulting 
peak from a refractive index detector. The retention time of the perturbation peak is 
determined using mobile phases of pure acetonitrile, pure water, and many binary 
mixtures of the two solvents. The void volume of the column is equal to the integral 
average calculated from a plot of the retention time of the minor disturbance peak against 
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the concentration of acetonitrile. This method eliminates the possibility that a compound 
injected to determine the void volume will have some retention, however small, on the 
reversed-phase material in the HPLC column. The void volume determined using this 
procedure differs by 4% from the void volume determined from the baseline perturbation 
after injection of a dilute solution of acetone. The void volume was found to be 1.58 mL 
using the minor perturbation method. The void volume determined from the baseline 
perturbation after injection of a dilute solution of acetone was 1.64 mL. 
Fujimura's Method 
Kr values for thirteen betamethasone-related steroids with a variety of ~- and y­
cyclodextrins were determined. HE-~-CD and HP-~-CD were chosen to be used in this 
research because they are commonly used derivatives of ~-CD. Ethanol or isopropanol 
are added to the primary alcohol in the 2-position of ~-CD via an ether linkage. This 
change increases the solubility of the derivatized cyclodextrins relative to ~-CD. This 
increase in solubility is one of the reasons that many derivatives of ~-CD are being 
synthesized, characterized, and utilized in industrial applications. Sulfated-~-CD was 
also investigated. Between twelve and sixteen sulfate groups are added to the primary 
and secondary alcohols of ~-CD. This negatively charged cyclodextrin has been used 
extensively as a modifier for CE run buffers due to its ability to generate countercurrent 
flOW. 89,90 The last cyclodextrins studied were y-CD and HP-y-CD. The largest Kr values 
were observed with y-CD. Table 3-II lists the apparent association constants obtained for 
each of the steroids studied with ~-CD, HE-~-CD, HP-~-CD, y-CD, and HP-y-CD. The 
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Table 3-11 Kf values obtained for five different cyclodextrins in acetonitrile : water 
I 

(35:65, v/v). I 
I 
i 
Compound I)-CD HE-~-CD HP-~-CD y-CD HP-y-CD 
9-bromo analogue 28 26 28 950 667 
I 
I 
~ beclomethasone 39 32 34 612 454 
betamethasone 27 21 19 212 180 
dexamethasone 22 17 17 215 173 
'I 9, 11-epoxide alcohol 14 7 9 144 119 
D 9,11 compound 39 20 20 151 145 
Dll,l2 compound 28 20 23 106 84I 
betamethasone 21-acetate 16 14 18 148 142t 
1 dexamethasone 21-acetate 15 13 16 148 132 
I 
9, ll-epoxide, 21-acetate 9 6 11 179 172 
betamethasone 17-monopropionate 2 6 102 70 
betamethasone 21-monopropionate 16 15 19 126 128 
I betamethasone 11 ,21-diacetate -2 2 5 47 35 
I 
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low values obtained for P-CD and its derivatives indicate that the size of the cavity is too 
small to allow a strong interaction with a steroid. Other researchers have reported the 
poor fit of steroids into the P-CD cavity.19,91 The length of a steroid is about 12 A, 
whereas the diameters of the secondary hydroxyl rim of P-CD and y-CD are 6.5 A and 
.1 8.3 A, respectively.91 This size restriction prevents the entire steroid from entering the 
1 cyclodextrin cavity. y-CD was used for the remainder of the work detailed in this 
I 
J 
dissertation because 	 it yields the strongest complexes with the steroids under 
~ , 	 investigation. 
i 
1 
I 
I 
I 
The results obtained using sulfate-p-CD were unique among the cyclodextrins 
investigated. Figure 3-4 shows the chromatograms for Test Mixture A when varying 
concentrations of sulfated-p-CD were added to the mobile phase. A slight increase inI 
1 
! 	
retention is observed when the sulfated-p-CD is added to the mobile phase. The effect is 
more pronounced for the later eluting peaks in the chromatograms. Clearly, no inclusion 
is taking place. It was thought that this effect might be due simply to the change in ionic 
strength of the mobile phase upon the addition of the highly changed cyclodextrin. To 
determine if this was the case, mobile phases were prepared containing sodium chloride. 
Concentrations of 35 mM, 70 mM, and 105 mM NaCI were selected. This concentration 
range yields an equivalent ionic strength as 2.5 mM to 7.5 mM of sulfated-p-CD. The 
resulting chromatograms are shown in Figure 3-5. The data shows that no significant 
change in retention can be attributed to ionic strength changes. It has recently been 
shown that the nature of the anion in solution can alter the solvation energy of a basic 
component in solution.92 While one step of the desolvation mechanism proposed is an 
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Figure 3-4 	 Chromatograms of Test Mixture A using mobile phases of acetonitrile: 
water (30:70, v/v) modified with no sulfated-~-CD (A), 2.5 mM sulfated­
~-CD (B), 5.0 mM sulfated-~-CD (C), and 10 mM sulfated-~-CD (D). 
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Figure 3-5 Chromatograms of Test Mixture A using mobile phases of acetonitrile: 
I water (35:65, v/v) modified with no sodium chloride (A), 35 mM sodium 
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chloride (B), 70 mM sodium chloride (C), and 105 mM sodium chloride ! (D). 
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electrostatic attraction between the ionized basic compound and the anion in solution, it 
may be possible for a similar desolvation to occur without this charge attraction. In this 
case, simply matching the ionic strength of the sulfated-p-CD mobile phase with sodium 
chloride would not be expected to yield the same results, since properties of these anionic 
species are different. This is simply speculation without further evidence that the 
sulfated-p-CD is changing the solvation energy of the steroids present in solution. It is 
just as likely that the sulfated-p-CD may be altering some property of the stationary 
phase which leads to a greater retention of the steroids being investigated. Further work 
needs to be performed to determine exactly why this unusual phenomenon occurs. 
The reproducibility of Fujimura's method was investigated by performing five Kf 
determinations using mobile phases modified with y-CD five times over a three-month 
period. This work was performed using two different HPLC systems and three different 
columns. Mobile phases were prepared fresh each time the analysis was performed. The 
results are shown in Table 3-II. Relative standard deviations for the Kf values obtained 
using y-CD ranged from 1.0% to 7.0% with an average RSD of 2.8% for all thirteen 
steroids. The largest standard deviation was observed for betamethasone 11,21-diacetate 
(13). This steroid had the lowest Kf of the thirteen steroids studied. It would be expected 
that the reproducibility for a complex with a low Kf would be poor because the change in 
] retention due to experimental errors (e.g. mobile phase organic content) is on the same 
f scale as the change in retention due to complexation. However, even though this is the 
I 
case, a relative standard deviation less than 10% is quite good for the measurement ofI 
1 
association constants. I 
I 
! 68 
1 
Dependency ofKjon Mobile Phase Organic Content 
I 
The dependency of Kr on the amount of acetonitrile present in the mobile phase 
was investigated. A plot of the natural logarithm of Kr for y-cyclodextrin with the 
steroids studied versus the percent acetonitrile contained in the mobile phase can be 
found in Figures 3-6A through 3-6C. Linear regression analysis of the data generated for 
all of the steroids studied resulted in an average correlation coefficient of 0.9918. Only 
the correlation coefficient for the 9-bromo analogue was below 0.99. A correlation 
coefficient of 0.9655 was obtained for this compound. The other correlation coefficients 
ranged from 0.9903 to 0.9973. The linear nature of these plots indicates that the 
inclusion process follows a similar trend of linear solvent strength as seen in reversed-
phase chromatography. As the amount of acetonitrile increases, the solubility of the 
steroid in solution increases. Much of the driving force for inclusion is removed when 
the guest is highly soluble in the solution in which inclusion is occurring. This data 
indicates that there is no change in the mechanism of inclusion as the acetonitrile content 
is varied from 20% to 45%. Lower concentrations of acetonitrile could not be evaluated 
using the method described by Fujimura because retention times became prohibitively 
long when no cyclodextrins were present in the mobile phase. A less retentive column 
packed with a stationary phase such as C4 or Cs derivatized silica gel or a size exclusion 
polymer could be used to study the steroid set at a lower concentration of acetonitrile. 
~ 
This work would be interesting because the mechanism of inclusion may change at very 1 
i 
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Figure 3-6A 	 Dependency of Kr on percent acetonitrile for y-CD inclusion complexes of 
the 9-bromo analogue (diamond); beclomethasone ( square); 
dexamethasone (x); the 8 9,11 compound (circle); and the 8 11 ,12 compound 
(cross). 
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Figure 3-6B 	 Dependency ofKf on percent acetonitrile for y-CD inclusion complexes of 
dexamethasone 21-acetate (diamond); betamethasone 17 -monopropionate 
(x); betamethasone 21-monopropionate (square); and betamethasone 
11 ,21-diacetate (circle). 
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Figure 3-6C 	 Dependency ofKf on percent acetonitrile for y-CD inclusion complexes of 
betamethasone (diamond); betamethasone 21-acetate (x); 9, l1-epoxide 
alcohol (square); and 9,11-epoxide, 2 I-acetate (circle). 
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low organic compositions, perhaps resulting in the formation of a 1:2 complex between 
the steroid and cyclodextrin. 
Dependency ofKj on Steroid Structure 
The Kr values calculated for the cyclodextrins and steroids studied provide 
information about the nature of the inclusion complex formed. The primary objective of 
this study was to determine which region of the steroid is included in the cyclodextrin 
cavity for betamethasone-related steroids. Complexation could occur with either the 
AlB-rings or the CfD-rings being included into the cyclodextrin cavity. No 1 :2 
complexes were observed for the thirteen steroids investigated at the cyclodextrin 
concentrations analyzed. 
The halide in the 9-position of the steroid has a tremendous impact on the strength 
of the inclusion complex. Betamethasone (1) has a fluorine atom present in the 9­
position and is observed to have the lowest Kr of the halide series studied. The 9-bromo 
analogue (4) was found to have the highest Kr. For the halide in the 9-position, the order 
of decreasing Kr was found to be Br > CI > F. No significant differences were observed 
between the Kr values for betamethasone (1) and dexamethasone (2) for any of the 
cyclodextrins studied. Other researchers have observed the preferential inclusion of 
bromine-containing compounds.93 Connors and Pendergast proposed that the preferential 
inclusion of bromine-containing compounds occurs due to the polarizability of the 
bromine atom.93 Bromine is more polarizable than chlorine and thus able to disperse its 
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electrons over a larger area. This allows for a stronger association with the glycosidic 
bonds that make up the interior of the cyclodextrin cavity. This evidence supports the 
inclusion of the AlB rings of the steroids into the cyclodextrin cavity. The halide at the 
9-position would be located within the cyclodextrin cavity if the AlB-rings were 
included. The trend observed for the halide in the 9-position would indicate that the 
halide is located within the cyclodextrin cavity. The opposite trend would be observed if 
the C-D rings were included into the cavity. In this case, the halide would be interacting 
with the hydroxyl rim of the cyclodextrin. It might then be expected that a very 
electronegative halide such as fluorine would stabilize the resulting CID-ring complex 
due to hydrogen bonding with the secondary hydroxyl groups of cyclodextrin. 
Continuing with this logic, a less electronegative halide such as bromine would be 
expected to have a lower Kr because it could not participate in strong hydrogen bonding. 
The data reported here shows that this is the opposite of what is observed; therefore, 
inclusion must be occurring primarily at the AlB-ring. There may be some small amount 
of a C/D-ring inclusion complex forming with the cyclodextrin. This complex would be 
indistinguishable from the AlB-ring inclusion complex using Fujimura's method. This 
HPLC method monitors any interaction between the steroid and cyclodextrin, with the 
resulting value ofKr being the sum of these individual interactions. This concept will be 
developed further in Chapter 5. 
The results obtained using HP-y-CD provide some insight as to how the steroid 
molecule resides in the y-cyclodextrin cavity. Hydroxypropyl groups are added to the 
primary alcohol groups located at the narrower end of the cyclodextrin torus. The depth 
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of the cyclodextrin cavity is effectively increased. A decrease in Kr of about 113 is 
observed for most steroids when HP-y-CD is used as the host when compared to Kr 
values when y-CD is used. It is interesting to note that the compounds that do not show a 
decrease in Kr with HP-y-CD all possess alkyl ester groups instead of hydroxyl groups at 
the 2 I-position. Assuming that the A-B rings are included, it seems likely that the 21-0H 
of the steroids studied here are interacting with the secondary hydroxyl groups along the 
wider rim of the cyclodextrin cavity to increase the strength of the inclusion complex. 
When the steroids penetrate further into the cyclodextrin cavity (as with HP-y-CD) this 
interaction may be disrupted, resulting in a weaker complex. This decrease is not 
observed for those compounds with alkyl ester groups in the 21-position. This data is as 
expected, since no complex stabilization is achieved with y-CD by the hydrogen bonding 
of the 21-0H with the secondary hydroxyl groups along the rim of the cyclodextrin torus. 
While electrostatic forces are critical in determine the strength of inclusion, steric 
factors are also very important. It is obvious from the low Kr values generated for P-CD 
that its cavity is too small to properly host the steroids screened. The cavity of P-CD is 
too constricting to allow the bromine group of the 9-bromo compound (4) to enter. This 
explains the trend CI > Br ~ F for the halide in the 9-position with P-CD and its 
derivatives. Another steroid series that demonstrates the effect of steric repulsion is 
betamethasone (1), betamethasone 2 I-acetate (8), and betamethasone 21-propionate (11). 
A decrease of about 60 M-1 in Kf is observed when the alcohol in betamethasone (1) is 
replaced with a methyl ester. The addition of another methyl group to generate an ethyl 
ester results in a further decrease of about 20 M-1• The larger increase observed for the 
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replacement of 21-0H for 21-acetate relative to the replacement of 2 I-acetate with 21­
propionate could be due to the additional loss of hydrogen bonding with the secondary 
hydroxyl groups of cyclodextrin when the 2I-OH is lost. A more dramatic decrease in Kc 
is observed when a bulky substituent is placed in the I7-position. The replacement of the 
alcohol in the 17-position of betamethasone with an ethyl ester results in a drop of 
approximately 110 M- I . This data suggests that the I7-position is in closer proximity to 
the cyclodextrin molecule than the 2I-position. 
The steroid C-ring is intimately involved with the cyclodextrin molecule. A 
comparison ofbetamethasone (1) and the 9,lI-epoxide alcohol compound (5) shows that 
a 68 M- I decrease in Kc occurs when the proton in the II-position is not available for 
hydrogen bonding. Comparing betamethasone 21-acetate (8) to betamethasone 11,21­
diacetate (13) shows that when an acetate group is present in the II-position, a loss of 
101 M-I in the value of Kc is observed. This data suggests that the II-position is 
interacting with the secondary hydroxyl groups along the rim of the cyclodextrin. This 
finding supports the results of Djedaini and Perly. They found that the presence of an 
alcohol at the ll-position of prednisolone promoted a strong I: I complex with ~-CD, 
while an oxo group at the II-position of prednisone resulted in the formation of a weaker 
1 : 1 complex.82 These authors also found that 1:2 complexes are formed for steroids with 
no hydrophilic groups on the D-rings. These results indicate that a steroid : cyc10dextrin 
complex is forming with the AlB-ring of the steroid occupying the cyclodextrin cavity, 
leaving the C-ring and D-ring to interact with the rim of the cyclodextrin. Spencer and 
Purdy propose a similar model for inclusion of a series of steroids related to estrone.82 
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They observed significant changes in Kf when a hydroxy group was added to the 2- or 4­
position of the A-ring. 
Interpreting the results obtained for the A9,1l compound (7) and the A1l,12 
compound (6) poses an interesting challenge. The presence of a double bond in the 9,11­
position disrupts the cis-configuration of the B-C ring junction. Molecular modeling 
Allshows that this should result in a bulkier steroid backbone compared to the ,12 
compound (6) as shown in Figure 3-7. These structures were energy-minimized using the 
MM2 feature of Chem3D Pro (Cambridge Software, Cambridge, MA). The energy­
minimized structures for both steroids are viewed with the 3-ketone group of the A-ring 
in the foreground. The molecular model shows that the C-ring and D-ring are out of 
plane for the A9,11 compound (7), resulting in a less compact structure. If size were the 
only factor involved in complex formation then it would be expected that the A9,11 
compound (7) would have a lower Kf than the All ,12 compound (6). This is not the case 
however, with values of 151 M-l for the A9,1l compound and 106 M-l for the All ,12 
compound. Having demonstrated that the 9- and II-positions are intimately involved in 
the inclusion process, one might speculate that the presence of n-electrons in this region 
may promote interaction with hydrogen atoms present in the secondary alcohol groups of 
y-CD. 
All of the results generated using Fujimura's method show that a 1: 1 complex is 
formed between the betamethasone-related steroids and the cyclodextrins studied. These 
data support that the A-B rings of the steroids studied penetrate into the cavity ofy-CD, 
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I Figure 3-7 Energy minimized structures for the /l9,11 compound (A) and the /l11,12 
compound (B). 
I 

B 

78 

with the 11-, 17-, and 21-positions interacting with the secondary hydroxyl rim of y-CD. 
Hydrogen bonding of the 21-0H seems to play an important role in stabilizing the 
complex for those steroids that possess this functionality. The addition of bulk to the 17­
position greatly decreases the stability of the cyclodextrin complex, indicating that this 
region of the steroid is in close proximity to the cyclodextrin molecule. 
Thermodynamics ofComplexation 
The thermodynamics of the inclusion process were investigated by determining 
the Kr for each steroid using mobile phases with varying concentrations of y-CD at 
temperatures ranging from 10°C to SO°C. Figure 3-SA shows the chromatography 
obtained for Test Mixture A at various temperatures in the absence of cyclodextrin. The 
retention times of the peaks present in this test mixture increase as the temperature 
decreases, as expected for a typical reversed-phase separation. When cyclodextrin is 
present in the mobile phase the trend of decreasing retention is observed at higher 
temperatures, but a decrease in retention is observed at lower temperatures due to the 
increased association of the steroids with y-CD. This data is shown in Figure 3-SB. The 
peak area for the 9-bromo analogue (4) decreases as the column temperature increases 
due to the conversion of this steroid into the 9,11-epoxide alcohol (5). The peak 
disappears completely at a column temperature of SO°C. However, the decrease in the 
peak area does not affect the retention factor of the peak. 
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Figure 3-8 	 Overlaid chromatograms for a steroid test mixture with no y-CD in the 
mobile phase (A) and with 7.5 mM y-CD in the mobile phase (B) at the 
column temperatures indicated. The 9-bromo analogue peak is denoted by 
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Van't Hoff plots were generated by plotting the natural logarithm of chromatographic 
retention factors obtained for each mobile phase concentration of y-CD against the 
reciprocal of absolute temperature and are described by the following equation: 
In k -Mf.OIRT+ !:SIR + In ~ (3-2) 
where k is the retention factor at a particular absolute temperature (T), Mf.O and !:S are 
the standard enthalpy and entropy changes associated with the chromatographic process, 
R is the gas constant, and ~ is the phase ratio of the column. Typical Van't Hoff plots 
generated for the steroids investigated using mobile phases containing 0 mM, 2.5 mM, 
5.0 mM, and 7.5 mM y-CD are shown in Figures 3-9A and 3-98. The Van't Hoff plots 
for all of the steroids studied can be found in Appendix B. Non-linear Van't Hoff plots 
are observed when a process occurs which changes the enthalpy or entropy of the 
96separation system.94- Numerous researchers have observed a deviation from linearity in 
Van't Hoff plots when cyclodextrins are present in the mobile phase.97-99 This is due to 
the competing retention processes at work when cyclodextrin is in the mobile phase. As 
the column temperature is lowered, the strength of inclusion increases due to the increase 
in the strength of hydrogen bonding between the guest and the hydroxyl groups of the 
cyclodextrin. This results in an increase in the residency time of the guest in the mobile 
phase, and thus a decrease in the retention factor measured for that guest. Opposing this 
process is the increase in retention as temperature decreases due to the change in the 
equilibrium between the stationary phase and the mobile phase for a particular guest 
compound. The natural logarithm of the retention factor is expected to decrease in a 
linear fashion for a reversed-phase HPLC system when cyclodextrins are absent from 
the mobile phase and the processes 
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Figure 3-9 	 Van't Hoff plots generated using retention factors of beclomethasone (A) 
and betamethasone 11,21-diacetate (B) with no y-CD (diamonds), 2.5 mM 
y-CD (squares), 5.0 mM y-CD (circles), and 7.S mM y-CD (triangles) in 
the mobile phase. 
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controlling retention are not changing. A slight deviation from linearity is observed at a 
temperature of about 25°C in the Van't Hoff plot generated in the absence of y-CD in the 
mobile phase. This deviation has been observed by other research groups, and has been 
attributed to a change in the configuration of the stationary phase, which effects the 
separation process. lOO-102 Differential scanning calorimetry has been used to study the 
stationary phase used for this work to demonstrate that a change in the conformation of 
the stationary phase is the cause of the deviation from linearity observed in the Van't 
Hoff plot when no y-CD is present. A transition was observed at a temperature of 28°C. 
Cole and Dorsey103 observed similar results for a reversed-phase column with similar 
bonding density as the one used in this research. These researchers found transition 
temperatures of 26.7°C and 35.7°C for stationary phases with bonding densities of 2.84 
Ilmollm2 and 4.07 Ilmollm2, respectively. The bonding density of the Symmetry CI8 
column on which DSC was performed was 3.18 Ilmollm2. 
A more interesting (though somewhat expected) result is the inflection observed 
in Van't Hoff plots for the mobile phases containing y-CD. The inflection becomes more 
pronounced as the concentration of y-CD in the mobile phase increases. The change in 
slope observed in the Van't Hoff plots is related to Kr. Figure 3-9A shows a large 
deviation in the slope obtained for bec1omethasone (3) as temperature decreases. Figure 
3-9B shows a much less severe departure from linearity in the Van't Hoff plot for 
betamethasone 1l,21-diacetate (13). The Krvalues obtained with y-CD at 25°C are 612 
M- I for bec1omethasone (3) and 47 M- I for betamethasone II ,21-diacetate (13). 
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It may appear that a very complicated change in retention process is occurring at 
lower temperatures when y-CD is present in the mobile phase. However, further analysis 
of the data reveals that this is not the case. Kf values can be calculated at each 
temperature studied since several concentrations of y-cyclodextrin were used. 
Additional Van't Hoffplots were generated by plotting the natural logarithm of Kf values 
(instead of retention factors) against the inverse of absolute temperature. By relating AGO 
directly to an equilibrium constant and not to a retention factor the value of <P is no longer 
needed to explicitly calculate t3.SO from the y-intercept of the Van't Hoff plot. The 
thermodynamic parameters extracted from Van't Hoff plots generated in this way relate 
only to the process of inclusion. Van't Hoff plots generated using retention factors are 
more difficult to interpret due to the complex nature of reversed-phase retention. Figures 
3-l0A through 3-1 OC show the plots of the natural logarithm of Kf against the inverse of 
absolute temperature for the thirteen steroids studied. Linear regression analysis of this 
data for all of the steroids studied resulted in an average correlation coefficient of 0.9963, 
with a range from 0.9930 to 0.9996. Values for I!JJO and ASO for the inclusion process 
extracted from the slope and intercept of the Van't Hoff plots using the natural logarithm 
of Kf are listed in Table 3-III. Similar results were obtained by Sadleg-Sosnowska for 
four steroids that were not used in this study.91 Kf values reported by Sadleg-Sosnowska 
were obtained using the Hummel-Dreyer method.91 
The overall process of inclusion for betamethasone (1) and the related steroids 
investigated here is enthalpy driven. A plot of -ASO against -I!JJO for the thirteen steroids 
studied is shown in Figure 3-11. A linear relationship exists (r2 = 0.983) between ASO 
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Figure 3-10A Van't Hoff plots generated using Kf values for y-CD complexes of the 9­
bromo analogue (x); beclomethasone (diamond); betamethasone (triangle); 
dexamethasone (circle); and 9, ll-epoxide alcohol (square). 
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Figure 3-10B 	Van't Hoff plots generated using Kfvalues for y-CD complexes of the 
/;/,11 compound (x); betamethasone 21-acetate (triangle); dexamethasone 
21-acetate (circle); and the All,12 compound (diamond). 
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Figure 3-10C Van't Hoffplots generated using Kfvalues for y-CD complexes of9,11­
epoxide, 21-acetate (x); betamethasone 21-monopropionate (triangle); 
betamethasone 17 -monopropionate (diamond); and betamethasone 11,21­
diacetate (circle). 
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Table 3-111 Thermodynamic properties of complex 
acetonitrile: water (35:65, v/v). 
Compound 

9-bromo analogue 

beclomethasone 

betamethasone 

dexamethasone 

9, l1-epoxide alcohol 

D9,11 compound 

D 11 ,12 compound 

betamethasone 21-acetate 

dexamethasone 21-acetate 

9, l1-epoxide, 21-acetate 

betamethasone 17-monopropionate 

betamethasone 21-monopropionate 

betamethasone II ,21-diacetate 

-ABO 
(kJ/mole) 
32.4 
27.4 
20.6 
20.2 
20.2 
20.1 
19.2 
19.1 
18.4 
17.6 
16.0 
15.0 
14.6 
formation with 1-CD In 
-ASO 
(kJ/mole*K} 
0.0501 
0.0374 
0.0239 
0.0248 
0.0227 
0.0289 
0.0322 
0.0226 
0.0201 
0.0189 
0.0121 
0.0084 
0.0104 
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Figure 3-11 Enthalpy-entropy plot for thirteen steroids. 
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and I:!J:F for all but two of the steroids. As the magnitude of the enthalpy associated with 
inclusion increases, an offsetting decrease in entropy occurs. A relationship of this type 
is referred to as enthalpy-entropy compensation. This data exhibits a compensatory 
enthalpy-entropy relationship for all of the steroids examined except betamethasone 
11,21-diacetate (13) and betamethasone 17-monopropionate (12). Enthalpy-entropy 
compensation is frequently observed when a series of related compounds undergo a 
similar process.104-106 Due to the offsetting variance in the entropy, the change in free 
energy of the process is always lower than the change in enthalpy of the process. This is 
represented by the linear dependence of the plot shown in Figure 3-11. Only 
betamethasone Il,2I-diacetate (13) and betamethasone 17-monoprionate (12) deviate 
significantly from this line. Assuming that this deviation is not due to experimental error, 
it would indicate that these two steroids are not forming a complex with y-CD in exactly 
the same way as the other betamethasone-related steroids studied. Further evidence that 
these two steroids undergo a slightly different mechanism of inclusion arises from plots 
of 1)..0° versus the inverse of absolute temperature. One of the requirements for enthalpy­
entropy compensation outlined by Krug is that plots of IJ.G versus the inverse of absolute 
temperature must intersect at a single temperature for all of the compounds undergoing 
the same process in the same manner.107 This intersection occurs at a temperature of 
about 450°C for all of the steroids tested except betamethasone 11 ,2I-diacetate (13) and 
betamethasone I7-monopropionate (12). From the thermodynamic data shown here, it is 
clear that the II-position and the I7-position are critically involved in the inclusion 
process. This conclusion is in agreement with the conclusion drawn from the analysis of 
Kr values. Significant changes to the chemical structure at these positions of the steroid 
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series studied result in changes in the stability of the inclusion complex, as well as a 
change in the mechanism of the inclusion process. 
Conclusions 
The inclusion complexes of thirteen steroids with several cyclodextrins were 
investigated using the HPLC method described by Fujimura. It was found that precise Kr 
values can only be determined if the void volume of the HPLC column is known exactly. 
Stronger inclusion complexes were obtained with y-CD and HP-y-CD than with P-CD 
and its derivatives. A combination of steric factors and electronic factors were found to 
control the inclusion process. A decrease in Kr and a change in the inclusion mechanism 
were observed when the hydroxyl groups in the 11- or 17-position are replaced with alkyl 
esters. A decrease in Kr was observed as the bulkiness of the substituent at the 21­
position was increased. The mechanism of inclusion was found to remain constant using 
mobile phases with acetonitrile content between 20% to 40%. Non-linear Van't Hoff 
plots generated using the natural logarithm of retention factor data versus 1fT are due to 
the competitive process of retention and inclusion, not a change in the mechanism of 
either of these processes. No change was observed in the inclusion mechanism from 
lOoC to 80°C, based on the linear results of the Van't Hoff plots generated using the 
natural logarithm of Kr versus liT. Enthalpy-entropy compensation was observed for 
eleven of the thirteen steroids studied. 
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Chapter 4. 
Using the Hummel-Dreyer Method to Determine Kr 
Summary 
The goal of the research described in this chapter was to determine Kf using a 
second HPLC technique. The Hummel-Dreyer method was chosen. A mobile phase 
containing a known quantity of steroid is used and a solution of cyclodextrin is injected. 
The chromatograms generated in this way contain a positive peak eluting at to and a 
negative peak eluting at the time the steroid elutes when injected into the HPLC system. 
A novel approach to determining Kf from the negative peak observed in a chromatogram 
was developed. A response factor is used to quantify the amount of steroid deficiency 
represented by the negative peak. The deficiency is due to the introduction of a solution 
containing no steroid, as well as the presence of cyclodextrin in that solution. The 
method developed can differentiate between the peak areas due to each of these factors. 
Solutions containing various concentrations of cyclodextrin were injected. A plot of the 
negative area obtained versus the concentration of cyclodextrin was found to be linear. 
The y-intercept of this plot is equal to the peak area of the steroid deficiency due to the 
sample diluent. Accurate values for the amount of steroid present in the complex can be 
determined by subtracting this amount from the peak area obtained for each cyclodextrin 
solution. Kr values calculated using this method compared favorably to those obtained 
using Fujimura's method. Discrepancies between the two methods are not due to an error 
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in the assumptions used to determine Kr by Fujimura's method, but rather are due to the 
imprecision of calculating low Kr values using the Hummel-Dreyer method. 
Introduction 
The general approach for calculating association constants developed by Hummel 
and Dreyer was described in Chapter 1.50 They used an internal calibration method to 
calculate the amount of 2' -cytidylic acid bound by pancreatic RNAase. Solutions 
containing a constant amount of RNAase and varying amounts of 2'-cytidylic acid were 
placed on a column of cross-linked dextran and then eluted with a mobile phase 
containing 2' -cytidylic acid. A negative peak corresponding to the amount of ligand 
bound to the RNAase substrate was observed. This magnitude of this negative peak was 
found to decrease as the concentration of the ligand in the solution being analyzed 
increased. A plot of the concentration of the ligand versus the peak area showed the 
concentration of ligand that would yield a peak area of zero (the x-intercept). This value 
is the amount of ligand bound to the substrate and relates to the equilibrium constant as 
shown in Equation 1-12. 
The internal calibration method used by Hummel and Dreyer to calculate the 
binding of 2' -cytidylic acid by pancreatic RNAase using gel filtration has been extended 
to analyze other systems. Sebille et ai. determined the binding parameters of warfarin 
and furosemide with human serum albumin (HSA) using a size-exclusion HPLC 
column. lOS Similar work has been done to study the binding of propanolol to human al­
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acid glycoprotein. 109 Sun and Hsiao modified the internal calibration so that the second 
peak observed would be a positive peak rather than a negative peak. 110 This was done 
simply by increasing the concentration of the ligand in the solution being analyzed, so 
that it was greater than the concentration in the mobile phase. A plot of the peak area 
obtained for the positive peak versus ligand concentration will still reveal the 
concentration at which the peak area will be zero. They studied the competitive binding 
of five drugs and a detergent to bovine serum albumen. 
A modification of the internal calibration method was used by Thuaud et al. to 
analyze the binding properties of warfarin, indomethacin, propanolol, and hydrocortisone 
with ~-CD, carboxymethyl-~-CD, and hydroxypropy1trimethylammonium-~-CD.III 
Scatchard plots55 were generated using the peak areas obtained by varying the 
concentration of the guest molecules in the mobile phase and injecting a solution 
containing cyclodextrin. Scatchard plots show r / [(G)r] versus r; where r is equal to 
[(G)b] / [CD] and (G)f and (G)b are the free and bound guest molecules, respectively. The 
slope of the resulting line is equal to -Kf. 
The amount of the ligand represented by the negative peak was not directly 
calculated for any of the internal calibration methods described above. Data regarding the 
complex is extracted from concentration plots or Scatchard plots using an internal 
calibration Hummel-Dreyer method. Variations of the Hummel-Dreyer method which 
use the amount of the bound compound derived from the chromatographic peak to 
calculate Kf are referred to as external calibration methods. These methods have been 
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used to quantify the amount of the negative peak without varying the concentration of the 
ligand in either the injection solution or the mobile phase. Sun and Hsiao used such a 
method to study the binding of L-tryptophan to bovine serum albumin. 112 They found 
that similar results were obtained using external and internal calibration. Various ways of 
determining peak areas were used, including planimetry, integration, and geometrical 
analysis. The external method employed by Sun and Hsiao used only one concentration 
of substrate and corrected the peak areas for all solutions against a blank injection. 
Sadleg-Sosnowska used the area of the positive peak that elutes at to to study the 
inclusion of several steroids with cyclodextrin.51 ,113 The peak areas were corrected for 
the shift in molar absorptivity observed when cyclodextrin was added to solutions 
containing the steroids of interest. A molar absorptivity shift of 12% to 20% was 
reported for the steroids studied. Different results are obtained using the peak areas of 
the first and second peaks observed to calculate Kf for cyclodextrin complexes if this 
correction is not made. 114 However, this approach adds an additional source of error to 
the calculation of Kf, since the determination of the molar absorptivity change is made 
off-line. This error is demonstrated by the result obtained for estriol, which was more 
than double the value obtained using Fujimura's method. This difference may be due to 
limitations in the method described by Fujimura, but the potential for experimental bias 
introduced by this technique makes it difficult to draw any meaningful conclusions from 
the data. When the interaction of a ligand with a substrate does not significantly effect 
the molar absorptivity of the ligand, the area of the earlier eluting peak can be used 
successfully to determine Kf. 52 
95 

A modification of the external standard method was used by Pinkerton and 
Koeplinger to analyze the binding of warfarin to HSA. 115 They varied the concentration 
of warfarin in the mobile phase, rather than in the injected solution. Only HSA was 
injected into the HPLC system. A blank injection was made to correct the peak areas. 
The values obtained using the variations of the Hummel-Dreyer described above 
were reported to compare favorably with values cited in the literature determined by 
other methods. However, no statistical analysis was found in any reference to compare 
data generated by different methods. The external calibration method is not frequently 
used because of the difficulty in calculating an exact amount of ligand that is absent in 
the negative peak. The internal calibration method requires the analysis of a large 
number of samples to determine a single apparent association constant. Before the 
Hummel-Dreyer method could be used to verify the results obtained using Fujimura's 
method for the steroids being investigated in this dissertation, it was necessary to 
establish a fast and reliable way to calculate Kf from the later eluting negative peak. 
Difficulties were encountered using the Hummel-Dreyer method that needed to be 
overcome prior to the generation ofuseful data. 
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Experimental 
Apparatus 
The HPLC systems used were Hewlett Packard 1050 Series HPLCs (Agilent 
Technologies, Palo Alto, CA) with in-line degassers. One system was equipped with a 
variable wavelength detector while the other had a diode array detector. Symmetry CI8 
columns, 150 mm x 4.6 mm LD., 5 f.lm particle size (Waters Corporation, Milford, MA) 
were used. Refrigerated circulating baths (Neslab Instruments, Portsmouth, NH) were 
used to control column temperature. A flow-rate of 1.5 mLimin was used to maintain 
reasonable run times. The steroids studied possess a UV absorpion maximum at a 
wavelength of 240 nm, so this wavelength was used for detection. Turbochrom 4.0 
(Perkin-Elmer, Norwalk, CT) was used to acquire and process the chromatographic data. 
Chemicals 
HPLC grade acetonitrile, methanol, and water (Fisher Scientific, Springfield, NJ) 
were used without further purification. y-cyclodextrin (y-CD) was purchased from 
Cerestar USA, Inc. (Hammond, IN). Hydroxypropyl-y-cyclodextrin (HP-y-CD; average 
degree of substitution 4.6) was purchased from Fluka Chemical Corporation 
(Milwaukee, WI). The Schering-Plough Research Institute (Kenilworth, NJ) generously 
provided betamethasone, beclomethasone, and the 8.9,11 compound. Dexamethasone was 
purchased from Fluka Chemical Corporation (Milwaukee, WI). 
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Mobile Phase Preparation 
Mobile phases were prepared by pipetting 2.0 mL of a stock solution ofeach 
steroid into alL volumetric flask and diluting to volume with acetonitrile: water (35:65 
or 20:80, v/v). The resulting solution was then degassed using an ultrasonic bath (Fisher 
Scientific, Springfield, NJ). The steroid stock solutions were prepared by weighing 
approximately 300 mg of each steroid into a 50 mL volumetric flask and diluting to 
volume with methanol. Mobile phases prepared in this way contained approximately 
0.03 mM ofthe steroid. 
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Results and Discussion 
Figure 4-1 shows a typical chromatogram obtained using the Hummel-Dreyer 
method. A solution of y-CD was injected into an HPLC system. A mobile phase of 
acetonitrile: water (35:65, v/v) containing beclomethasone was used. The positive peak 
observed at 1.3 minutes is produced by the beclomethasone : y-CD complex. The 
negative peak at 5.8 minutes shows the deficiency of beclomethasone in the system due 
to the injection of the y-CD solution. A simplified graphical representation of what occurs 
within the column is illustrated in Figure 4-2. In panel A, a solution of cyclodextrin has 
entered the column. The shaded regions of the mobile phase and stationary phase 
represent the steroid molecules that are present. Circles represent cyclodextrin 
molecules. Some of the cyclodextrin molecules are shown with a dot in the circle to 
represent the inclusion of a steroid molecule. The cyc10dextrin reaches an immediate 
equilibrium with the steroid present. A fast rate of equilibrium between the substrate and 
ligand is a requirement for the Hummel-Dreyer method to be valid. 116 Inclusion probably 
occurs in the mobile phase prior to the injection plug reaching the analytical column. 
Regardless of where inclusion occurs, the equilibrium between the steroid in the mobile 
phase and the steroid associated with the stationary phase is disrupted when the 
cyclodextrin and the solvent containing no steroid reach the head of the column. In 
accordance with Le Chatelier's principle, the steroid will move from the stationary phase 
to the mobile phase to reestablish equilibrium. Arrows indicate this transfer of steroid 
from the stationary phase to the mobile phase. Panel B shows the free and complexed 
cyc10dextrin moving through the column without any retention on the stationary phase. 
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Figure 4-1 A typical chromatogram obtained using the Hummel-Dreyer method. 
440 

420 

400 

:> 380 

E 
'-" 
~ 360 

C 

o 
~ ~ 340 

I-< 
B 
U 320 

~ 
o 
300 

260 

260 

Retention Time (Minutes) 
100 

Figure 4-2 Illustration of the process occurring using the Hummel-Dreyer method. 
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The positive peak shown in Figure 4-2 is observed as the steroid: cyclodextrin complex 
passes the detector. Meanwhile, the transfer of steroid from the stationary phase to the 
mobile phase has resulted in a deficiency of steroid on the stationary phase. Although 
this deficiency is illustrated as being complete in panel B (Le. the stationary phase is 
shown to contain no steroid), this is not the case. Only a small amount of the steroid 
originally on the stationary phase is pulled into the mobile phase. The resulting "hole" in 
the stationary phase will be "filled" by steroid from the mobile phase. This process 
continues, as shown in panels C and D of Figure 4-2, until finally a negative peak is 
observed in the chromatogram. The retention time of this negative peak is equal to the 
retention time of the steroid in the HPLC system because the region of low steroid 
concentration migrates through the column in the same way as an injected sample of 
steroid. 
The value of Kr for the steroid cyclodextrin inclusion complex can be 
determined from the following equation: 
QG-CDKr = -----'---- (1)[(G)m] (QeD - QG-CO) 
where QCD is the amount of cyclodextrin injected, QG-CD is the amount of the inclusion 
complex that is formed, and (G)m is the concentration of the guest compound in the 
mobile phase. QCD can be calculated since the concentration of the cyclodextrin solution 
and the injection volume are both known. [(G)m] is also known. It is the amount of 
complex that forms, QG-CD, which needs to be determined. Two values are needed to 
quantify QG-CD from the negative peak: 1) a response factor for the steroid and 2) the 
amount of this peak that is due to the injection of a solution which does not contain the 
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steroid into the HPLC system. The response factor is readily obtained and shall be 
discussed first. The accurate determination of peak area due only to the introduction of 
cyclodextrin will then be discussed. 
Response factor determination 
The mobile phase that was used for this work was prepared to contain 
approximately 0.03 mM of the steroid of interest. This value was chosen so that the 
detector response for the system would be between 0.3 AU and 0.4 AU. If the 
absorbance due to the steroid in the mobile phase is too high then the detector will be 
operating outside of its linear range, and thus accurate quantification will not be possible. 
If the absorbance is too low then the signal measured due to complexation will be small 
and system noise will become a significant source of experimental error. Solutions 
containing between 0.01 mM and 0.3 mM of the steroid being studied were injected into 
the system. An overlay plot of typical chromatograms obtained for a set of steroid 
solutions is shown in Figure 4-3. The most negative peak shown in this figure was 
generated by injecting a solution of acetonitrile : water (35:65, v/v) with no steroid 
present. The peak area becomes less negative as the concentration of steroid in the 
solution is increased. A positive peak is observed when the amount of steroid injected 
exceeds the amount of steroid present in the mobile phase. The peak areas can be plotted 
as a function of the amount of steroid introduced onto the column, as shown in Figure 4­
4. The amount of steroid injected can be determined since the injection volume and the 
concentration of steroid are both known. A correlation coefficient greater than 0.99 was 
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Figure 4-3 	 Overlaid chromatograms of a blank injection and solutions containing 
between 0.01 mM and 0.3 mM beclomethasonse. Mobile phase = 
acetonitrile: water (35:65, v/v) containing 0.025 mM beclomethasone. 
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Figure 4-4 A typical calibration curve generated using the Hummel-Dreyer method. 
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achieved for all calibration curves used for this work. The slope of the calibration curve 
was used as a response factor for the analysis of solutions of cyclodextrin. A series of 
standard solutions were injected on each day that the Hummel-Dreyer method was 
performed. 
Determination ofQ(G-CD) 
The response factor can be used to calculate the deficiency of steroid that results 
from injecting a solution containing cyclodextrin. However, calculating the amount of 
the steroid : cyclodextrin complex (Q(G-CD») formed is more complicated. The 
introduction of a plug of solvent that contains no steroid will disturb the equilibrium 
established between the steroid present in the mobile phase and the steroid interacting 
with the stationary phase. 
The oversimplified diagram of the process governing the Hummel-Dreyer method 
shown in Figure 4-2 serves to illustrate the challenge inherent in determining Q(G-CD). A 
deficiency is observed in the system when a solution is injected (unless that solution 
contains exactly the same amount of steroid as the mobile phase) regardless of whether 
cyclodextrin is present or not. This can be easily seen by removing the circles 
representing cyclodextrin molecules from the injection plug in panel A of Figure 4-2. 
While no positive peak will be seen in the resulting chromatogram, the negative peak will 
still be observed due to the absence of steroid in the injected solution. Initial studies 
showed a discrepancy between the area of a blank injection and the y-intercept of the 
calibration curve. The y-intercept of the calibration curve represents the peak area of a 
solution with a steroid concentration of zero. Two sets of standards were analyzed in 
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duplicate on two separate days. Blank injections were made before each set. The y­
intercept value and the average area of two blank injections were 109200 and 103400 on 
day 1, and 128600 and 106600 on day 2. A difference of 5% and 17% was observed 
between the y-intercept values and the average blank peak areas. 
This work was performed without controlling the temperature of the mobile 
phase. While column temperature was controlled with a water bath, the temperature of 
the mobile phase entering the column was unregulated. Two problems can occur if the 
mobile phase is not at the proper temperature when it reaches the column. First, the 
formation of the inclusion complex may occur at an unknown temperature. Second, the 
equilibrium between the stationary phase and mobile phase will be disrupted since this 
equilibrium is temperature dependent. When a solution is injected, the deficiency of 
steroid in the HPLC column is initiated at the column head. It is the temperature there 
that determines the quantity of steroid molecules that are going to be removed from the 
stationary phase. If the mobile phase is at a different temperature than the column then 
there will be a temperature gradient formed along the head of the column. The result will 
be irreproducible peak areas observed when solutions are injected. The mobile phase was 
kept at the same temperature as the column by immersing the bottle containing the 
mobile phase into the water bath used to control the column temperature. This technique 
yielded acceptable results when using a mobile phase containing 35% acetonitrile. 
However, the baseline became very erratic when the acetonitrile content was lowered to 
20%, even with mobile phase temperature control. An additional length of steel tubing 
was added just before the column in the water jacket. Figure 4-5 illustrates the 
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Figure 4-5 Effect of temperature on baseline stability using the Hummel-Dreyer 
method. Solutions containing 25,50, 75, 100, and 150 mg ofy-CD in 50 
mL of acetonitrile: water (20:80, v/v) were analyzed in the presence ofa 
steel coil before the head of the column (top) and in the absence of the 
steel column (bottom). Mobile phase =acetonitrile: water (20:80, v/v) 
containing 0.025 mM dexamethasone. 
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significant effect this had on baseline stability when a mobile phase containing 20% 
acetonitrile was used. Mobile phase temperature changes will have a more significant 
impact at the lower acetonitrile concentration since more steroid is associating with the 
stationary phase. These chromatograms were generated by injecting increasing 
concentrations of y-CD into an HPLC system with a mobile phase of 20:80 (v/v) 
acetonitrile : water containing dexamethasone. The set of chromatograms at the bottom 
of the figure was obtained in the absence of a length of steel tubing added to the head of 
the column. The top set of chromatograms was obtained after the steel tubing was added 
to the system. The effect of the steel tubing is obvious. The relative standard deviations 
calculated for the analysis of the dexamethasone: y-CD inclusion complex dropped from 
9.6% to 3.5%. It is noteworthy that the experiments using mobile phases containing 
20% acetonitrile were performed during the winter, when lab temperatures can fluctuate 
drastically. This may have exacerbated the baseline fluctuation observed during these 
experiments. 
A set of standards containing five concentrations of bec1omethasone ranging from 
0.01 mM to 0.3 mM was analyzed with the mobile phase temperature controlled. The 
average y-intercept obtained from the resulting calibration curve was 139900 ± 3800. 
Blank injections were made in duplicate before each set. The average area for eight 
blank injections was found to be 131500 ± 2800. A difference of 6% is observed 
between these values. Even with mobile phase temperature controlled, it seems that the 
direct injection of blank may not yield the most accurate results. Unfortunately, using 
either of these values for the amount of steroid removed from the system by the sample 
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diluent gave poor results for Kf. Table 4-1 summarizes the results for a set of y-CO 
solutions ranging in concentration from 0.8 mM to 3.9 mM. Kf values generated using 
the peak area from blank injections and from the y-intercept of the calibration curve are 
shown. Either method of calculation results in a large standard deviation for the valued 
of Kc calculated. A second set of y-CO solutions with concentrations ranging from 0.8 
mM to 1.2mM was prepared to eliminate the possibility of a weighing error. Both sets of 
solutions were analyzed. The same solution used to dilute the first set of solutions was 
used to prepare the second. Plots of the peak areas for both sets are shown in Figure 4-6. 
It is immediately obvious that the y-intercept for each set of solutions is different. The 
slight evaporation of acetonitrile from the sample diluent during a twenty four hour 
period changed the composition of the sample diluent enough to yield a significant 
difference in the area of the negative peak: being measured. The graph shown in Figure 
4-7 was obtained by subtracting out the area represented by the y-intercept for each set of 
y-CO solutions, and plotting the new area versus y-CO concentration. Both sets of 
solutions give the same results once corrected for the blank value unique to that set of 
solutions, as determined by the y-intercept for that set. The Kc values obtained using the 
corrected areas are shown in Table 4-11. The standard deviation for this data is reduced 
from 71 (RSO = 9.2%) to 30 (RSO = 3.9%) when the results for the 0.15 mM y-CO 
solution are eliminated. The average Kf of 769 M-1 compares favorably with the value 
obtained using Fujimura's method (612 M-1). However, the two sets of data were fOurId 
to be statistically different. This will be discussed in greater detail later. 
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Table 4-1 Comparison of results for beclomethasone, using the y-intercept of the 
standard curve and blank injections 
cyclodextrin injections. 
[y-CD] (mM) 
0.8 
1.5 
2.3 
3.1 
3.9 
Average 
S.D. 
Area corrected 

Using y-intercept 

558 

698 

762 

779 

790 

717 

96.2 

to correct the peak area of 
Area corrected 

Using blank inj. area 

724 

785 

820 

823 

825 

795 

43.3 
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Figure 4-6 	 Comparison of two sets of 'Y-CD solutions prepared on different days. See 
text for details. 
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300 
Table 4-11 Results for two sets of y-CD solutions prepared on different days after 
correcting peak areas using the y-intercept for each set. 
[y-CD] (mM) 
0.08 
0.15 
0.49 
0.66 
0.77 
1.18 
0.81 
1.55 
2.32 
3.12 
3.91 
Average 
S.D. 
~(M-l) 
799 

966 

728 

776 

794 

736 

717 

727 

760 

731 

732 

769 

71 
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In order to confirm that the concentration of acetonitrile in the sample diluent affects the 
negative peak area in the way described above, three sets of y-CD solutions were 
prepared. Cyclodextrin samples were weighed into 50-mL volumetric flasks. One set of 
flasks had 0.5-mL of water added and another set had 0.5-mL of acetonitrile added. All 
three sets were then diluted to volume with the acetonitrile : water (35:65, v/v). 
Concentrations of y-CD ranged from 0.4 mM to 1.9 mM y-CD. These solutions were 
then analyzed with standard sets containing five different concentrations of steroid run 
before each set of samples. The peak areas versus concentration plots for all three sets of 
solutions are shown in Figure 4-8. As expected, a decrease in organic content of the 
sample diluent results in a decrease in the steroid deficiency due to the injection of the 
diluent. Table 4-III shows that similar Kf values are obtained from all three sets of data. 
Determination ofKj 
The modified Hummel-Dreyer method was used to analyze the inclusion 
complexes of beclomethasone with y-CD and HP-y-CD. The acetonitrile: water content 
of the mobile phase used was 35:65 (v/v). This concentration was chosen so that the 
results generated could be compared to the data generated using Fujimura's method. Five 
separate measurements of Kf for y-CD were made using Fujimura's method at this 
organic : aqueous ratio, and thus a reliable standard deviation has been generated. Plots 
of the uncorrected and corrected peak areas obtained using the Hummel-Dreyer method 
versus cyclodextrin concentration are shown in Figure 4-9 and 4-10, respectively. 
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Figure 4-8 	 The effect of sample diluent acetonitrile concentration on the peak areas of 
y-CD solutions. Acetonitrile: water content (v/v) of sample diluent 
34:66 (diamonds), 35:65 (squares), 36:64 (triangles). Mobile phase = 
acetonitrile: water (35:65, v/v) containing 0.025 mM betamethasone. 
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Table 4-111 Effect of sample diluent acetonitrile concentration on Kr after correcting 
peak areas for each concentration. 
[y-CD] Acetonitrile Content 
(mM) 34% 35% 36% 
0.4 159 159 185 

0.75 165 183 174 

1.2 155 164 180 

1.5 150 178 172 

1.9 164 170 183 

Average 159 171 179 

S.D. 6.2 9.9 5.7 
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Figure 4-9 	 Results of the injection of solutions containing y-CD (circles) and HP-y­
CD (squares) using a mobile phase of acetonitrile: water (35:65, v/v) 
containing 0.025 mM beclomethasone. 
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Figure 4-10 	 Corrected results for the injection of solutions containing y-CD (circles) 
and HP-y-CD (squares) using a mobile phase of acetonitrile: water (35:65, 
v/v) containing 0.025 mM beclomethasone. 
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Similar data was observed for all of the steroids that were studied using the Hummel­
Dreyer method. 
A Kr value for complexation with y-CD was also determined for betamethasone 
using an acetonitrile: water content of35:65 (v/v). The amount of the negative peak area 
due to betamethasone consumed by complexation with y-CD was found to be about 5% 
of the total area of the negative peak for the lowest concentration of y-CD tested. 
Approximately 24% of the negative peak area was due to complexation for the highest 
concentration of y-CD studied. The small area is a consequence of the low Kr for the 
betamethasone : y-CD complex in acetonitrile: water with a concentration of 35:65 (v,v). 
Work done using Fujimura's method showed that Kr increases logarithmically as 
acetonitrile content is decreased. The acetonitrile : water composition of the mobile 
phase was lowered to 20:80 (v/v) and Kr values for the y-CD complexes of 
betamethasone, dexamethasone, and the A9,11 compound were determined. The amount 
of the negative peak related to complexation increased to between 25% and 75% when 
the lower acetonitrile concentration was used. However, some accuracy is lost due to 
band broadening. The negative steroid peak elutes very late in the chromatogram at an 
acetonitrile: water composition of20:80 (v/v). 
The results for all of the steroids analyzed using the Hummel-Dreyer method are 
summarized in Table 4-IV. Kr values determined using Fujimura's method are also 
shown. A comparison of means was performed using the student t -test to determine if the 
two data sets are statistically the same. The pooled standard deviation for the Kr of 
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Table 4-IV Summary of results obtained using the modified Hummel-Dreyer method 
and Fujimura's method. 
Ky.(M-t) 
Hummel-Dreyer 
Method 
beclomethasone 713 (7.8%) 
beclomethasonea 480 (10.0%) 
betamethasone 169 (6.5%) 
betamethasoneb 818 (6.7%) 
dexamethasoneb 1026 (3.5%) 
,6.9.1 1 compoundb 995 (6.0%) 
Fujimura's 

Method 

612 (3.0%) 

454 (*) 

212 (2.7%) 

902 (*) 

981 (*) 

827 (*) 

Comparison 

of Means 

fail 

pass 

fail 

pass 

pass 

pass 

a value for HP.y.CD complex 
b value for y.CD complex in acetonitrile: water (20:80, v/v) 
.. only one set of data was analyzed so the average standard deviation for y·CD 
complexes at acetonitrile: water composition of35:65 (v/v) were used for t-test 
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betamethasone and beclomethasone with y-CD in acetonitrile: water (35:65, v/v) was 
calculated with eighteen degrees of freedom. Ten degrees of freedom were available for 
the calculations of the beclomethasone : HP-y-CD complex. All other pooled standard 
deviations were calculated using eleven degrees of freedom. The results show that both 
methods gave the same results in four of the six cases studied. The two cases which 
failed the t-test are y-CD inclusion complexes with betamethasone and beclomethasone in 
acetonitrile: water (35:65, v/v). One possible reason why these results are different 
could be that these complexes have some retention on the stationary phase. Fujimura's 
method assumes that the complex has no retention. It is this assumption that allows Kr to 
be determined from the dependency of I I k on the concentration of cyclodextrin. If the 
complex did have some slight retention then k would be artificially higher and thus Kr 
would be lower when measured using this method. This is the case for beclomethasone, 
but the Kr value obtained for betamethasone using Fujimura's method is higher than the 
value determined by the Hummel-Dreyer method. There are three reasons why it is 
unlikely that the complex is retained by the column. First, the peak for all of the 
complexes studied using the Hummel-Dreyer method was observed at the void time. 
Second, it is unlikely that the beclomethasone : y-CD complex would be retained but the 
beclomethasone : HP-y-CD would not be retained. Third, if any of the steroid : 
cyclodextrin complexes studied were retained by the column then a greater difference in 
results between the two methods used would be expected at the lower concentration of 
acetonitrile studied. The data shows that all of the steroids tested at the lower 
concentration of acetonitrile yielded equivalent results using both methods. Clearly there 
must be another reason which could explain the differences observed. The effect of an 
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error in the void volume of the HPLC system was discussed in Chapter 3. If the void 
volume were in error then all of the results obtained using Fujimura's method would be 
either higher or lower than the results from the Hummel-Dreyer method, depending on 
whether the void volume measurement was low or high, respectively. The error in the 
measurement of the void volume was minimized using the minor perturbation method 
described in Chapter 3. 
A more reasonable explanation for the differences observed between the two sets 
of data generated may be the inherent accuracy of the Hummel-Dreyer method when Kr 
is low. In this case, the amount of the negative peak due to complexation may be as low 
as 5%. However, when Kris high between 50% and 75% of the negative peak was found 
to be due to complexation. These two situations are depicted in Figure 4-11. The use of 
peak areas to calculate values of Kr that are low is not as precise as the use of retention 
factors. This demonstrates the major weakness of the Hummel-Dreyer method for 
studying cyclodextrin complexation. However, the use of this method demonstrates the 
validity of the data generated using Fujimura's technique. It also serves to show how 
difficult it can be to compare Kr data obtained from different methods, even when this 
data is generated in the same laboratory under rigorously controlled experimental 
conditions. 
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Figure 4-11 	 The amount of negative peak area due to complexation and sample diluent 
when Kf is low (A) and high (B). The shaded region represents the area 
due to complexation. 
A 	 B 
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Conclusions 
A modified Hummel-Dreyer method was developed to evaluate the inclusion 
complexes of five steroids with y-cyclodextrin and one steroid with HP-y-CD. This 
method was found to be accurate when Kr is large. The effects of temperature and sample 
diluent composition on the accuracy of the method were found to be significant when 
using the Hummel-Dreyer method to calculate Kr. The use of a second HPLC technique 
to analyze the complexes of steroids with cyclodextrins confirmed the results obtained by 
Fujimura's method in four of six cases studied. A failure of the assumptions of 
Fujimura's method was not the cause of the deviation of the two differing results. The 
inaccuracy of the Hummel-Dreyer method when calculating low Kf values explains the 
differences between the data generated by the two different HPLC techniques. The 
inaccuracy for determining low Kr values is due to the small percentage of the negative 
peak due to complexation. 
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Chapter 5. 
Using Spectroscopy and Kinetics to Determine Kr 
Summary 
In Chapters 3 and 4, it was shown that HPLC could be used to determine accurate 
Kr values. However, neither of the methods used could distinguish between different 1: 1 
complexes that might be formed between a steroid and cyclodextrin. The Kr values 
measured with HPLC represent a sum of all of the possible interactions of a steroid with 
cyclodextrin. Inclusion of the steroid AlB-ring and the steroid CID-ring will both 
contribute to the Kr values obtained. 
UV spectroscopy was used to determine Kr values. However, the change in the 
extinction coefficient measured due to the presence of cyclodextrin in solution was found 
to be on the same order as the experimental error. Relative standard deviations (RSDs) 
of 0.7% to 4.3% were achieved for three replicate measurements of the extinction 
coefficient of solutions containing beclomethasone and various concentrations of y-CD. 
The RSD measured for the extinction coefficients obtained from seven different 
concentrations of y-CD between 0 mM to 15 mM was found to be between 5.7% and 
6.5% for the same three sets of data. 
Kr values can be determined by monitoring changes in the rate of a reaction as the 
concentration of cyclodextrin in the reaction solution is increased. The rate of the 
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intramolecular epoxidation of the 9-bromo analogue of betamethasone was monitored in 
this way. HPLC was used to quantify the amount of the 9-bromo analogue remaining and 
the amount of 9,11-epoxide alcohol formed. Pseudo-first order kinetics were observed 
for the reaction, both in the presence and absence of cyclodextrin. The resulting Kf was 
found to be 531 M-1• This value is significantly lower than the Kf determined using 
Fujimura's method, indicating that the kinetics technique may be monitoring only the 
AlB-ring inclusion complex. However, a mathematical model developed to describe the 
system with two different 1: 1 complexes being formed shows that it is impossible to 
determine the exact Kf values for the AlB-ring complex and CID-ring complex using this 
technique. 
Introduction 
While HPLC is a powerful technique for studying molecular interactions, it does 
have a critical limitation for monitoring the inclusion complexes of steroids and 
cyclodextrins. HPLC cannot differentiate between inclusion at the steroidal AlB-ring and 
inclusion at the steroidal CID-ring. The Krvalues obtained using this technique are a sum 
of both interactions between the steroid and cyclodextrin. Fujimura's method does not 
show how much of the change in retention factor is due to one inclusion complex and 
how much is due to the other. Likewise, the negative peak area observed using the 
Hummel-Dreyer method could not be proportioned to two different 1: 1 inclusion 
complexes. For this reason, another analytical technique is needed to study the inclusion 
process. Initially, UV spectroscopy was pursued. Since the chromophore of the steroid 
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is located within the A-ring, Kf values could be determined for only the inclusion of the 
AlB-ring. Inclusion at the CID-ring would not affect the molar absorptivity of the 
steroid. However, the change in the extinction coefficient observed upon the addition of 
cyclodextrin to a solution containing a steroid was found to be so small that the 
experimental error was greater than the change being measured. 
Kf values can be determined by monitoring the change in that rate of a reaction as 
the concentration of cyclodextrin in solution is increased. The reaction rate changes 
because the cyclodextrin molecule can shield a particular region of a guest compound 
from the bulk solution. Similarly, the rate can increase upon inclusion because an area 
may be more exposed to the bulk solution. The catalytic nature of cyclodextrins is well 
known and was described in great detail by Griffiths and Bender.7 
Using the approach described by Lineweaver and Burckll7 in 1932 or Eadie1l8 in 
1942, an expression can be derived to relate the change in the reaction rate to Kf . 
Consider the following reaction scheme: 
(8) + (CD) (8: CD)!k, !~ 
Products Products 
Kf is defined as kt / kd and the fraction of steroid, S, present as a cyclodextrin complex, Fe, 
can be defined as: 
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Fe = [(S : CD)] / [(S)o] (5-1) 
where [(S)o] is the total concentration of steroid present in solution. Kf can be related to 
the concentrations of S and CD: 
Kr= [(S:CD)] (5-2)([(S)o] - [(S: CD)]) [(CD)o] 
assuming that the total concentration of cyclodextrin in solution, [(CD)o], is much greater 
than the amount of cyclodextrin present as a complex with the steroid. The reaction rate 
observed when cyclodextrin is present, kobs, can be related to Fe as follows: 
Substituting (1) into (2) and solving for Fe results in the following equation: 
Fe = Kr [(CD)o] (5-4) 
1+Kr [(CD)o] 
This equation can be substituted into (3) and rearranged to give: 
kobs _ kl = (b - kJ)[(CD)o] (5-5) 
(1 IKr) + [(CD)o] 
Taking the inverse of both sides of (5) and multiplying by (kobs - kJ) (k2 k1) yields: 
(/cobs- kl) = -(/cobs - kl) + (k2 - kl)
K.r [(CD)o] (5-6) 
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This expression is in the form y mx + b. Plotting (kobs - k/) versus (kobs - k/) / [(CD)o] 
results in a straight line, the slope of which is equal to - (1/ Kf). The y-intercept is equal 
to (k2 - kl ). The reaction rate for the steroid included in the cyclodextrin cavity can be 
determined since k, (the reaction rate in the absence of cyclodextrin) is known. 
Experimental 
Apparatus 
The HPLC system used was a Hewlett Packard 1050 Series HPLC (Agilent 
Technologies, Palo Alto, CA) with an in-line degasser. The system was equipped with a 
variable wavelength detector. A Symmetry CIS column, 150 mm x 4.6 mm LD., 5 !lm 
particle size (Waters Corporation, Milford, MA) was used. A refrigerated circulating bath 
(Neslab Instruments, Portsmouth, NH) was used for temperature control of the HPLC 
column and the reaction solutions. A flow-rate of2.0 mLlmin was used. UV detection at 
a wavelength of 240 nm used. Turbochrom 4.0 (Perkin-Elmer, Norwalk, CT) was used to 
acquire and process the chromatographic data. 
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Chemicals 
HPLC grade acetonitrile, methanol and water (Fisher Scientific, Springfield, NJ) 
were used without further purification. P-CD and y-CD were purchased from Cerestar 
USA, Inc. (Hammond, IN). Phosphoric acid and dibasic sodium phosphate were 
purchased from Fluka Chemical Corporation (Milwaukee, WI). The Schering-Plough 
Research Institute (Kenilworth, NJ) generously provided beclomethasone, the 9-bromo 
analogue ofbetamethasone, and the 9,II-epoxide alcohol compound. 
Methods 
UV Spectroscopic Experiments 
A Cary 3E equipped with a Cary temperature control module (Varian, Inc., 
Mulgrave, Australia) was used to measure the absorbance of a solution containing 25 !lM 
beclomethasone in water in the presence of various concentrations of y-CD ranging from 
o mM to 15 mM. Beclomethasone solutions containing P-CD were also studied. All 
readings were made in triplicate, with the entire set of solutions being measured before a 
solution would be measured again. The sample cell was maintained at 25°C using a 
refrigerated water circulator. The solution was equilibrated in the spectrophotometer for 
thirty minutes before the UV spectra was collected. The solutions were filtered through a 
0.45 !lm Gelman Acrodisc LC PVDF syringe filter (Pall Corporation, Port Washington, 
NY). No difference in the results was observed when y-CD was weighed directly into the 
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sample flask and dissolved versus when a stock solution containing y-CD was added to 
the sample flask. 
Kinetics Experiments 
A stock solution containing approximately 1 mg/mL of the 9-bromo analogue of 
betamethasone was prepared in methanol. Using a to-deliver pipette, 1.0 mL of the stock 
solution was added to separate 50 mL volumetric flasks containing 0 mg, 32.1 mg, 50.4 
mg, 65.4 mg, 78.1 mg, 97.2 mg, 122.2 mg, 199.5 mg, 255.3 mg, 320.3 mg, or 490.0 mg 
of y-CD and diluted to volume and diluted to volume with acetonitrile: buffer (35:65, 
v/v). A 10 mM dibasic sodium phosphate buffer was used. The buffer pH was adjusted 
to 7.8 using phosphoric acid. Temperature was controlled at 25°C by immersing the 
volumetric flasks in a water bath. Aliquots were withdrawn and immediately injected 
into an HPLC. The area of the 9-bromo analogue peak was used to calculate In (c/co). 
The area of the 9,Il-epoxide peak was also monitored, but was not used in the 
calculations of rate constants. 
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Results and Discussion 
UV Spectrophotometric Technique 
Typical results for the absorbance readings obtained for beclomethasone in the 
presence of various concentrations of ~-CD are shown in Table 5-I. This data shows the 
difficulty in using UV spectrophotometry to measure Kc values for steroid : cyclodextrin 
complexes. The use of aqueous solutions containing no acetonitrile should yield very 
high Kc values. This was demonstrated in Chapter 3. However, relatively small changes 
were observed in the absorbance for solutions containing no ~-CD and solutions 
containing high concentrations of ~-CD. The RSD for three replicate measurements of a 
solution containing beclomethasone and a given amount of ~-CD ranged from 0.7% to 
4.3%. The RSD for the absorbance obtained for seven concentrations of ~-CD ranging 
from 0 mM to 15 mM was found to be between 5.7% and 6.5%. 
A plot of 11(£-£0) versus the inverse of [y-CD] is shown in Figure 5-1. £ is the 
extinction coefficient of beclomethasone in the presence of cyclodextrin and £0 is the 
extinction coefficient in the absence of cyclodextrin. The Ketelaar equation (Equation 1­
5) shows that the inverse of the slope of this line should equal Kc multiplied by (Ec EC), 
where Be is the extinction coefficient of the beclomethasone : cyclodextrin complex and EC 
is the extinction coefficient of free beclomethasone. These values are determined from 
the y-intercept of the plot shown in Figure 5-1. The Kc value determined from this data 
was found to be 117 M- I . This value is much too low for the formation of the 
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Table 5-1 Results obtained for a solution of beclomethasone in water with the 
specified amount of P-CD present. 
Absorbance Measurement 
[B-CDJ Reading Reading Reading 
(mM) One Two Three Average %RSD 
0 0.3974 0.3956 0.3922 0.3951 0.7 
1.1 0.3337 0.3322 0.3273 0.3311 1.0 
2.5 0.3364 0.3565 0.3283 0.3404 4.3 
5.1 0.3424 0.3584 0.3389 0.3466 3.0 
7.6 0.3375 0.3521 0.3401 0.3432 2.3 
9.9 0.3377 0.3376 0.3366 0.3373 0.2 
15 0.3546 0.3605 0.3540 0.3564 1.0 
Average 0.3485 0.3561 0.3453 
%RSD 6.5 5.7 6.5 
, 
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Figure 5-1 Ketelaar plot generated from beclomethasone UV data. 
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7 
beclomethasone : y-CD complex in pure water. A value of over 16000 M-1 is predicted 
for a pure aqueous solution based on the results of the acetonitrile dependency study 
described in Chapter 3. The UV spectroscopic technique was not investigated further. 
An alternate method was chosen to differentiate between AlB-ring inclusion and C/D­
ring inclusion. 
Kinetics Technique 
The 9-bromo analogue of betamethasone undergoes a base-catalyzed 
intramolecular epoxidation to form the 9, ll-epoxide alcohol. This reaction is 
summarized in Figure 5-2. Preliminary work indicated that a reasonable reaction rate is 
achieved at room temperature at pH values slightly above neutral. A pH of 7.8 was 
chosen for this study. A phosphate buffer was used to control the pH. y-CD was added 
to solutions containing approximately 22 IlM of the 9-bromo analogue. The final 
concentrations of y-CD in the various solutions studied were 0 mM, 0.5 mM, 0.75 mM, 1 
! 
I 
j 
I 
1.0 mM, 1.25 mM, 1.5 mM, 2.0 mM, 3.0 mM, 4.0 mM, 5.0 mM, and 7.5 mM. At various 
times, an aliquot of each concentration was injected into an HPLC system to quantifY the 
I 
amount of the 9-bromo analogue remaining in solution and the amount of the 9,11­
epoxide alcohol formed. A typical chromatogram of the separation achieved using a 
i mobile phase containing acetonitrile: water (35:65, v/v) is shown in Figure 5-3. A flow ~ 
.1 
1 rate of 2.0 mLlmin was chosen to minimize the run time. The analysis of each solution ! 
was performed in five minutes. 
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Figure 5-2 Intramolecular epoxidation of the 9-bromo analogue of betamethasone. 
OH 
OH­
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Figure 5-3 Typical chromatogram of a solution of the 9-bromo analogue of 
betamethasone (A) partially converted to the 9,1l-epoxide alcohol 
compound (B). 
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Pseudo-first order rate constants were obtained at each concentration of 
cyclodextrin used. Plots of In (c/co) versus time for each concentration of cyclodextrin 
are shown in Figure 5-4. The slope of each line is the rate constant for the epoxidation 
(kobs). The rate constants obtained are listed in Table 5-II. The reaction was monitored 
for approximately 1250 minutes for solutions containing less than 2 mM y-CD and 
approximately 1900 minutes for solutions containing more than 2 mM y-CD. This was 
done to assure that enough data points were collected to determine accurate rate 
constants. During this time period, almost 65% of the 9-bromo analogue converted to the 
9,II-epoxide alcohol in the solution containing no y-CD, while only 25% of the 9-bromo 
analogue converted to the 9,II-epoxide alcohol in the solution containing 7.5 mM y-CD. 
The presence of y-CD in solution decreases the rate of the base-catalyzed 
intramolecular epoxidation of the 9-bromo analogue. This would be expected if the A/B­
ring is included into the cyclodextrin cavity. In Chapter 3, it was proposed that the 
hydroxyl group in the II-position interacts with the secondary alcohols along the rim of 
the cyclodextrin cavity. This limits the ability of the 11-0H to attack the carbon atom at 
the 9-position to form the 9, ll-epoxide. It is also likely that the inclusion complex also 
stabilizes the 9-bromo analogue to some degree. If it is assumed that there is no 
inclusion of the steroid CID-ring, then Kr and k2 can be extrapolated from a plot of (kobs ­
k l ) versus (kobs - k l ) I [(CD)o]. Such a plot was constructed and is shown in Figure 5-5. 
A correlation coefficient of 0.998 was achieved. The Kr value calculated from this plot 
was found to be 531 M-I and k2 was found to be 5.07 x 10-5 min-I. The rate of the 
reaction in the absence of cyclodextrin was 7.73 x 10-4 min-I. 
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Figure 5-4 	 Pseudo-first order kinetics analysis of the degradation of the 9-bromo 
analogue at 25°C in acetonitrile: water (35:65, v/v). A 10 mM dibasic 
sodium phosphate buffer adjusted to a pH of 7.8 with phosphoric acid was 
used. The concentrations ofy-CD in solution are (from bottom to top): 0 
mM, 0.49 mM, 0.78 mM, 1.01 mM, 1.20 mM, 1.50 mM, 1.88 mM, 3.08 
mM, 3.94 mM, 4.94 mM, 7.56 mM. 
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Table 5-11 	 Summary of the pseudo-first order rate constants obtained for the 
intramolecular epoxidation of the 9-bromo analogue of betamethasone at 
25°C in acetonitrile: buffer (35:65, v/v) in the presence of the specified 
concentration of y-CD. A 10 mM dibasic sodium phosphate buffer 
adjusted to a pH of7.8 with phosphoric acid was used. 
[y-CD] kobs 
(mM) (min-I, xlO-4) 
0.00 7.73 
0.49 6.25 
0.78 5.64 
1.01 5.18 
1.20 4.92 
1.50 4.51 
1.88 4.07 
3.08 3.27 
3.94 2.85 
4.94 2.52 
7.56 1.97 
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Figure 5-5 	 Analysis ofkinetics data generated for the intramolecular epoxidation of 
the 9-bromo analogue at 25°C in acetonitrile: water (35:65, v/v). A 10 
mM dibasic sodium phosphate buffer adjusted to a pH of 7.8 with 
phosphoric acid was used. 
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Kf for the 9-bromo analogue was calculated using Fujimura's method with mobile 
phases containing the phosphate buffer used for the kinetics experiments instead of pure 
water. A value of 792 M- l was determined. It seems reasonable to subtract these values 
and thus determine the Kf value for a CID-ring inclusion complex between the 9-bromo 
analogue and cyclodextrin. However, the mathematical model used to determine the Kf 
from changes in reaction rates was developed assuming that there is only one complex 
formed between the steroid and cyclodextrin. The approach taken to derive Equation 5-6 
was used to determine a similar equation when there are two different complexes formed 
between the steroid and cyclodextrin. Now the reaction scheme can be summarized as: 
kf(ClD) kf(AlB{, (S : CD}clD ----, (S) + (CD) ~ (S : CD)A/B 
kd(CID) kd(AIB)1k, 
~
lkl l~ 
Products Products Products 
Terms for the fraction of steroid present as the AlB-ring complex (F AlB) and as the CID-
ring complex (FclD) can be described in the same way as they were in Equation 5-1. The 
new equation for Kf{AIB) when including the CID-ring complex is: 
[(8: CD)AIB] (5-7) 
K.QAIB) = ([(8)0] _ [(8: CD)AIB] - [(8: CD)CID]) [(CD)o] 
where Kf{AIB) is the apparent association constant for the AlB-ring inclusion complex. A 
similar expression can be derived for Kf(B/C)' The equations for F AlB and FCID are then 
substituted into Equation 5-7 and the following expression is derived: 
FAIB = Kf(AIB) [(CD):!] (5-8) 
Kf{AIB) [(CD):!] + K.QCID) [(CD):!] +1 
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A similar formula can be developed for FCID. The rate constant observed in the presence 
of cyclodextrin can now be described as: 
kobs = (1- K.i(AIB) [(CD)o] + Kr(CfD) [(CD)o] ) kl 
K.i(AIB) [(CD)o] + K.i(CfD) [(CD)o] +1 
+ ( 	 Kr(AIB) [(CD)o] ) k2 (5-9) 
K.i(AJB) [(CD)o] + Kr(CfD) [(CD)o] +1 
+ ( 	 Kr(CfD) [(CD)o] ) k3 
K.i(AIB) [(CD)o] + K.i(CfD) [(CD)o] +1 
This equation can be rearranged to a form similar to Equation 5-6: 
(kohs _kl) = - (kobs - kl) + K.i(AIB) (k2 - k3) + Kr (k3 - kl) (5-10) 
Kr [(CD)o] Kr 
where Kf is equal to the sum of Kf(AIB) and Kf{clD) determined by HPLC. Unfortunately, 
this mathematical treatment of the kinetics data for a system with two 1: 1 steroid : 
cyclodextrin complexes results in more unknowns than can be solved for using a 
graphical method. The y-intercept shown in Equation 5-10 contains three unknowns. 
This limitation is illustrated in Figure 5-6, which shows the plots obtained using Equation 
5-9 to generate theoretical kobs values for three different situations: 1) k3 kl, 2) kl > k3 
> k2, and 3) k3 > kl > k2. The experimental kobs are shown in Figure 5-6 for reference. 
In each case, the Kf value used was determined by Fujimura's method and the Kf(AIB) 
value used was determined using the kinetics method assuming no CID-ring complex is 
formed. Similar plots could be generated using other values of Kf{AIB), with different 
slopes being obtained from each plot. While no exact values for Kf{AIB), Kf{clD), k2, or k3 
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Figure 5-6 	 Plots of theoretical kobs data generated using the kinetics model developed 
for AlB-ring and elD-ring inclusion and experimental kobs data. Open 
squares: theoretical kobs when k3 > kJ > k2. theoretical kobs when open 
circles: k3 kJ. theoretical kobs when open triangles: kJ > k3 > k2, filled 
circles: experimental kobs. 
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can be obtained from this model, it serves to illustrate the difficulty in studying the 
complexation mechanism between steroids and cyclodextrins. 
Conclusions 
The use of UV spectrophotometry to study the inclusion complexes of 
betamethasone-related steroids with cyclodextrins proved unsuccessful. The 
experimental error was on the same order as the changes in molar absorptivity being 
measured. However, monitoring the change in the rate of the intramolecular epoxidation 
of the 9-bromo analogue ofbetamethasone provided a useful technique for distinguishing 
AlB-ring inclusion from C/D-ring inclusion. The results generated could not be used to 
calculate KqAIB) and KqclD), but did serve to illustrate the complexities of studying steroid 
: cyclodextrin inclusion complexes. 
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Chapter 6. 
Two HPLC Applications Using Steroid: Cyclodextrin Complexes 
Summary 
The utility of cyclodextrin complexation for the separation of steroids by 
reversed-phase HPLC was demonstrated. Two methods were developed to achieve the 
separation of steroids from several related compounds, including impurities and 
degradants. In one method, a steroid and two diasteriomeric impurities were separated 
from each other and from an unknown impurity. The steroid is a precursor on the 
synthetic route to dexamethasone. The addition of1-CD to the mobile phase resulted in a 
change in the elution order of the four main peaks. Two of the peaks coeluted when 1­
CD was not present in the mobile phase. 
The second method developed separates all of the impurities and degradants of 
betamethasone 21-acetate. The method was fully validated in accordance with the 
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) guidelines. The method was demonstrated to 
be linear, precise, accurate, robust, and specific for the quantification of betamethasone 
acetate and related compounds. The limit of quantitation (LOQ) for betamethasone 21­
acetate was determined to be 0.05%, with a limit of detection (LOD) of 0.01 %. Linearity 
was established from the LOQ to 150% of the concentration used for the analysis. The 
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method was found to be more selective than the current United States Pharmacopeia 
(USP) method. 
Introduction 
Modifying selectivity (a.) in reversed-phase HPLC is the best way to achieve the 
separation of coeluting peaks. The master resolution equation shows that a change in 
efficiency (N) or a change in retention factor (k) will not yield a proportional increase in 
resolution: 
R = IN (a. -1) (_k_) (6-1) 
4 k+l 
Doubling efficiency will result in an increase in resolution of approximately 1.4 units. 
Doubling the retention factor from, for example, 10 to 20 would yield only a 5% increase 
in resolution. On the other hand, an increase in selectivity from 1.5 to 2.0 will double the 
resolution observed between two chromatographic peaks. 
Typically, selectivity is enhanced in the following ways: changing the stationary 
phase used for a separation, changing the type and concentration of the organic modifier 
in the mobile phase, changing the type, concentration, and pH of the aqueous buffer used 
in the mobile phase (especially useful for the separation of ionizable compounds), and 
adjusting column temperature. These techniques are effective for most applications, and 
successful separations are routinely developed without additional modifications to 
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improve selectivity. However, when these conventional approaches to method 
development fail to produce the desired separation, other ways to enhance selectivity are 
needed. 
The addition of cyclodextrin to the mobile phase is an excellent way to enhance 
selectivity. It was shown in Chapter 3 that small modifications to the structure of a 
compound can result in large changes in the value of Kr. Stronger interactions with 
cyclodextrin in the mobile phase will result in a decrease in the retention of a compound. 
When several components are present in a sample solution injected into an HPLC, the 
retention of each component will change by a different amound due to inclusion into the 
cyclodextrin cavity. Screening mobile phases with several different concentrations of 
cyclodextrin can quickly yield a functional HPLC method. This technique also has the 
advantage of revealing if peaks are coeluting at a particular mobile phase composition 
since they will be moving through the retention window at different rates as the 
concentration of cyclodextrin is changed. 
Numerous researchers have capitalized on the properties of cyclodextrins to 
achieve separations in chromatography. Most of the literature published using 
cyclodextrins in chromatography concerns the separation of enantiomers. This is due to 
the inherent chirality of the cyclodextrin molecule. Many reviews have been written on 
the use of cyclodextrins to achieve the separation of chiral compounds, including those 
by Han1l9, Bressollo et al. 120, and Fanali and Kilar l21 • Reviews have also been published 
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describing the use of cyclodextrins to resolve geometrical isomers and other compounds 
which are structurally similar. 1o,44 
In this chapter, two novel applications are described using cyclodextrin as a 
mobile phase modifier for HPLC. The first method resolves DOB-A, a steroidal 
precursor of dexamethasone. from two know impurities (which are diasteriomers of the 
analyte) and one unknown impurity. The second method was developed for the assay of 
betamethasone 21-acetate drug substance. including the separation and quantification of 
related compounds. This method was fully validated in compliance with ICH guidelines. 
Experimental 
Apparatus 
The HPLC systems used were Hewlett Packard 1050 Series HPLC (Agilent 
Technologies, Palo Alto, CA) with an in-line degasser and Shimadzu LC-I0 HPLCs 
(Shimadzu Scientific Instruments. Columbia, MD). The HP 1050 system was equipped 
with a diode array detector for determining peak purity. The Shimadzu system was 
equipped with a variable wavelength ultraviolet detector. YMC J'Sphere H-80 columns, 
150 mm x 4.6 mm I.D., 4 /lm particle size (Waters Corporation, Milford, MA) were used. 
Column temperature was controlled using a blown air column heater/chiller (Jones 
Chromatography, Lakewood, CO). Flow-rates of 1.5 mLimin and 2.0 mLimin were used. 
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UV detection at a wavelength of 240 nm used. Turbochrom 4.0 (Perkin-Elmer, Norwalk, 
CT) was used to acquire and process the chromatographic data. 
Chemicals 
HPLC grade acetonitrile, methanol and water (Fisher Scientific, Springfield, NJ) 
were used without further purification. P-CD and y-CD were purchased from Cerestar 
USA, Inc. (Hammond, IN). The Schering-Plough Research Institute (Kenilworth, NJ) 
generously provided DOB-A, DOD-B, betamethasone acetate, and related compounds. 
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RESULTS AND DISCUSSION 
DOB-A Application 
The structures of DOB-A, DOD-B, and ll-j3-0H-DOD-B are shown in Figure 6­
1. DOB-A and DOD-B are epimers that differ only in the orientation of the methyl group 
located in the 16-position. DOB-A is a precursor in the synthesis of dexamethasone, 
whereas DOD-B is a precursor of betamethasone. It is important for the synthetic 
chemists who are working with these materials to know the purity of the compounds they 
have made, and the exact nature of impurities that are present. The separation of all of 
the impurities present in a sample ofDOB-A from each other and from DOB-A could not 
be achieved with organic: aqueous mobile phases. However, the addition ofy-CD to the 
mobile phase showed a significant change in the retention times and elution order of the 
peaks present in a chromatogram of a DOB-A sample. Figure 6-2 shows that DOD-B 
separates from an unknown impurity present in the DOB-A sample as the concentration 
ofy-CD in the mobile phase is increased from 0 mM to 3.2 mM. The elution order with 
no y-CD present in the mobile phase is DOB-A (27 minutes), and then DOD-B and an 
unknown impurity (30 minutes). When 3.2 mM ofy-CD were added to the mobile phase, 
the elution order changed to DOD-B (7 minutes), DOB-A (8 minutes), and then the 
unknown impurity present in DOB-A (10 minutes). The elution of DOD-B prior to 
DOB-A is advantageous when analyzing DOB-A for impurities. This is because an 
impurity that elutes immediately after the major peak in a chromatogram is often difficult 
to quantify due to the tailing of the major peak. The identity of DOD-B was established 
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Figure 6-1 Structures of DOB-A (A), DOD-B (B), and 11-~-OH-DOD-B (C). 
OH 
A B 
OH 
c 
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Figure 6-2 Effect of y-CD on the retention of DOB-A (1), DOD-B (2), and an 
unknown impurity of DOB-A. Concentration of y-CD: 0 mM (A), 1.6 
mM (B), 2.4 mM (C), 3.2 mM (C). 
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by injecting a solution containing 0.1 mg/mL of DOD-B. Figure 6-3 shows the results 
obtained for both the DOB-A and DOD-B solutions when no y-CD was present in the 
mobile phase and when 3.2 mM y-CD were present in the mobile phase. The retention of 
11-~-OH-DOD-B is shown in Figure 6-3. 
Kr values were calculated for DOB-A, DOD-B, 11-~-OH-DOD-B, and the 
unknown impurity present in DOB-A. The values were found to be 112 Mol, 148 Mol, 
212 M- l , and 93 M- l for DOB-A, DOD-B, l1-~-OH-DOD-B, and the unknown impurity 
present in DOB-A, respectively. This data supports the conclusion drawn in Chapter 3 
that the II-position plays a critical role in the interaction of steroids with cyclodextrins. 
Comparing the results for DOD-B and 11-~-OH-DOD-B shows that the change in 
orientation of the hydroxyl group from a. to ~ results in a 50% increase in the value of Kr. 
The data generated for these steroids also demonstrates that small differences in the value 
of Kr can result in large changes in the resulting chromatography. The Kf values for 
DOD-B and the unknown impurity in DOB-A differ by only 50 M- l , yet this is enough of 
a variance to result in the separation of these peaks using a y-CD modified mobile phase. 
The separation of DOD-B from DOB-A was improved by increasing the column 
length from 15 cm to 30 cm. The resulting chromatogram is shown in Figure 6-4. 
Acceptable resolution is observed for all of the peaks present in a sample of DOB-A. 
The run time is still quite reasonable for an impurity method which would be used in the 
pharmaceutical industry. 
ISS 
I Figure 6-3 Effect ofy-CD on the retention of DOB-A (1), DOD-B (2), an unknown 
I impurity of DOB-A (3), and 11-~-OH-DOD-B (4). Injections ofDOB-A solution with no y-CD in mobile phase (A) and 3.2 mM y-CD in mobile phase (C) and DOD-B solution with no y-CD in mobile phase (B) and 3.2 
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Figure 6-4 
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Betamethasone 21-Acetate Application 
A method was developed for the analysis of betamethasone 2I-acetate drug 
substance, using a mobile phase modified with ~-CD. The method accurately quantifies 
the drug substance and all related impurities, including degradation products, present in 
the drug substance above the limit of quantitation (LOQ = 0.05%). Complete validation 
in accordance with ICH guidelines was performed on the method. Four known related 
compounds were available for development and validation: betamethasone, 
betamethasone Il,2I-diacetate, betamethasone 21-cathylate, and the 9, Il-epoxide, 21­
acetate compound. The structures of these steroids are shown in Figure 6-5. The method 
was found to be linear, precise, accurate, robust, and specific. 
A typical chromatogram generated usmg the method to analyze a batch of 
betamethasone 21-acetate drug substance is shown in Figure 6-6. The method uses an 
acetonitrile: aqueous (35:65, v/v) mobile phase. The aqueous portion of the mobile 
phase contains 20 rnM of ~-CD and 0.1 M of sodium sulfate. The sodium sulfate is used 
to improve the solubility of ~-CD. A YMC J'sphere ODS-H80 column (150 x 4.6 mm 
ID, 4 J.lm particle size) was used, with a flow rate of 1.5 mLimin and a column 
temperature of 25°C. An injection volume of 25 J.lL was used to analyze a solution 
containing 0.4 mg/mL of betamethasone 21-acetate. 
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Figure 6-5 	 Structures of betamethasone 21-acetate (A), betamethasone (B), the 9,11­
epoxide, 21-acetate compound (C), betamethasone 11,21-diacetate (D), 
and betamethasone 21-cathylate (E). 
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Figure 6-6 Chromatogram of a typical sample of betamethasone 21-acetate drug 
substance. 
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Quantitative Validation Parameters 
Limits of detection and the limits of quantitation for betamethasone 21-acetate, 
betamethasone, the 9, II-epoxide, 21-acetate compound, betamethasone II, 21-diacetate, 
and betamethasone 21-cathylate were determined. Chromatograms are shown in Figures 
6-7 through 6-9. 
At the concentration of 0.4 mg/mL, the limits of detection for betamethasone 21­
acetate, the 9, II-epoxide, 21-acetate compound, betamethasone 11,21-diacetate, and 
betamethasone 21-cathylate were determined to be 0.0 I %. The limit of detection for 
betamethasone was found to be 0.003%. The limits of quantitation for betamethasone 
acetate, betamethasone 9, II epoxide 21-acetate, betamethasone II, 21-diacetate, and 
betamethasone 21-cathylate were determined to be 0.05%. The limit of quantitation for 
betamethasone was determined to be 0.01 %. 
Linearity was established by preparing a serial dilution of betamethasone 21­
acetate standard solution at concentrations of 0.24 - 0.56 mg/mL, corresponding to 60 ­
140% of the analytical level. Linearity was also established for betamethasone 21-acetate 
at concentrations of 0.2 - 20 Jlg/mL, corresponding to 0.05 - 5% of the analytical 
concentration. It is important to determine linearity at a low concentration to assure that 
the method will accurately quantify low level impurities using a betamethasone 21­
acetate standard solution at a concentration of 1 % of the analytical concentration. For 
each concentration, injections were made in triplicate. Three linearity studies were 
performed, with new solutions prepared for each study. A summary of the data obtained 
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Figure 6-7 Chromatograms of the sample diluent (A), limit of detection (B), and limit 
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Figure 6-8 Chromatograms of the sample diluent (A). limit of detection (B), and limit 
of quantitation (C) for betamethasone. 
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Figure 6-9 	 Chromatograms of the sample diluent (A), limit of detection concentration 
(B), and limit of quantitation concentration (C) for the 9,1l-epoxide, 21­
acetate compound, betamethasone 11,21-diacetate, and betamethasone 21­
cathylate. 
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is shown in Tables 6-1 and 6-11. Relative standard deviations (RSD's) of response factors 
for the assay range (60 - 140%) were found to be 0.09%, 0.55%, and 0.33%. RSD's of 
response factors for the range used for estimation of impurities (0.05 - 5%) were found to 
be 0.66%, 4.25%, and 0.85%. The data show that the response for betamethasone 21­
acetate is linear when measured using peak area. 
The linearity of betamethasone was also established at concentrations of 0.2 - 20 
Jlg/mL (0.05 - 5% of the analytical concentration). Betamethasone is a potential 
synthetic impurity and degradation product of betamethasone 21-acetate. In addition, 
linearity studies were performed for the 9, ll-epoxide, 21-acetate compound, 
betamethasone 11 ,21-diacetate, and betamethasone 21-cathylate at concentrations of 0.2 ­
20 Jlg/mL (0.05 - 5% of the analytical concentration). The RSD of the response factors 
for all four steroids ranged from 0.46% to 1.22%. This data demonstrates that the method 
is linear for the quantification of low levels of impurities that may be present in 
betamethasone 21-acetate. 
The precision of the assay method was determined by making five replicate 
injections of a standard solution containing 0.4 mg/mL of betamethasone 21-acetate. The 
response was measured and a RSD was calculated. This procedure was carried out on 
three instruments. An RSD of 1.5% or less is considered acceptable for the assay level. 
RSD's of 0.09%, 0.23%, and 0.30% were obtained. This data is presented in Table 6-III. 
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Table 6-1 	 Linearity data for the betamethasone 21-acetate method (assay 
concentration). 
Concentration Amount on % Analytical Peak Area Response 
(mg/mL) Column (Ilg) Concentration Average Factor (xl 000) 
0.24336 6.084 61 3045619 1251 

%RSD 0.09 

%RSD 0.55 

%RSD 0.33 

0.32448 8.112 81 4062047 1252 

0.4056 10.14 101 5067310 1249 

0.48672 12.168 122 6084311 1250 

0.56784 14.196 142 7101533 1251 

Average 1251 

0.24291 6.073 61 3856589 1588 

0.32388 8.097 81 5156485 1592 

0.40485 10.121 101 6443852 1592 

0.48582 12.146 121 7822918 1610 

0.56679 14.17 142 9035000 1594 

Average 1595 

0.24333 6.083 61 3821823 1571 

0.32444 8.111 81 5108647 1575 

0.40555 10.139 101 6347565 1565 

0.48666 12.17 122 7644441 1571 

0.56777 14.194 142 8870963 1562 

Average 1569 
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Table 6-11 	 Linearity data for betamethasone 2 I-acetate method (estimation of 
impurities concentration). 
Concentration Amount on % Analytical Peak Area Response 
(mglmL) Column (!lg) Concentration Average Factor (xl 000) 
0.000203 0.0051 0.05 2542 1252 
0.000304 0.0076 0.08 3751 1234 
0.000406 0.0102 0.10 5122 1262 
0.002028 0.0507 0.51 25351 1250 
0.004056 0.1014 l.01 50670 1249 
0.008112 0.2028 2.03 101549 1252 
0.02028 0.5070 5.07 253427 1250 
Average 1250 
%RSD 0.66 
0.000202 0.0051 0.05 2878 1422 
0.000405 0.0101 0.10 5981 1477 
0.002024 0.0506 0.51 31329 1548 
0.004049 0.1012 l.01 63661 1572 
0.008097 0.2024 2.02 129326 1573 
0.02024 0.5061 5.06 320144 1582 
Average 1529 
%RSD 4.25 
0.00203 0.0051 0.05 3148 1552 
0.000406 0.0102 0.10 6303 1554 
0.002028 0.0507 0.51 32070 1582 
0.004056 0.1014 l.01 64007 1578 
0.008112 0.2028 2.03 127968 1578 
0.02028 0.5070 5.07 319718 1577 
Average 1570 
%RSD 0.85 
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Table 6-111 Precision data for the betamethason~ 21-acetate method. 
Instrument 
I 

2 

3 

Injection 

1 

2 

3 

4 

5 

6 

Average 

%RSD 

1 

2 

3 

4 

5 

6 

Average 
%RSD 
1 

2 

3 

4 

5 

6 

Average 
%RSD 
Assay Level 

Response Factor 

(x 1000) 

1586 

1585 

1584 

1583 

1583 

1584 

0.09 
1579 

1580 

1584 

1587 

1590 

1584 

0.30 
1562 

1566 

1570 

1569 

1567 

1567 

0.23 
1% Level LOQ Level 

Response Factor Response Factor 

(x 1000) (x 1000) 

1583 1595 

1582 1377 

1600 1406 

1585 1386 

1600 1473 

1349 

1590 1431 

0.59 6.30 
1582 1757 

1583 1706 

1583 1668 

1586 1656 

1588 1632 

1653 

1585 1679 

0.16 2.72 
1617 1249 

1637 1284 

1658 1300 

1631 1208 

1613 1231 

1289 

1636 1260 

1.04 2.90 
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The precision of the estimation of impurities was determined by making multiple 
injections of a solution containing 0.05% of the analytical concentration and a solution 
containing 1 % of the analytical concentration. These solution represent the LOQ 
concentration and the concentration of the standard solution used to quantify low level 
impurities present in betamethasone 21-acetate, respectively. RSD's of 10.0% or less for 
LOQ solution and 5.0% or less for the 1% standard solution are considered acceptable. 
The data obtained for both solutions is presented in Table 6-III. The data shows that the 
method is precise for both the assay and the estimation of impurities and degradation 
products. RSD's of 0.16%, 0.59%, and 1.04% were obtained for the 1% standard 
solution. RSD's of2.72%, 2.90%, and 6.30% were obtained for the LOQ solution. 
The method developed using a P-CD modified mobile phase was compared to the 
current USP method. Three current batches and three expired batches of betamethasone 
21-acetate drug substance were assayed using both methods. The results are presented in 
Table 6-IV. The assay results demonstrate that there is good agreement between the data 
obtained by the current USP method and by the new procedure. 
The current USP procedure for estimation of impurities is performed by thin-layer 
chromatography (TLC). Three current batches and three expired batches of 
betamethasone 21-acetate drug substance were analyzed using the current USP TLC 
procedure and the new HPLC method. Solutions of the 9,ll-epoxide, 21-acetate 
compound and betamethasone II, 21-diacetate were spotted on the TLC plate. The 9,11­
epoxide, 21-acetate compound was found to coelute with betamethasone 11, 21-diacetate 
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Table 6-IV Comparison of assay results for betamethasone 21-acetate determined 
using the proposed method and the current USP method. 
Batch Number Age (Years) Proposed Method Current USP Method 
6-DOH-J1-6002 004 98.0 98.6 
5-DOH-JJ-6009 1 98.1 98.0 
5-DOH-JJ-6008 96.9 97.4 
0-DOH-JJ-6005 6 95.6 96.3 
0-DOH-JJ-6004 6 95.6 96.7 
0-DOH-JJ-6003 6 97.1 98.4 
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using the current USP method. Two unknown secondary spots were observed in all 
batches tested. The results of the estimation of impurities using both the new HPLC 
method and the current USP procedure are summarized in Table 6-V. Comparable 
results were obtained using both methods, although the new procedure provides more 
accurate quantification and separates more compounds than the current USP method. 
This is to be expected since HPLC is used instead of TLC. 
The proposed HPLC method provides better resolution and sensitivity and 
therefore enables detection and quantitation of peaks that were not separated by the 
current TLC method. Two potential process impurities - the 9, ll-epoxide, 21-acetate and 
betamethasone 11, 21 diacetate - are well separated and quantified using the proposed 
HPLC method. These two impurities were not separated using the current USP 
procedure. 
Qualitative Validation Parameters 
The specificity of the method (the ability of the method to separate all impurities 
from each other and from betarnethasone 21-acetate) was demonstrated by stressing the 
drug substance in acidic, basic, and oxidative conditions and analyzing the resulting 
solutions. The drug substance was also stressed by exposing a solution to UV light and 
by heating a solution at 70°C for twenty four hours. A final stress solution was prepared 
by holding the drug substance at its melting point for ten minutes and then dissolving the 
melt for analysis. All of the resulting degradation peaks were resolved and peak purity 
was established for the betamethasone 21-acetate peak using an HP 1050 series diode­
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Table 6-V 	 Comparison of the estimation of impurities results for betamethasone 21­
acetate determined using the proposed method and the current USP 
method. 
Proposed Method Current USP Method 
Batch Number Age (Years) # of Peaks Total Percent # of Spots % Total 
6-DOH-JJ-6002 004 13 1045 2 1.3 
5-DOH-JJ-6009 18 1.64 2 1.5 
5-DOH-JJ-6008 15 2.25 2 1.8 
0-DOH-JJ-6005 6 19 2.74 2 2.5 
O-DOH-JJ-6004 6 19 2.76 2 2.5 
O-DOH-JJ-6003 6 13 1.47 2 1.5 
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array detector equipped with ChemStation software (Agilent Technologies, Palo Alto, 
CA). A summary of the results is shown in Table 6-VI. 
System robustness was established by varying one chromatographic condition 
while holding all others constant. A solution containing many impurities was analyzed to 
assure that adequate separation was achieved for each condition. The parameters 
investigated (and the conditions used) were: column lot (3 different batches of packing 
material), flow rate (1.3 mLimin, 1.5 mLimin, and 1.7 mLlmin), column temperature 
(20°C, 25°C, and 30°C), injection volume (20 ilL, 25 ilL, and 30 ilL), mobile phase 
organic: aqueous ratio (34:66, 35:65, and 36:64, v/v), mobile phase ~-CD concentration 
(19 mM, 20 mM, and 21 mM), and mobile phase sodium sulfate concentration (0.09 M, 
0.10 M, and 0.11 M). 
No significant changes in the separation was observed for any parameter changes 
except column temperature and mobile phase organic : aqueous ratio. The 
chromatograms obtained for each of these parameters are shown in Figures 6-10 and 6­
11. As column temperature increases, the separation decreases between the 9,11­
epoxide, 21-acetate compound and an unknown eluting after it. This is due to the 
decrease in the strength of complexation as the temperature increases. More dramatic 
changes are observed in the chromatograms obtained as the mobile phase organic content 
was changed. Retention for all components decreased as the organic content was 
decreased. Typically, the opposite trend is observed in reversed-phase HPLC. However, 
the increase in complexation as the organic content decreases dominates the retention 
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Table 6-VI 	 Summary of the specificity data generated for the betarnethasone 21­
acetate method. BMA betarnethasone, UNK = unknowns, ACE = 
betamethasone 21-acetate. 
Temp Time Degradation Assay Mass 
Solvent (0C) Point Peak Area % % Balance % 
0.1 N Hcl 55 4 fir BMA 24.2 
UNK 0.1 
ACE 76.2 
Total 24.3 76.2 100.5 
0.01 N NaOH 0 2 min BMA 20.8 
UNK 1.6 
ACE 77.7 
Total 22.4 77.7 100.1 
10%H20 2 ambient 24 hr BMA 13.2 
UNK 1.1 
ACE 84.4 
Total 14.3 84.4 98.7 
Water 70 24 hr BMA 15.5 
UNK 1.9 
ACE 83.1 
Total 17.4 83.1 98.7 
Water UV light 2min BMA 0.9 
UNK 4.1 
ACE 85.4 
Total 5.0 85.4 90.4 
Solid State 196-208 10 min UNK 4.8 
ACE 95.2 
Total 4.8 95.2 100.0 
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Figure 6-10 Robustness data - variations in column temperature. Column 
temperatures used: A) 30°C, B) 25°C, C) 20°C. 
4 
Peak Identity 
1. Solvent Peak 
2. Betamethasone 
3. Unknown 
4. Betamethasone 21-acetate 
5. Betamethasone 9, 11 epoxide-21 acetate 
R. Unknown Impurity Peak Used for System Suitability 
6. Betamethasone 11, 21-diacetate 
7. Betamethasone 21-cathylate 
6 
5 
3 
c 
B 
A 
2510 
Retention Time (minutes) 
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Figure 6-11 Robustness data - variations in mobile phase organic: aqueous ratio. 
Acetonitrile: aqueous (v/v) ratios used: A) 36:64, B) 35:65, C) 34:66. 
4 
2 
I ,6 
Peak Identity 
1. Solvent Peak 
2. Betamethasone 
3. Unknown 
4. Betamethasone 21-acetate 
5. Betamethasone 9, 11 epoxide-21 acetate 
R. Unknown Impurity Peak Used for System Suitability 
6. Betamethasone 11,21-diacetate 
7. Betamethasone 21-cathylate 
6 
3 
k3~_C~_ 
A 
, i 
I 26 25 
Retention Time (minutes) 
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process. Adequate separation was achieved at all conditions despite these changes in 
chomatography. 
Conclusions 
Two applications using steroid : cyclodextrin complexes to achieve HPLC 
separations were described. Small changes in the value of Kr were shown to result in 
large changes in retention time for DOD-B and II-P-OH-DOD-B when y-CD was 
present in the mobile phase. In addition to enhanced selectivity, the presence of 
cyclodextrins in an HPLC mobile phase results in a decrease in run time, and thus an 
increase in sensitivity due to a decrease in band broadening. 
The method developed for the assay of betamethasone 21-acetate and the 
estimation of impurities in the steroid was fully validated according to the ICH 
guidelines. The use of P-CD as a mobile phase modifier did not prevent the method from 
being linear, precise, accurate, robust, and specific for the quantification of 
betamethasone 21-acetate and related compounds. 
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Chapter 7. 

Overall Conclusions and Future Work 

Inclusion complexes of steroids and cyclodextrins have been used for several 
decades because of their beneficial properties. Enhanced solubility, improved dissolution 
rates, increased drug product stability, and improved chromatographic selectivity are 
some of the applications that have been reported. However, the nature of steroid : 
cyclodextrin complexes has been poorly defined, with uncertainty even about which ring 
of a steroid is located in the cyclodextrin cavity. 
The work detailed in this dissertation determined the key structural features that 
affect the complexation of a series of betamethasone-related steroids with cyclodextrin. 
The nature of the functional groups in the 11-, 17-, and 21-positions were found to 
critically effect inclusion. The presence of hydroxyl groups in these positions enhanced 
the strength of the resulting inclusion complex. When bulky alkyl esters replace the 
hydroxyl groups, a decrease in the stability of the resulting cyclodextrin complex was 
observed. The thermodynamics of the inclusion process exhibit entropy-enthalpy 
compensation for eleven of the thirteen steroids studied. This data supports that the 
mechanism of inclusion is similar for all the steroids except betamethasone 17­
monopropionate and betamethasone 11,21-diacetate. 
Two different HPLC techniques were used to measure Kr values. Fujimura's 
method provided a fast, simple way to study the inclusion complexes of many different 
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guest molecules, while the Hummel-Dreyer method determined Kr values for a variety of 
host compounds with a single guest compound. The data generated using both methods 
was found to be similar, with four of six sets of data being statistically equivalent. The 
limitation of the Hummel-Dreyer method for determining low Kr values was described. 
Some of the practical aspects of the Hummel-Dreyer method were investigated, including 
mobile phase temperature and sample diluent organic concentration. A new method was 
developed to determine Kr values using a modification of the Hummel-Dreyer method. 
This method should help other researchers measure more accurate and reproducible Kr 
values when using the Hummel-Dreyer method. 
The inability of HPLC to differentiate between different steroid : cyclodextrin 
complexes with 1: 1 stoichiometries was realized. Other techniques were employed to 
determine if Kr values for an AlB-ring complex and Kr values for a CID-ring complex 
could be elucidated. The use of UV spectroscopy to measure the Kr value of an AlB-ring 
inclusion complex proved unsuccessful because experimental error was on the same 
order as the changes in molar absorptivity being measured. However, the use of a 
kinetics method yielded a Kr value that was lower than the one determined using HPLC. 
A novel mathematical approach to determining KrAlB and Ktt:/D values from this data 
failed to provide an exact value for either from the data obtained, yet served to provide 
some insight into the system. In particular, the failure of conventional equations used to 
determine Kr when multiple 1: 1 complexes exist was demonstrated. 
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While this work has provided a better understanding of the characteristics of 
steroid : cyclodextrin complexes, additional research needs to be undertaken to fully 
i 
~ 
reveal the structure of the complex. Using NMR, it should be possible to calculate a Kf 
1 
value for a proton on the A-ring and a proton on the D-ring when cyclodextrin is present f 
I 
~ 
f 
in solution. This would allow the direct evaluation of the inclusion of the AlB-ring and 
I the CID-ring of a steroid. The inclusion process also needs to be studied at a lower 
i 
J 
concentration of acetonitrile using Fujimara's method. A size exclusion column could be 
,I 
used to maintain reasonable retention times. In this way, a change in complexI 
I stoichiometry could be monitored. I! 
1 
1 
i 
Finally, other compounds could be developed which exhibit multiple 1: 1
1 
1 
complexes with cyclodextrins. The techniques described here could be applied toI 
I 
1 
monitor these complexes. It is very likely that many compounds exhibit multiple 1: 1 
'I complexes with cyclodextrins. Since HPLC is commonly used to study inclusion, these 
complexes may currently be overlooked. 
1 
I 
i 
I j 
I 
i 
I 
I 
J 
1 
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Appendix A. 

Calculations Used to Determine Kr by Fujimura's Method 

This appendix contains the spreadsheets used for the calculation of Kf values from 
the retention factors of each steroid studied. The general approach used was to plot the 
inverse of the retention factor for each steroid versus the concentration of cyclodextrin 
and determine the slope of the linear regression. Microsoft Excel 97 was used for this 
purpose. The spreadsheets contained herein include the weights of the cyclodextrin used 
for each mobile phase preparation, as well as the retention factors for each mobile phase 
used. The plots used to extract slopes and the formula for the regression line are shown 
on each spreadsheet. Finally, the Kf values calculated for each steroid are given at the 
bottom of each spreadsheet. 
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Figure A-I Data generated using a mobile phase of acetonitrile water (20:80, v/v) 
modified with y-CD, 1.8 mLimin flow rate, 25°C. 
File Sample 
Name Name 
720102 A:no G-CD 
720107 A:2.5mM G-CD 
720112 A:5.0mM G-CD 
720117 A:7.5mM G-CD 
A:2.5mM G-CD 
A:5.OmM G-CD 
A:7.5mM G-CD 
720103 6:00 G-CD 
720108 6:2.5mM G-CD 
720113 6:5.0mM G-CD 
720118 B:7.5mM G-CD 
6:2.5mM G-CD 
B:5.0mM G-CD 
6:7.5mM G-CD 
720104 C:oo G-CD 
720109 C:2.5mM G-CD 
720114 C:5.0mM G-CD 
720119 C:7.5mM G-CD 
C:2.5mM G-CD 
C:5.OmM G-CD 
C:7.5mM G-CD 
Weig/ltof 
Gamma-CD {Gamma-CDl 
3.2423 0.002500 
6.4864 0.005001 
9.8043 0.007559 
OOOr­
betamethasone 
k 
43.59 
13.7 
8.05 
5.63 
11k 
0.07299 
0.1242 
0.1776 
bocIomelilasone 
80.1 
7.99 
4.17 
2.78 
11k 
0.12690 
0.2398 
0.3597 
dexamethasone 
47.34 
14.04 
8.18 
5.68 
11k 
0.07123 
0.1222 
0.1761 
betamethasone 
0.07299 
0.1242 
0.1776 
9~bromo analogue 
k 
63.38 
6.21 
3.21 
2.12 
11k 
0.1610 
0.3115 
0.4717 
apoxide alcohol 
66.07 
28.45 
16.41 
11.75 
11k 
0.0378 
0.0609 
0.0851 
delta 9,11 
94.69 
31.41 
18.71 
13.15 
11k 

0.0318 

0.0534 

0.0780 

9-bmmo analogue 

0.1610 

0.3115 

0.4717 

____________________________________~ 
0 .. 
D.'" 
0." 
0.30 
0.:25 
020 
0.15 
010 
005 
000 
delta 11,12 
k 
82.86 
38.05 
24.41 
17.73 
11k 

0.02628 

0.04097 

0.05640 

delta 11,12 bedome1hasone 
0.02628 0.1269 
0.04097 0.2398 
0.05640 0.3597 
y .. 1S1.~+0OO65 
y-4/3,Ol9'x+0.o111 
y" 2Il681X + 0,0211 
y. 20.1'211" 0.011'12 
y" 9.34S1bt .. 0.01+4 
0000 0.001 0.002 0003 0004 0.005 0.006 0001 0005 'I- 5.9537x'" 0.0113 
omponen ope no us 
anaogue 
bedomethasone 46.019 80.1 2766 
betametbasone 20.681 43.59 901 
dexamethasone 20.721 47.34 981 
apoxide .Ico~ol dexamethasone delta 9,11 
0.03781 0.07123 0.03184 
0.06094 0.1222 0.05345 
0.08511 0.1761 0.07805 
o betamethasone 
o 9-bromo analogue 

.. deltal1,12 

o beciomethasone 
• epoxide alcohol 
" dexamethasone 
• delta9,11 
- Linear (9-bromo analogue) 
- Linear (beclomethasone) 
_ Linear (belamethasone) 
- Linear (dexamethasone) 
_ Linear (epoxide alcohol) 
_ Linear (deHa 9,11) 
11,12) 
01 9.3492 66.07 618 
8.7383 94.89 827 
5.9537 82.66 492 
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Figure A-2 Data generated using a mobile phase of acetonitrile water (25:75, v/v) 
modified with y-CD, 1.8 mLimin flow rate, 25°C. 
Flio 
514002 
Sample 
Ana CD 
belemettlesone
•1227 
9-btomo analOgue
•1749 
deb 11,12
•22.15 
betameth.•~tat.
•52.63 
514006 A:2"SmM G-CD 5.61 2.99 14.31 24.97 
814010 A:SJlmM G-CD 354 1,48 9.75 15.47 
614015 A 10.0mM Go-CO 1,95 0.66 5.03 6.91 
'''' '''' '''' '''' A:2.5mM G-CD 0.1721 0.3344 0._ 0.04005 
A:5.0mM G-CO 0.2825 0.6757 0.1026 0_ 
A 10.0mM G-CO O.S12B 1.471 0.1658 0.1122 
beclomethasone epQxide aJeohol 17-monoprop betamelh diacetate 
614003 S:noCO 1656 18.S1 75.13 96.33 
614007 ScHmMG-CO 3.76 10.75 4251 119.50 
614011 Sc5JJmM G-CD '.95 7.01 27.55 49.96 
61401(; SC100mMG-CD 0.94 4.18 16.49 32.51 
'''' '''' 
,;1< ,;1< 
ec2.5mM G-CD 0.2550 0.09302 002352 0,01437 
8:5.0mM G-CD 0.5128 0.1427 0.03630 002002 
B:10,OmM G-CO '.004 0.2404 0.06064 0.03048 
delI:amethasone de1l.89,11 dexamethasone a;::etete 
614004 C:noCQ 13.25 26.18 65.59 
814008 Cc2.5mM G-CD 6,04 134, 30.16 
614012 Cc5.0mM G-CD 3.85 8.47 18.57 
614017 C:100mM G-CD 2.00 489 10.62 
1;1< 1;1< ,;1< 
e:2.5mM a.CD 0.1656 0.01451 0.03316 
ec5 Omld G-CD 0.2140 0.1181 0,05385 
B:10.0mM G-CD 05000 0.2045 0.09416 
Weightot 
Gamma-CO (Ga~DJ betarnethasone 9-bfomo analOgue delta 11,12 bedomethasone 
6.4852 0.002551 0.1721 0.334. 0.00968 0.2000 
12.B7lI7 0.005105 0.2525 05757 0.1026 0.5128 
25.9165 001019 0.5128 1411 0.1656 1.004 
{Gamma-CDJ betameth. acetate. t!!fXl:dde acetate 21...f'Mnoprop 17~monoprop 
6,4852 0.002551 0.04005 0.02771 
12.9767 0.005105 0._ 004610 
25.9165 0.01019 0.1122 0.06210 
,... 
,..., 
,.".,J 
y -105.0;h:-(I.(I1OS 
y • .4o(.... o.• 
! 
,,"43.11•• 0,0522: 
y.1t.J$2•• {U)" 
y.17.o:n:. ... CUlll 
.... j 
1·U.538K+O. ~ 

•."" +-I--_-~.------~
'" 
(1.(»0 0.012
.- .
.... 
0.01800 0.02352 
0.02960 0.03630 
0.04692 0._ 
0­
'" 
.,. 
.11~
• apoxidiItIt:GhoI
.-
.... 
.-­
0 ....,11 
o.ot i 
_u-r~ .....) 
, ••.01•• 11.1,1&2 _U-~.~) 
_u..~) I 
y_7.fn1J..OA)129: _u-r{~_ 
_U-~) 
_I•." 
_u--(--"--; 
_u-r(lIIpOJIicMI~ 
_~(....,11) 1._J);4I3:b:.0.0011 _~(tl~) 
epoxide acetate 21~noprop 

k k 

96.24 110.64 
36.09 55.55 
21.69 34.97 
12.18 20.44 
'''' ''''0,02771 0.01800 

004610 0.02960 

0.08210 004892 

epoxide aloohol dexamethasone de1te9,11 
0,09302 0.1656 001460 
0.1427 0.2740 0.1161 
0.2404 0.5000 0.2045 
betameth diaeeblte dexamethasone ~tate 
001431 003316 
002002 005365 
0,03048 0.09416 
.21~ 
_U-(""',17) 
,.,.,.".. ,...., I 
,.""
....~.-----.-"'-- ...........:--.c-_---.-.,-.--.-." 

no s 
..... 
00."' 
'-.--J 
i 
F wuelAlmponenIt;omponen ,~- 0."..i-
.' no"""J 
.
omo ana 
f.ef 
"..
asone I~·cetate
..... I~ea().aeI..·...~.on. 
.ff'ItmoprQP11>.<0 
,""".. ,,9.20, -monoprnp
..• ... ....Ilf.uu,
. 
" 
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1523 
• • • 
Figure A-3 	 Data generated using a mobile phase of acetonitrile water (30:70, v/v) 
modified with y-CD, 1.8 mLimin flow rate, 25°C. 
betamett!osone 9-bromo analOgUe deb 11,12 betameth, acetate ep(Ixide acetate 21 wmonoprop

File Sample k k k 

61e<103 AnoG-CO 4.7 6.57 8.21 19.02 30.54 37.74 
616008 A2.5mM G-CD 268 1.61 5.89 11.55 17.03 23.99 

616013 A:S.OmM G-CO 
 1.91 0.87 4.79 a.61 12.25 18.39

.,6020 A:.l0.0mM G-CO 1.01 0.35 31. 5.3 7,34 11.6 

"'e '''' 	 "e1I:2.5mM G-CD 0.3731 0.5988 '''' 0.1&.10 '''' 	 ''''O.Oee58 0.05872 0.04168 
1I:5.OmM G-CD 0.5236 1.149 02086 0.1161 0.06'83 0.05436 

1I:10.0mM G-CD 0.9346 2.857 0.3165 0.1887 0.,362 OJ)8621 

bedomethasQl'le epoxide alcohol 17-monQProp betameth diacetate 

.'6004 B:no G-CD 6.23 1.34 24.27 32.54

.,6009 B:2.5mM G-CO 2.03 4.76 16.63 26.4 

616014 8:5.0mM G-CO 1.16 3.67 13.32 23.53 

61&021 B:10.0mM GwCO 0.52 2.29 8.67 17.23 

'''' ,'" 	 ,'''S:2.SmM G-CD 0.4926 	 '''' 0.037680.2092 006013 

8:5.OmM G-CD 0.6621 0.2725 0.07500 0.04250 

8:10.0mM G-CO 1.923 0.4367 0.1153 005604 

dexametna'one delta 9,11 dexamethasone aoeblte 
616005 C:no G..cD 5.06 9.88 2344 
616010 C:2.5mM G-CD 2.83 6.1S 14.04 
616015 C:5,QmM GwCD 1.99 4.63 1Q.42 
616022 C; 10.(nnM G-CO 1.12 2.64 6Al 
,''' 	 "'eC:2.SmM G-CD 0.3$34 '''' 0.1626 007123 

C:5.0mM G-CD 0.5025 02160 0.09597 

C:10.0mM G-CO 0.8929 0,3521 01560 

IMot 
Gamma-CO (GammaoCO] b4:Ital:'netnalOne 9-bromo analogue delta 11,12 bacIomethasone epoxide alcohol dexamethasone de1te9,11 
6.4688 0.002545 0.3731 Q.598S 0.1698 0.4926 02092 0.3534 0.1626 
12.9623 0.005099 0.5236 1.149 02066 0,8621 0.2725 0.5025 0.2180 
25.9329 0.010>0 0.9346 2.657 0.3165 1.9231 0.4367 0.1l921l 0.3521 
[Gomma-CO] betamath. acetate epoxldft acetate 21..monoprop 17wmonoprop betameth diacetate dexemethelOne acetate 

6.4686 0.08658 0.0&112 0.04168 0.06013 0.03788 0.07123 

12.9623 0.1161 008163 005438 
 007508 0.04250 0.09597 

25.9329 0.01020 0.lS81 0.1362 0.08621 0.1153 o05e04 0.1580 

... l~-·-.-----~....·..~_-_-_ 
0,001 0,010 
,.. 
'.5O 
,... 
,.. 
... 
_u--{~~ 
I • "'~1,12 .:!1.~0.16 
0­
.11~ 
.-­
_U-(bIIaI\'iIIti,ICiIUfe'1 
.... 
!,-1.3016. + 0.004... _~(11~) I 
1_'-"-__,'" .... 
.­
,-UI43h'-O.1161 
:_U-(d!l!b11,1l} 
0.012 o.otO 0.012 ===-J.... 	 L ____ .......J 
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Figure A-4 Data generated using a mobile phase of acetonitrile: water (35:65, v/v) 
modified with y-CD (seven concentrations),1.0 mUmin flow rate, 25°C. 
doIbt1.12
... ...... . , , , , , 
"-
-- -- "-­
l!XlelQe; A:noG-CD 3.10.-
--
... 
-­
2.1. 1001 15,. lIUIIS 
UXlSH3 A:O.~G-CD 2.S1 2.19 .,. U. 11.501<4.•' U1O$121 A:O.75dil G-CO '.<0 ,... t.Ol 11.02•.'" ".,100512& A:l.\ftIMG-CO 2.22 ,U5,.'" e.ro 13,21 18.50 
11""'05 A:l.iSmM G-CO 2.12 '.93 '.ll 12,4(1 15,1"~.. 
l00.t113 A:,.SmNG-CO 1.31 ,.. 7." HUl7 
1004121 A:5mUG-CD ,."'  0.13 ,.. 0." 8.17 11.31,... 
u.~ 
lCJCi.411& 11.'7 ,!rnM G-eD 1.04 .46 .... .... 9.41 
'" 'IkA:O.!r!"IoIG-CO '" O.St 0.1071 0 .... '" 0._ '" O.12!l15 0_ 
A'O.7SmII G-CO 0.41$1 0._ 0._ 0.1110 o.am 0_ 
A:U)','MG-CD 0..... 
..- 0.". 
.Ik 
.....0.2a 0.0754 

A:l.25rii G-CO •.m3 0.121t
0.5191 0- 0.0801 000» 
A:'.5rrM GeD ..... 0.111:2$ 0.2138 0.1_ ...... 0.0700 
A::sm.tG-CO 1.3133..= OJ7&4 0.'22:" 0..... 
":7~G-CO 2.1592 0.2155 0,1521 0.1063__hoi...... ."".­
..­
1005108 8:noG-CD 3.51 ".24 "-H.13 1U~ 

10051104 8:O.5tnU G..co ,... ,... 11.15 --15,M; 

1005122 B;O.l5mM G-CO ,OO la, 10.M 15.58 
tOQS1lO B:l.OrnMG-cO 3.11 10.81 15.44 

1004108 8:1.2'5rrAIG-eD 2,11 ,... 10.15 15.00 

100411. B:2.5trJMG-CO ,.. ).11 0.43 

.." 
'<1.70 
1Q(W122 B;5mMG-CO .0> ,... 7.70 13.01 
1004130 S:7,5trJM G-CO ..., ,... ... ,1,86 
'Ik 
8;0.$mM G-CO 0._ '"0.252<1 .....,'" 
a-Q.75rrM G-CO ..- ".,,"
.."'" O.08HI ..... 
B:1.OmMG-Co 0...196 
.."'" ..-
.Ik 
0._ 
S·'.25mM G-CO 0.4141 o.VS70 ...... "'081S:2.5trJMG-CO 0.851' 0.l2t2 0.10EJ0 
B.5mM o.co 1.0757 0.<1106 
.,'" 
..0.0185 ­.,.,.EP.StrnMG-CO 0.1525 0.0841,.­
debi.ll ...-.­
...-
'531005101 C:noG-CD 12.14 
1005115 C;O.StrnM G-CO 11.21 '" ". 
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1005131 C 1- OmMG-CO ..,. 10.• 
1004101 C.l.25mM Qi.co ,.",." 4.51 .... 
1004115 C:2.5mM c.cO ,.. 4,01 .... 
1004123 C::5mM<reD '.40 31. 6.8, 
1004131 C:7.5mM G-CD 
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C:O.5mUQ-CO "' ..,.... '" 0.3162 "' 
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 "....
..­C:I.OmMG-CO 0.4124 ,,- 0..... 

C:l.25mM G-CO 0.:m8 0.1005 
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FigureA-5 Data generated using a mobile phase of acetonitrile water (35:65, v/v) 
modified with y-CD, 1.8 mLimin flow rate, 25°C. 
File 

N.... 

6'23003 
623008 
6'23015 
623022 
623004 
623009 
623016 
6'23023 
623005 
623010 
623017 
623024 
Weijjlt.f 
Gammo-eD 
6.4369 
12.9823 
19,4493 
Weigtrtef 
Gamrna~CD 
6.4389 
12.9823 
19.«93 
uo 
3.00 
2.50 
2.00 
1.50 
1.00 
0.50 
betamethasooe 9-bt()l'n() analogue delta 11,12 belameth.llIcetate epoxlde acetate 21.monoprop 

Sample I< I< k k k k 

Name 
knoeD 2.24 3.07 3.87 8.59 13,57 16.18 
A:2.5mM G-CD 1.48 1.05 3.07 6.23 9.33 12.19 
A:5.0mM G-CD 1.1 0.55 2.61 5.01 7.27 10.08 
A:7.5mM G-CD 0.81 0,3 2.15 3,99 5.69 8.16 
11k 11k 11k 11k 11k 11k 
A:2.5mM G-CD 0.6757 0.9524 0.3257 0.1605 0.1072 0.08203 
A:5.0mM G-CD 0,9091 1818 0,3831 0.1996 01376 0,0992 
A:7.SmM G-CD 1.235 3.333 0.4651 0.2506 0.1757 0.1222
_111_ 
becknnethasone epOXIde alcohol 11..monoprop 

k k k k 

B:n<>CD 2,92 3.55 10.18 13.94 
B:2,SmMG-CD 1.25 2.61 8.05 12.37 
B:5.OmMG-CD 0.72 2,1 6.69 11.6'2 
8:7.SmM G-CD 0.45 1,66 5.69 10,25 
11k 11k 11k 11k 
B:2.5mMG-CD 0,8000 0.3831 0.1242 0.080&4 
B:5.0mM G-CD 1.389 0.4762 0.1451 0,08606 
B:7.5mM G-CD 2.222 0.6024 0.1757 0.09756 
dexamethasone detta 9,11 dexamethasone acetate 

k k k 

C:noCD 2.39 4.67 10.4 
C:2.5mMG..cD 1.57 3.38 7.54 
C:5.0mM G-CD 1.16 2.7 6.07 
C:7.5mM G-CD 0.85 2,14 4.84 
11k 11k 11k 
C:2.5mM G-CD 0,6369 0.2959 0.1325 
C:5.0mM G-CD 0.6621 0.3704 0.16<17 
C:7.5mM G-CD 1.176 OM73 0.2066 
[Gamma-CDI betamethasone _emo analogue 
_",'2 bedome1hasooe epoxlde alcotu:>J Hnmeti1asone delta 9,11 
0.002533 0.6757 0.9524 

0.005107 0.9091 1.818 

0.001651 1.235 3.333 

IGamma-CDI betameth. acetate epokide acetate 
0.002533 0.1605 0,1072 
0.005107 0.1996 0,1375 
0.007651 0.2506 0,1757 
0 
y.., 484.96x ~ Q,3352 
'1 =m.79x +00545 
Y"" 109.17x ... 0 3834 
y '" 105-381 +0 3547 ~ 'I" 42J~3x + 0.2689 ., =33.487. -+ 0:15)12 
., ... Zl,mx" 0.2526 
0.00 
0.000 0002 0.00< 0.006 0008 0.010 
0.3257 
0.3631 
0.4651 
21.monoprop 
0,08203 
0.09921 
0.1222 
I.~ 0.30 • 0 ........,.­
• 	 delta 1112 
025 
C_""'" 
• epoxiOfatoohot 
e",
,,­
.. -"$,11 
O.tS 

- tJnur (9-b'omo

-_I 
-linov 
(bedQl'I'.1hno"'1 
-Uno" 
(btltam.thI*,ne) 
_u.....r 
(dftIlfYW1tlHoIW) 
-Linear (lIPOxide 0." 
-) 
_LlMat(dltbI 9,1') 
-UnHr(detta 11.12) 
e.oo 
0000 COO> 0.010C- O.'" 	 diacetalllj 
0.80D0 0,3631 0.6389 0.2959 
1.389 0,4762 0.66'21 0.3704 
2.222 0.602 1.176 0.467 
17-monoprop bemmeth diacetate dexame1h8$one acetate 
0.1242 0.06064 0.1325 
0.1451 0,06606 0.1647 
0.1757 0.09156 0.2066 
• epoxide~
.21_ 
.. 17-n'1Onoprop 
.. be!ameltldiaet1lttt 
.danmtthiulont ~ 
_unur(be(amattt 
""""to) 
y .. t7.&o:b:*O.11Je 
y"1.,~+O,0IiI043 ~ _Uleat (dulmoltl'll1sone .-...)y",10,CI.I::b + 0091. _t.near{17~) 
'J • 13,38rU '" 0.01'9 
~tnar (epoxidit
".71553w: .0.0911 
-I 
_UWM {21-monoprop}'1"3.~ +O.O11!'1 
! 
:_Ulur(bNmeth0._ 
,~,i""'mp...., ""'PO K-{no\,;U} ",Y.~ .......,......, ""'PO '·(n."o) 

~-'~".-~~ .'00;;;;.:;;;;::=; 27;; ~:~ 811' dexameth. acetate 140452 7;~ ;~ 
betamelhasone 109.17 2.24 245 17-monprop 10.063 10.18 102 
~methaeone 105.38 2.39 252 epoxide acetate 13.394 13,57 182 
epoxlde alcohol 42.83 3.55 152 21_ 7.8553 18.18 127 
delta 9,11 33.487 4,67 156 betameth. clacetate 3.2645 13.94 46 
_",12 27.225 3.87 105 
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Figure A~6 Data generated using a mobile phase of acetonitrile water (35:65, v/v) 
modified with y-CD, 1.0 mLimin flow rate, 25°C. 
FDa Sample 
Name Name 
714003 kno G-CO 
714010 A:2,5mM G-CO 
714011 A:5.0mM G-CO 
714024 A:7,SmM G-CO 
A:2.5mMG-CO 
A:S,OmM G-CO 
A:7.SmM Q.CO 
714004 9:no G-CO 
714011 8:2.5mM G-CO 
714018 a:S.OmM G-CO 
714025 B;7.5mM G-CO 
S:2.5mM G-CO 
S:5.0mM G-CO 
8;7.SmM G-CO 
714005 Cno G-CO 
714012 C:2.5mM G-CO 
714019 C:5.0mM G-CO 
714026 C;7.5mM G-CO 
C;2.5mM G-CO 
C;5,OmM G-CO 
C;7,SmM G-CO 
Weight of 
Gamma..(;O [Gamma-eOI 
13.0253 0.002562 
25.9390 0.005102 
38.9914 0.007689 
weight of 
Gamma-CO IGamma-eD1 
13.0253 0.002562 
25.9390 0.005102 
38,9914 0.007689 
3.50 
betamethas.OM 9-bromo analogue 
k k 
247 3.4 
162 1.1 
1.17 0.57 
0.87 0.33 
Iii< Iii< 
0,6113 0,9091 
0,8547 1.75« 
1.1494 3.0303 
bedomethasone epoxide alcoh~ 
3.23 3.87 
1.32 2.84 
0.76 2.22 
0.48 1.76 
Iii< Iii< 
0.7576 0.3521 
1.3158 0.4505 
2,0833 0,5682 
dexameth8$Ofle deHa 9,11 

2,63 5.09 

1.7 3.69 
1.23 2.87 
0.91 2,27 
Iii< 1.1< 
0.5882 0.2710 
0.8130 0.:1484 
1.0989 0,4405 
betametha.<me 9--bromo analOgOe 
0.6173 0.9091 
o.a547 1.75« 
1,1494 3.0303 
betameth. acetate _"..Ide_to 
0.14368 0.09814 
O.IMa 0.13038 
0,2320 0,1_ 
y.415.4!h:~02256 
'I- 259.66. + 0.0585 
'( a104.21x + 0.3412 
y - 100.01x" 0.3222 
y' 42.313>< + 0.2407 
y' 27.285x + 0.229 
"I" 33.198x + 0.1836 
0.000 0.002 0.004 0.006 
eon~«.." 
I~omo ana ogue 
beclomethasone 
betamethasona 
dexamethasone 
epaxide alcohol 
delta 11.12 
delta 9,11 
0.008 0.010 
Slope k'(noCO) 
;;; 
104.2' 
100.01 
42,313 
27.285 
33.198 
~;3 
2.47 
2.63 
3.87 
4.16 
5.09 
delta 11.12 bet8meth, acetate 
k k 
4.16 9.67 
3.32 6.96 
2.75 S.41 
227 4.31 
Iii< Iii< 
0,3012 0.1437 
0.J6J6 O,IMa 
0,4405 0.2320 
17__op betameth c1acetate 
11,12 15.6 
8.8 14,03 
7.27 12.72 
6.00 11.26 
Iii< Iii< 
0.1136 0.07128 
0,1376 0.0768 
0.1667 006881 
dexamethasone acetate 
11.73 
8.43 
6.56 
5.22 
Iii< 

0.1186 

0,1524 
0,1916 
delta 11,12 bedomethdOOe 
0.3012 0.7576 
0.J6J6 1.3158 
0.4405 2,0833 
21-l'IWJnopfOp 17·mo!lOJll'op 
0.07353 0.11364 
0,09200 0.13755 
0.11364 0.16667 
() betamethasone 0.25 
9 &-bromo analOflJe 
• delta 11,12 
o beciomethllSOl"le 
020 
• epoxlde aleohoi 
A dexamethasone 015 
_ Linear {9-bromo analogue' 
010 
_ Uoear {betameth••one) 
_ 
_ 
Unear (dexameIhMQne} 
Uoear (epoxide alcohol:} 
0.05 
_Line.. {delta 11.12) 
_Unear{delta 9,11} 
0000 
~----..........-­
r.,. aue 
839 

257 

263 

184 

114 

169 

epoxide acetate 21·monoprop 
k k 
15.11 18,1 
10.19 13.6 
7,67 10.87 
5.99 8.8 
Iii< Iii< 
0.09814 0.073S3 
0.1304 0.09200 
0.1689 0.1136 
eporide alcohol dexamethaaone delta 9.11 
0.3521 0.5882 0.2710 
0.4505 0.8130 0.:1484 
0.5682 1.0989 0.4405 
belameth diacetate dexamethalSOf'Ie acetate 
0.07128 0.11862 
0.07882 0,15244 
0,08881 0.1916 
o dexamethasone 
acetate 
"I -17.2991c + 0,0984 
_ Unear (betameth, 
acetate) 
"I - 14.285:x + 0.0812 
_Unear 
(d&xarneihMOne 
"I - 10.385x .. O.oa62 
y -13,474x .. 0.063 
y a 7.854h+0.0529 
0.002 0.004 0.006 0008 0010 
_l'fn".':1"~7. 
!!IO!IO!>'O!» 
eo_ Slope .. (no CD) '" "OJ". 
=== 17__op :~~:; 10.385 ~;O~3 11.12 ;; 115 
epa.1de acetate 13,474 15.11 204 
21~monoprop 
betameth tiacetate 
7.8541 
3.4:142 
18,1 
.5,6 
142
,. 
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